連続反応による骨格構築を鍵とした

lyconesidine B の全合成

 $2 \ 0 \ 2 \ 0$

黒瀬 朋浩

目次

序論		
第一節	リコポジウムアルカロイドについて	
第二節	Fawcettimine 型リコポジウムアルカロイドについて	5
第三節	Fawcettimine 型リコポジウムアルカロイドのこれまでの合成戦略について.	6
第四節	本研究の概要と構成	10
第一章	四置換エンカーバメートのシクロプロパン化とその開環を利用したオクタ-お。	よびデカヒド
ロキノリン	ンの合成	
第一節	シクロプロパン化による第四級炭素の導入と、その全合成への応用	13
第二節	シクロプロパン化と開環反応を基盤とした合成計画	
第三節	核間位に第四級炭素を持つオクタ-およびデカヒドロキノリン骨格の合成	17
第四節	結論	22
第二章 I	Lyconesidine B の全合成	
第一節	Lyconesidine 類について	
第二節	ドミノエニンメタセシスについて	
第三節	遷移金属触媒によるジアゾ化合物とアルケンの不斉シクロプロパン化につい	τ 26
第四節	Lyconesidine B の合成計画	
第五節	(±)-Lyconesidine B の全合成	
第六節	(−)•Lyconesidine B の不斉合成研究	
第七節	結論	
第三章 約	古論	43
実験項		
参考文献.		
論文目録.		129
謝辞		130

略語表

Ac	acetyl
acac	acetylacetonate
ADMP	2-azido-1,3-dimethylimidazolinium hexafluorophosphate
aq	aqueous
AZADOL	2-hydroxy-2-azaadamantane
BAr _F	tetrakis[3,5-bis(trifluoromethyl)phenyl]borate
Bn	benzyl
Boc	<i>tert</i> -butyloxycarbonyl
Вру	2,2'-bipyridyl
Bu	butyl
cap	caprolactamate
Cbz	benzyloxycarbonyl
CSA	10-camphorsulfonic acid
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DMSO	dimethyl sulfoxide
DMAP	N,N-dimethyl-4-aminopyridine
DMF	dimethyl formamide
dr	diastereomeric ratio
eq	equivalent
er	enantiomeric ratio
esp	$\alpha, \alpha, \alpha', \alpha'$ -tetramethyl-1,3-benzenedipropionic acid
Et	ethyl
hfacac	hexafluoroacetylacetonato
HMDS	hexamethyldisilazane
i	iso
JohnPhos	2-(di-tert-butylphosphino)biphenyl
LDA	lithium diisopropylamide
L-Selectride [®]	lithium tri-sec-butylborohydride
Me	methyl
Mes	methanesulfonyl
MS	molecular sieve
п	normal
NBS	N-bromosuccinimide
NIS	N-iodosuccinimide
NMO	<i>N</i> -methylmorpholine <i>N</i> -oxide
NMR	nuclear magnetic resonance
Ns	2-nitrobenzenesulfonyl
Р	para
Ph	phenyl
pin	pinacolato
PMHS	polymethylhydrosiloxane
Pr	propyl

t	tertiary
TBAF	tetrabutylammonium fluoride
TBS	tert-butyldimethylsilyl
TES	triethylsilyl
Tf	trifluoromethanesulfonyl
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TMS	trimethylsilyl
TPAP	tetrapropylammonium perruthenate
Ts	<i>p</i> -toluenesulfonyl (tosyl)

序論

第一節 リコポジウムアルカロイドについて

ヒカゲノカズラ科の植物は、世界中に広く分布するシダ植物であ り、古くから止血、消炎、解毒作用などを目的とした伝統薬として 利用されてきた¹。このような背景から、これら植物からの生理活 性天然物の単離研究が精力的に行われており、1881 年 Bödeker らに



よる lycopodine²の単離以来、「リコポジウムアルカロイド」と呼ば Figure 1. examples of lycopodium alkaloids れる特徴的な多環性骨格の天然物が現在までに250種類以上単離されてきた (Figure 1)^{la}。本天然物群 の中には、有用な生物活性を持つものが多数報告されている。その代表的な例は、1981年に Huperzia Serrata より単離された huperzine A である³。本天然物は、既存のアルツハイマー病治療薬と同等の高 い可逆性アセチルコリンエステラーゼ阻害活性を有しており、毒性や副作用が少ない為、米国では記 憶障害改善のためのサプリメントとして販売されている⁴。また、huperzine A の他にも、抗 HIV 活性⁵ や抗腫瘍活性⁶、抗炎症作用⁷などを持つ天然物が報告されている。リコポジウムアルカロイドは、そ の生物活性が注目される一方で、その生合成研究は発展途上であり、生合成酵素もほとんど明らかに なっていない¹°。これは、ヒカゲノカズラ科の植物の成長速度が非常に遅く、栽培も難しいことが原 因である。しかしながら、放射性同位体標識したリシンを用いたトレーサー実験より、リシン (1) 由 来の4-(2-piperidyl)acetoacetate (3) と pelletierine (4) との脱炭酸を伴うカップリング成績体 phlegmarine (5) が生合成中間体と提唱されている (Scheme 1)⁸。5 から脱窒素や骨格転位を伴って生合成されるリ コポジウムアルカロイドは、その構造的特徴から lydcodine グループ、lycopodine グループ、 fawcettimine グループ、その他 (miscellaneous group) の4種類に大別される% Lycodine に代表される lycodine グループは、二つの窒素原子を含んでおり、ピリジン環やピリドン環を有することがその特 徴である。Lycopodine に代表される lycopodine グループは、lycodine 型天然物の A 環が開環してピペ リジン環を形成した構造である。また、fawcettimine に代表される fawcettimine グループは、BD 環部 の cis-ヒドリンダン骨格と AC 環部のヒドロアゾニン環を有することがその特徴である。なお、これ らに属さないリコポジウムアルカロイドはその他に分類される。

Scheme 1. Biosynthesis and classification of lycopodium alkaloids. Đ, H₂N H₂N -CoA h ١Н lysine (1) 3 phlegmarine (5) CO_2 Fawcettimine Lycopodine Lycodine Miscellaneous group group group aroup 0 Me OI А Mé fawcettimine lycopodine lycodine cernuine

4

第二節 Fawcettimine 型リコポジウムアルカロイドについて

Fawcettimine は 1959 年に Burnell によって *Lycopodium fawcetti* より過塩素酸塩の結晶として単離された¹⁰。その後、犬伏、 Burnell、Ayer らによってヘミアミナール **6a** とケトアミン **6b** の 平衡混合物であることが提唱された (Figure 2)¹¹。この時点では、 4 位の立体化学については明らかでなかったが、後述の Heathcock



らの全合成により 4S 体であることが明らかとなった。Fawcettimine の単離以来、fawcettimine グルー プに属する天然物は 80 種類以上が単離されており、構造的多様性に富んでいる。著者は、本化合物 群の構造の中で、13 位の酸化度に着目し、それぞれをヘミアミナール型、エナミン型、アミン型の三 種類に分類した (Figure 3a, b, c)。



^aAsymmetric synthesis. ^bFormal synthesis

Figure 3. Classification of fawcettimine-type *lycopodium* alkaloids based on the structure of C13 and examples of total synthesis. The numbers and names in the right side of each compound are the years of publication and the authors of their synthetic studies. The biactivities (onyl for reported compounds) are showed below each compound.

ヘミアミナール型は、fawcettimine に代表される 13 位にヘミアミナール構造を有する天然物群であ り、fawcettimine を基準として、その炭素骨格の酸素官能基化の度合いによって、「基本骨格 (basic skeleton)」と「酸素官能基化骨格 (oxygen-functionalized skeleton)」に細分化した。エナミン型、アミン 型の天然物も同様に、それぞれ fawcettidine と lannotinidine B を基準として分類した。これらのグルー プについてその全合成報告数を比較すると、ヘミアミナール型の天然物は比較的合成研究が進んでお り、その合成報告数は、基本骨格天然物が 16 報、酸素官能基化天然物が 12 報である¹²。エナミン型 天然物の合成報告数は、ヘミアミナール型程多くないが、基本骨格天然物、酸素官能基化天然物の合 成がそれぞれ 5 報と 1 報である。一方で、アミン型の天然物は、lannotinidine B の全合成の 1 報に留 まり、酸素官能基化骨格のアミン型天然物の合成は、本博士課程の研究で著者が報告するまで達成さ れていなかった。

第三節 Fawcettimine 型リコポジウムアルカロイドのこれまでの合成戦略について

Fawcettimine 型リコポジウムアルカロイドの合成報告数には偏りがあるが、おおまかな合成戦略で 分類して、これまでの合成研究を紹介する¹³。

① 犬伏らによる(±)-fawcettimine の初の全合成

Fawcettimine 型リコポジウムアルカロイドの初の全合成は、1979年に京都大学の犬伏らによって報告された fawcettimine の全合成である (Scheme 2)^{12a}。本合成では、BD 環部から構築し、最後にヘミアミナールを形成する戦略が採用された。具体的には、まずシクロヘキセノン誘導体 7 とブタジエンとの Diels-Alder 反応により、四つの置換基全てが炭素原子の sp³炭素(以下、第四級炭素)の導入とD 環部の構築を一挙に行った。その後、オゾン分解と分子内アルドール縮合による B 環部の五員環形成で、シスヒドリンダン化合物 9 へと導いた。さらに、Horner-Wadsworth-Emmons 反応による増炭と分子内アミド化による 9 員環ラクタムの形成を含む 6 工程の変換で、三環性化合物 10 へと変換した。アルケンの接触水素化後、トリフルオロアセチル基を除去すると、分子内でヘミアミナール構造が形成され、(±)-fawcettimine の初の全合成が達成された。なお、本合成では接触水素化後に 4 位のジアステレオ混合物となったため、天然物の 4 位の立体化学は明らかになっていなかった。

Scheme 2. Inubushi's first total synthesis of (±)-fawcettimine.



② Heathcock らによる(±)-fawcettimineの全合成と4位の立体化学の決定

1986 年、Heathcock らは、4 位の立体化学の決定を目的として fawcettimine を全合成した (Scheme 3)^{12c}。彼らは、まず、シクロヘキセノン誘導体 12 とアリルシラン 13 との細見・櫻井反応によって得

られたアリルアルコールを酸化して α,β-不飽和アルデヒド 14 を得た。14 とイリド 15 との Wittig 反応 に続く分子内 Michael 付加による第四級炭素の導入と加水分解でカルボン酸 16 を合成した。その後、 Arndt-Eistert 合成で増炭して生じたエステルとニトリル、ケトンの還元で、アミノジオール 17 を 9:1 のジアステレオ混合物として得た。なお、主ジアステレオマーの構造は、X 線結晶構造解析によって 確認された。17 を TsCl で処理して、トシルアミド 18 とした後、分子内求核置換反応によりヒドロア ゾニン環を形成した。その後、トシル基の除去、第二級アルコールの酸化でアミノケトン 19 を合成 した。このとき、19 はヘミアミナール体として観測されなかったことから、4 位の立体化学はヘミア ミナール形成に影響を与えていることが示唆された。最後に、19 をオゾン分解すると、アミノジケト ン 20 が生成したが、20 は不安定であり、室温、数時間で 4 位が異性化した後、分子内でヘミアミナ ールを形成し、(±)-fawcettimine を与えた。最終的には、合成した (±)-fawcettimine の見化水素塩の X 線結晶構造解析により、fawcettimine の相対立体配置が確認された。

Scheme 3. Heathcock's total synthesis of (±)-fawcettimine and its structural confirmation.



犬伏・Heathcock らは共に、5-6-9 員環の三環性合成中間体を合成し、最後にヘミアミナール構造を 形成することで fawcettimine の四環性骨格を構築した。本合成戦略は fawcettimine 型リコポジウムア ルカロイドの効率的な骨格構築法であり、その後のヘミアミナール型天然物の全ての合成で採用され た。

③ Toste らによる(+)-fawcettimine の初の不斉全合成

2007 年 Toste らは fawcettimine の初の不斉全合成を達成した。本合成でも犬伏・Heathcock らの合成 戦略が用いられている。まず、ケトエステル 22 とクロトンアルデヒド (23) とのエナンチオ選択的な Robinson 環化反応でシクロヘキセノン誘導体 (-)-7 を 72% 収率、88% ee で得た (Scheme 4)¹²e。(-)-7 にプロパルギル基を導入した後、生じたエノラートはシリル基で捕捉し、続いてアセチレン末端をヨ ウ素化して、エノールシリルエーテル 24 を合成した。得られた 24 の金触媒による環化反応で、第四 級炭素を導入しつつ B 環部を構築した。その後、鈴木-宮浦クロスカップリングによる増炭と分子内 求核置換反応によるヒドロアゾニン環の構築を含む数工程で三環性化合物 26 を合成し、最後に Boc 基の除去で(+)-fawcettimine の初の不斉全合成を達成した。 Scheme 4. Toste's first asymmetric total synthesis of (+)-fawcettimine.



④ Williams らによる(±)-fawcettimine の全合成と(±)-fawcettidine への誘導化

犬伏・Heathcock らの合成戦略は、エナミン型天然物の合成へも応用可能である。2012 年、Williams らは、脱水反応によってヘミアミナール構造を持つ fawcettimine からエナミン構造を持つ fawcettidine への誘導化を達成した (Scheme 5)¹²ⁿ。まず、ジエン 27 と不飽和ケトン 28 との Diels-Alder 反応によって第四級炭素を導入しつつ D 環部を構築し、シクロペンタン環の開裂とヒドロアゾニン環の形成 を含む 9 工程の変換で三環性化合物 30 とした。最後に Ns 基の除去で(±)-fawcettimine を全合成した。さらに、 (±)-fawcettimine を、酢酸中、過剰量のシュウ酸存在下 160 °C で 12 時間攪拌することで (±)-fawcettidine への誘導化にも成功した。本脱水反応では、fawcettimine の窒素原子の n 軌道とヒドロキ シ基の σ^*c_o 軌道の重なりが悪いため過酷な条件が必要であった。





⑤ Yao らによる(-)-lannotinidine B の全合成

Fawcettimine 型リコポジウムアルカロイド特有の構造的特徴のためヘミアミナール型、およびエナ ミン型天然物を直接アミン型天然物に変換する手法は報告されていない。アミン型の合成では、BD 環部から合成する犬伏・Heathcock らの合成戦略とは異なり、CD 環部から構築する合成が1例報告さ れている。2012 年、Yao らは、官能基選択的かつ立体選択的な還元的アミノ化反応を鍵とした(-)lannotinidine B の全合成を報告した (Scheme 6)¹⁸。(+)-Pulegone より合成したメチルシクロヘキセノン 31 から導いたジケトン 32 をアクロレインに求核付加させ、第四級炭素を有するジケトアルデヒド 33 を合成した。続いて 33 とベンジルアミンとの還元的アミノ化で C 環部を構築し、ヒドロキノリン 34 とした。さらに、34 の末端アルケンの酸化的開裂に続く還元的アミノ化で三環性化合物 35 を合成し た。その後、Birch 条件で処理することで還元的に C-C 結合を形成し、ケトアルコール 36 とケトン 37 をそれぞれ得た。36 については SmI₂による還元的なケトン α 位水酸基の除去により 37 へと変換し、 最後に mCPBA でアミンを酸化して(-)-lannotinidine B の全合成を達成した。



⑥ Dake らによる(+)-fawcettidine の全合成

上記のように CD 環部からの合成については、2008 年 Dake らによりエナミン型天然物でも 1 例報 告されている^{12f}。本合成でも(+)-pulegone を出発原料とし、7 工程でアルキン 38 を合成した (Scheme 7)。続いて、白金触媒による環化反応で、第四級炭素を導入しつつ B 環部を構築し、三環性化合物 39 へと導いた。その後、5 位を酸化して生じたエノンに対して分子内でチオールを共役付加させ、スル フィド 40 を合成した。ケトンのアセタール保護とスルフィドの酸化でスルホン 41 とし、Ramberg-Bäcklund 転位で A 環部の 7 員環を合成した。その後のオレフィンの接触水素化とアミドの還元およ びアセタールの脱保護で、(+)-fawcettidine の全合成を達成した。





以上の合成報告をまとめると、犬伏・Heathcockらの合成戦略は特にヘミアミナール型の fawcettimine 型リコポジウムアルカロイド合成の効率的な手法である (Scheme 8)。しかしながら、本天然物群は橋 頭位に窒素原子を有するため通常のヘミアミナールとは反応性が異なり、エナミン型への変換には過 酷な条件が必要である。また、ヘミアミナール型からアミン型への変換は報告がない。一方、犬伏・ Heathcockらの合成戦略と異なり、CD 環部から構築する合成報告はエナミン型とアミン型の天然物で それぞれ1例ずつのみ報告されている。そのいずれも(+)-pulegone が出発原料として用いられた。 Scheme 8. Synthetic strategies of fawcettimine-type lycopodium alkaloids.



第四節 本研究の概要と構成

前述のように、これまで多くの fawcettimine 型リコポジウムアルカロイド合成で用いられてきた BD 環部から構築する大伏・Heathcock らの合成戦略は、ヘミアミナール型天然物の合成には効果的であ る一方で、エナミン型や、アミン型天然物の合成では必ずしも有効とは限らない。CD 環部から構築 することが、本課題の1つの解決策であるが、本合成経路が用いられた2つの合成では、いずれも同 じキラルシントンを用いており、これを高度に官能基化された天然物合成へ展開させるには対応する 原料の調製が必要である。そこで著者は、酸素官能基化されたエナミン型、アミン型天然物の合成に 対応し得る新たな合成法を立案し、これを用いて全合成が達成されていなかった酸素官能基化された アミン型天然物である lyconesidine B の全合成を目指すこととした。以下にその概略を述べる。

第一章では、核間位に第四級炭素を有するオクタ-およびデカヒドロキノリン骨格の新規合成法の 開発について述べる (Scheme 9)。本骨格は、fawcettimine 型リコポジウムアルカロイドの CD 環部に 相当する骨格である。これらの触媒的不育合成が可能となれば幅広い出発原料を利用して、様々な本 アルカロイドの誘導体合成に柔軟に対応可能な合成ルートを確立できる。本骨格の合成課題は、核間 位への第四級炭素の導入とその不育合成法の確立である。著者は、触媒的な不育合成を目指し、テト ラヒドロピリジンの分子内シクロプロパン化による核間位第四級炭素の導入の後、生じたシクロプロ パンの開環条件によってオクタヒドロキノリンとデカヒドロキノリンをつくり分けることを計画し た。実際に、テトラヒドロピリジン 43 を Rh₂(esp)₂ で処理すると第四級炭素の構築が進行し多置換シ クロプロパン 44 が得られた。これを、NaBH(OAc)₃ と TFA の組み合わせで処理すると、シクロプロ パン環の開裂によって生じるイミニウムイオン中間体 45 が還元され、デカヒドロキノリン 46 を得る ことに成功した。また、44 を TFA や MgBr₂·OEt などの酸のみで処理すると、オクタヒドロキノリン 47 への変換も可能であった。本反応で合成したヒドロキノリン誘導体 46、47 は、シクロへキサン、 または、シクロへキセン環上にケトンやニトリルを有しており、これら官能基を更なる誘導化や置換 基導入の足掛かりとして利用できる点で有用である。なお、本反応の不斉化については、lyconesidine Bの全合成の基質で検討しており、第二章で述べる。



Scheme 9. Chapter 1: Synthesis of octa- and decahydroquinoline with quaternary carbon center at angular position.

第二章では、第一章のデカヒドロキノリン合成法とドミノエニンメタセシス反応による骨格構築を 鍵とした lyconesidine B の全合成と、その不斉合成の検討について述べる (Scheme 10)。まず、第一章 のシクロプロパン化とその開環反応を基盤とした合成戦略で、テトラヒドロピリジン 48 からデカヒ ドロキノリン 49 を合成し、これをエニン化合物 50 へと導いた。さらに、50 を第四級アンモニウム塩 51 としてドミノエニンメタセシス反応で四環性第四級アンモニウム塩 52 を得た。その後、Na₂S でク ロチル基を除去して得られた四環性アミン 53 を誘導化して lyconesidine B の初の全合成を達成した。 本全合成のドミノエニンメタセシス反応では、51 を経由することで Grubbs 触媒の失活を抑えると同 時にクロチル基をアキシアル位に配置させて、反応点を接近させることが重要であった。





最後にテトラヒドロピリジン 48 からデカヒドロキノリン 49 への変換の不斉化を目指した (Scheme 11)。48 のように窒素原子が置換したアルケンに対する分子内不斉シクロプロパン化は報告例が少な く、実際に、不斉シクロプロパン化でしばしば用いられる不斉 Cu 触媒や不斉 Rh 触媒では低~中程 度のエナンチオ選択性しか得られなかった。そこで種々の触媒検討の結果、豊橋技術科学大学の岩佐 らが開発した不斉 Ru 触媒 54 のリガンドを修飾した触媒 55 を用いると 53%収率、88:12 er で(-)-49 が 得られることを見出した。

Scheme 11. Chapter 2: Studies toward asymmetric total synthesis of (-)-lyconesidine B using asymmetric cyclopropanation.



続く、第1章、第2章でその詳細を述べる。

第一章 四置換エンカーバメートのシクロプロパン化とその開環

を利用したオクタ-およびデカヒドロキノリンの合成

核間位に第四級炭素を持つオクタおよびデカヒドロキノリン 骨格は、fawcettimine型リコポジウムアルカロイドの CD 環部に 見られる構造である (Figure 4)。特に酸素官能基化されたアミン 型とエナミン型の天然物合成への展開を目指し、シクロプロパン 化による CD 環部の新規骨格構築法を開発することとした。本法 with の鍵となるシクロプロパン化についてその関連研究を以下に紹介する。



lyconesidine B fawcettidine **Figure 4.** Fawcettimine-type *lycopodium* alkaloids with amine or enamine structure at C13.

第一節 シクロプロパン化による第四級炭素の導入と、その全合成への応用

ジェミナル二置換アルケンのシクロプロパン化は、第四級炭素を構築可能な反応の1つである。また、不斉シクロプロパン化による不斉第四級炭素の合成も期待できることから近年注目を集めている¹⁵。中でも、電子求引基を有するアミノシクロプロパン誘導体は、ドナー-アクセプターシクロプロパンに特徴的な炭素-炭素結合開裂反応を利用した骨格の組み換え反応が可能なため、アルカロイド 合成にもしばしば利用されている¹⁶。

①電子豊富な2,3-二置換インドールと金属カルベン錯体とのシクロプロパン化とその誘導化について

インドール関連化合物では2.3-二置換インドール、すなわち四置換二重結合と金属カルベン錯体の シクロプロパン化と、その変換は多く報告されている。例えば、2000 年に Capretta らは、インドール 3 位の側鎖にジアゾ基を持つ 56 を Rh2(OAc)4 で処理してシクロプロパン化合物 57 を 65%で合成した (Scheme 12a)¹⁷。また、2008 年 Wee らは、ジアゾ基を持つインドール誘導体 58 を Rh₂(OAc)₄ で処理し て 5 置換シクロプロパン 59a、59b および 6 置換シクロプロパン 59c が合成出来ることを報告した (Scheme 12b)¹⁸。2008 年 Qin らは、インドールのシクロプロパン化とその開環反応を利用した(±)minfiensine の全合成を報告した (Scheme 12c)¹⁹。Qin らは、インドール誘導体 60 を Cu(OTf)2 で処理 して、分子内シクロパン化による第四級炭素の導入に続く、シクロプロパン環の開裂と生じたイミニ ウムイオンへのトシルアミド基の分子内求核付加反応により、四環性化合物 63 を合成した。その後、 9 工程の変換で(±)-minfiensine へと導いた。2009 年 Spino らは、三環性インドール 64 のシクロプロパ ン化でインドール3位に第四級炭素を導入し中間体65を経て、(+)-aspidofractinineの全合成を達成し た (Scheme 12d)²⁰。最近では、2017年に Qin らが複数のインドールアルカロイド合成に用いた(Scheme 12e)²¹。すなわち、四環性インドール 66 の分子内シクロプロパン化でシクロプロパン化体 67 を 52% で得た。このときエノールエーテル 68 が副生成物として 13%得られた。その後の 10-15 工程の変換 で(-)-isokopsine、(+)-methyl chanofruticosinate、(-)-kopsine、(-)-kopsanone、(-)-fruticosine を全合成した。 上記のように 2.3-二置換インドールのシクロプロパン化については多くの知見が得られており、確立 した手法となりつつある。

Scheme 12. Cyclopropanation of 2,3-substituted indoles.



② 二置換、三置換エナミド・エンカーバメートのシクロプロパン化とその生成物の誘導化について インドール誘導体を基質としない、二置換や三置換エナミド・エンカーバメートについてもそのシ クロプロパン化と生成物の誘導化が報告されている¹⁶。

例えば、2010年、Waser らは、アミノシクロプロパン誘導体の開環で生じるイミニウムイオンに対 するインドール1位の求核付加を利用した(±)-goniomitineの全合成を報告した(Scheme 13)²²。まず、 テトラヒドロピリジン誘導体 69 とジアゾ酢酸エチルのシクロプロパン化で、第四級炭素を持つアミ ノシクロプロパン誘導体 70 を合成した。その後、4 工程の変換でインドール部位を導入して化合物 71 へと導いた。71 を TsOH で処理すると、シクロプロパンの開環で生じたイミニウムイオンへのイ ンドール1位の求核付加で、天然物の骨格を持つ化合物 72 を構築した。その後、4 工程の変換で、 (±)-goniomitineの全合成を達成した。また、2013年には、アミノシクロプロパン 70 を共通の合成中間 体として用いた(±)-jerantinine E の全合成を報告した。すなわち、70 をインドール誘導体 73 へと変換 したのち、CH₃CN 中 Cu(OTf)₂で処理することでシクロプロパン環の開環で生じたイミニウムに対す るインドール 3 位の付加が進行し、四環性化合物 74 を得た。その後、8 工程の変換で(±)-jerantinine E の全合成を達成した。 Scheme 13. Cylopropane-ring-opening and C-N or C-C bond formation in total synthesis of (±)-goniomitine and (±)-jerantinine E.



2012 年 Reddy らは、ジアゾケトン 75 の分子内シクロプロパン化でシクロプロパン 76 としたのち、 ケトンの還元でアルコール 77 を得た (Scheme 14)²³。77 を、MeOH 中触媒量の硫酸で処理すると、ピ ロール誘導体 78 が得られた。また、CH₂Cl₂中、TMSOTf と Et₃SiH で処理すると、生じたイミニウム イオンが還元されてトシルピロリジン誘導体 79 へと変換された。さらに、Et₃SiH の代わりに、*mCPBA* を用いるとトシルピロリドン 80 が得られ、1,3,5-トリメトキシベンゼンや PhSH、1,2-ジチオエタンを 求核剤として用いると、付加体 81、82 および 83 がそれぞれ得られることを報告した。



③ 四置換エナミド・エンカーバメートのシクロプロパン化について

電子豊富な 2,3-二置換インドールや二置換および三置換エナミド・エンカーバメートと比較し、四 置換エナミドの状況は大きく異なる。すなわち、含窒素芳香環を基質としない四置換エナミンおよび エナミド、エンカーバメートと金属カルベン錯体とのシクロプロパン化は報告例がない。フリーカル ベンを用いたシクロプロパン化の報告が 3 例あるのみである (Scheme 15)。具体的には、1985 年に Cochran らは、トシルヒドラゾン 84 の熱分解で四置換エンカーバメートの分子内シクロプロパン化が 進行することを報告した (Scheme 15a)²⁴。また、同年 Castro らは、ジクロロカルベンとデヒドロアポ ルフィン 86 とのシクロプロパン化でジクロロシクロプロパン 87 を 86%で得た (Scheme 15b)²⁵。また、 2005 年に Padwa らも同様に、ジクロロカルベンと四置換エナミド 88 とのシクロプロパン化を報告し た (Scheme 15c)²⁶。このように、単純な四置換エンカーバメートのシクロプロパン化でも知見が少な く、これを用いるには、反応条件や基質の検討が必要である。





以上まとめると、四置換以外のエナミンや、エナミド、エンカーバメートのシクロプロパン化は、 天然物の合成などで有用な反応として用いられてきた。一方で、四置換エナミン(およびエナミド、 エンカーバメート)の利用はほとんどない。これは四置換エナミンが、その合成の煩雑さのために基 質として十分検討されていない点に加えて、立体障害のために反応性が低い点が理由として想定され た。このような背景のもと、著者は、前例のない四置換エナミン誘導体を用いたシクロプロパン化-環 開裂連続反応に着目し、酸素官能基化された fawcettimine 型リコポジウムアルカロイド合成に応用可 能な新規骨格構築法を開発することとした。

第二節 シクロプロパン化と開環反応を基盤とした合成計画

以上の背景から、四置換エナミン(もしくはエナミド、エンカーバメート)のシクロプロパン化に よる第四級炭素の導入、さらにその開環反応の反応条件の変更によるオクタヒドロキノリン骨格とデ カヒドロキノリン骨格の作り分けを計画した (Scheme 16)。すなわち、テトラヒドロピリジン 43 の分 子内シクロプロパン化で全置換シクロプロパン 44 を合成する。本シクロプロパンには電子供与基で ある窒素原子と電子求引基であるケトンが置換している。したがって、44 を酸性条件で処理すると、 窒素原子からの電子の押し出しにより、シクロプロパン環が開裂して、イミニウムイオン 45 が生じ る。その後、脱プロトン化が進行すれば、オクタヒドロキノリン 47 を与え、還元すればデカヒドロ キノリン 46 を与える。イミニウムイオン中間体 45 は置換基 R²の立体障害を活かして、立体選択的 に還元することを狙った。本法で合成される 47 と 46 は、8 位にケトンを有しており、酸素官能基化 された fawcettimine 型リコポジウムアルカロイド合成への応用が期待できる。また、ケトンα位の官 能基化や炭素鎖の導入も容易であることが予想された。



第三節 核間位に第四級炭素を持つオクタ-およびデカヒドロキノリン骨格の合成

モデル基質の合成

シクロプロパン化の検討のために、モデル基質 43a を合成した (Scheme 17)。まず、既知の条件に 従い、δ-バレロラクタム (90) の THF 溶液に 2 当量の *n*BuLi を加えて調製したジアニオンに対して、 EtI と CbzCl を順次添加してベンジルカーバメート 91a とした ²²。91a をエノールトリフラート 92a へ と変換した後、アクリル酸メチルとの Heck 反応で、不飽和エステル 93a を得た。次に 93a を CoCl₂ 存在下 NaBH₄ で処理することで 1,4-還元してエステル 94a を得た ²⁷。最後に、脱プロトン化したアセ トニトリルの 94a への付加と、ジアゾ転位でシクロプロパン化前駆体 43a を合成した ²⁸。43a は、ア ミン存在下高濃度に濃縮すると不安定であったため、本化合物を収率良く単離する為には、分液操作 後、完全に濃縮することなくシリカゲルカラムクロマトグラフィーで精製することが効果的であった。





② シクロプロパン化の条件検討

続いて、得られたジアゾケトン 43a を、金属カルベン錯体が生じることが知られている種々の遷移 金属触媒 (5 mol%) で処理してシクロプロパン化体 44a を得ることを検討した (Table 1)。まず、 Cu(OTf)₂を用いたとき、44a の生成の後シクロプロパン環が開裂して水和されたと予想されるジケト ン96a が 70%収率で得られた (entry 1)。これは、Cu(OTf)₂の Lewis 酸性によるものと予想し、代わり に Cu(hfacac)₂を用いると、望みのシクロプロパン化体 44a とオクタヒドロキノリン 47a がおよそ 1:1 の比率で得られた (entry 2)。次に、種々の Rh 二核錯体によるシクロプロパン化を試みた。ラクタム 配位子を持つ Rh₂(cap)₄²⁹を用いると、42% 収率で 44a が得られた (entry 3)。このとき 47a の生成は観 測されなかった。Rh₂(OAc)₄ では、反応時間の短縮と収率向上がみられ、最終的に、Rh₂(esp)₂³⁰を用い たとき 59% 収率で 44a が得られることを見出した (entries 4, 5)。本触媒での反応は非常に速く、触媒 0.1 mol%でも、15 分で原料が完全に消費され、触媒 5 mol% の場合と比較しても遜色ない収率を与え た (entry 6)。収率には改善の余地があるものの、中程度の収率でシクロプロパン化体 44a を得ること に成功したので、次に 44a の開環反応について検討した。



 Table 1. Transition metal catalyzed cyclopropanation of tetrahydropyridine 43a.

^aIsolated yield. ^b60 mol%. -: not detected.

③ シクロプロパン環の開裂条件の検討

シクロプロパン化体 44a からオクタヒドロキノリン 47a およびデカヒドロキノリン 46a への変換を 試みた (Table 2)。44a から 47a への変換は、TFA や BF₃· OEt₂ などの酸で処理すると収率良く 47a を 与えた (entries 1, 2)。このことから、46a は酸性条件で定量的にイミニウムイオンへと変換されること が示唆された。そこで、酸性条件下での開環後、生じたイミニウムイオン中間体を還元して 46a へと 変換することとした。まず、酸を TFA に固定して、種々の還元剤を検討した。その結果、Et₃SiH や Ph₃SiH、NaBH₃CN では 46a は得られず、47a が生成した (entries 3-5)。一方で、NaBH(OAc)₃ を還元剤 として用いると、47a との混合物ではあるものの、46a が 72%収率で得られた (entry 6)。その後、種々 の酸を検討したが、BF₃· OEt₂では、46a は低収率で得られ、MgBr₂· OEt₂、AlCl₃、Sc(OTf)₃では 46a を 与えなかった為、entry 6 の TFA と NaBH(OAc)₃ を組み合わせた条件を 46a への変換の最適条件とし た (entries 7-10)。

 Table 2. Selective formation of octahydroquinoline 47a and decahydroquinoline 46a.

	CH ₂ Cl ₂ , r	s t	NC O H Et N Cbz 46a	NC vu Et 47a
entry	conditions	\$	yiel	d ^a
	Lewis acid or H ⁺ (6 eq.)	reductant (10 eq.)	46a	47a
1	TFA ^b	-	-	96%
2	BF ₃ ·OEt ₂ ^b	-	-	95%
3	TFA	Et ₃ SiH	-	56%
4	TFA	Ph ₃ SiH	-	40%
5	TFA	NaBH ₃ CN	-	17%
6	TFA	NaBH(OAc) ₃	72% ^c	22% ^c
7	$BF_3 \bullet OEt_2^d$	NaBH(OAc) ₃ e	31% ^c	23% ^c
8	MgBr ₂ •OEt ₂	NaBH(OAc) ₃	-	60%
9	AICI ₃	NaBH(OAc) ₃	-	59%
10	Sc(OTf) ₃	NaBH(OAc) ₃	_	28%

^aIsolated yield. ^b1 equiv. ^cThe yield was calculated by ¹H NMR. ^d10 equiv. ^e6 equiv. –; not detected

```
④ デカヒドロキノリン 46a の相対立体配置の決定と還元のジアステレオ選択性の考察
```

デカヒドロキノリン 46a は、重クロロホルム中でケト-エノール互変異体の混合物であったため、 ¹H NMR で観測されるシグナルは複雑化していた。そこで、エノールシリルエーテル 97a とした後、 NOESY を測定しその相対立体配置を決定した (Scheme 18)。すなわち、図に示すような NOE 相関が 確認されたため 97a はトランス体であり、その原料となる 46a もトランス体であると決定した。44a から 46a への変換反応のジアステレオ選択性は次のように推察した。シクロプロパン 44a が酸性条件 で開環して生じたイミニウムイオン 45a が還元されるとき、期待通り核間位のエチル基が立体障害と なり、還元が紙面左側から進行してトランスデカヒドロキノリン 46a がジアステレオ選択的に得られ た。なお、オクタヒドロキノリン 47a を還元して 46a とするために、44a の還元と同様に TFA と NaBH(OAc)₃ で処理したが、反応は進行しなかった。47a の最安定配座を計算すると、二面角 C1-N1-C13-C14 はおよそ 73.5°であり、N1 の孤立電子対と C13-C14 のオレフィン部分は共役の寄与が小さい ことが予想された。このことから、47a からイミニウムイオン 45a の生成が困難であったと推測して いる。

Scheme 18. Determination of relative configuration of 46a and diastereoselectivity of reduction of iminium Intermediate 45a.



Calculated by Gausian 09 ω B97X-D/6-311G(d,p) level of theory.

⑤ シクロプロパン合成およびオクタヒドロキノリン合成の基質適用範囲

シクロプロパン合成とオクタヒドロキノリン合成について基質適用範囲を調査した(Table 3)。ま ず、アミンの保護基 R¹ について検討した。R¹ がメトキシカルボニル基および Boc 基を有する基質 では 43a と同程度の収率でシクロプロパン化体 44b、44c を与え、その後の 47b、47c への変換も収率 良く進行した (entries 1, 2)。このとき Boc 基を持つ 44c を BF₃·OEt₂ で処理すると、Boc 基の除去反応 が競合したため、BF₃·OEt₂ の代わりに MgBr₂·OEt₂を用いた (entry 3)。一方で、R¹ が Ts 基の 43d を Rh₂(esp)₂ で処理すると、酸で処理することなく、シクロプロパン環が開裂し、オクタヒドロキノリン 47d を 76%収率で与えた。続いて、ジアゾ基の β 位の置換基 R³をメトキシカルボニル基に変更した ところ、複雑な混合物を与え、シクロプロパン化体 44e の単離には至らなかった (entry 4)。これは、 メトキシカルボニル基がシアノ基より嵩高いため、混みあった四置換オレフィンとの反応が不利にな ったためと予想している。本結果から、シクロプロパン化には置換基 R³ がニトリルであることが重 要と明らかになった。最後に、アルケン上の置換基 R² ついて検討した。本反応は、ベンジルエーテル やシリルエーテルを持つ 43f、43g からも進行し、44f、44g を中程度の収率で与え、その後の 47f、47g への変換もそれぞれ 80%収率および定量的に進行した。一方で、R²が H の 43h を Rh₂(esp)₂ で処理す ると複雑な混合物を与え、シクロプロパン化体 44h の生成は確認できなかった。



 Table 3. Scope and limitations of synthesis of cyclopropane 44 and octahydroquinoline 47.

^alsolated yield. ^bMgBr₂•OEt₂ was used instead of BF₃•OEt₂ ^c **47d** was observed instead of **44d** under the first step reaction conditions. ^dnot detected. Bn = benzyl, TBS = *tert*-butyldimethylsilyl.

⑥ ワンポットでのデカヒドロキノリン合成とその基質適用範囲

続いて、デカヒドロキノリン 46 合成の基質適用範囲を検討した (Scheme 19)。本反応では、シクロ プロパン化と開環・還元反応をワンポットで実施することで、不安定なシクロプロパン中間体 44 の 単離を回避した。まず、テトラヒドロピリジン 43a を Rh₂(esp)₂ で処理して原料の消費を確認した後、 同一フラスコに NaBH(OAc)₃ と TFA を加えると、46a が 38%収率で 47a との混合物として得られた。 本反応は、アミンの保護基がメトキシカルボニル基、 Boc 基のとき良好に進行し、デカヒドロキノリ ン 46b、46c をそれぞれ 56%、67%で与えた。また、ベンジルエーテルおよびシリルエーテルを持つ 46f、46g の合成も可能であった。



Ratio of **46** and **47** was calculated by ¹H NMR. ^aRh₂(OAc)₄ was used instead of Rh₂(esp)₂.

① 三環性化合物 98 の合成

最後に本反応を三環性化合物の合成へと応用した。すなわち、無保護の水酸基を持つテトラヒドロ ビリジン 43i を Rh₂(esp)₂ で処理してシクロプロパンへと変換した後、BF₃·OEt₂を加えると、シクロプ ロパン環の開裂で生じたイミニウムイオンに対して水酸基の付加が進行して、三環性化合物 98 が 66% 収率で得られた (Scheme 20)。また、47g のシリル基を除去して調製したヘミアセタール 47i から 98 を得る目的で CH₂Cl₂ 中 BF₃·OEt₂存在下室温で攪拌、もしくは MeOH 中 CSA 存在下加熱還流したが、 反応は進行しなかった。47i と比較して 98 の方が熱力学的に安定であるにも関わらず 98 が得られな かったことから、47i からもイミニウムイオンが容易に生じないことが示唆された。以上の結果は、 本反応を全合成に応用する際の基質選択のための重要な知見となった。





第四節 結論

著者は、シクロプロパン化に続く開環反応を利用し、核間位に第四級炭素を持つオクタヒドロキノ リンおよびデカヒドロキノリン合成法を開発した (Scheme 21)³¹。Rh₂(esp)₂を触媒として用いて立体的 に込み合った四置換エンカーバメートのシクロプロパン化が中程度から良好な収率で進行すること を見出した。本反応の進行にはジアゾ基のβ位の置換基 R³にシアノ基を採用することが重要であっ た。また、得られたシクロプロパン化合物を TFA や MgBr₂·OEt₂ で処理して、オクタヒドロキノリン へ、TFA と NaBH(OAc)₃の組み合わせで処理してデカヒドロキノリンへの作り分けが可能であること を明らかにした。本反応の基質として、エナミン構造の保護基 R¹にはカーバメートを用いることが 可能であり、トシル基を用いた場合は系中でシクロプロパン環が容易に開裂することが明らかとなっ た。また、アルケンの置換基 R²にはエチル基だけでなく、シロキシエチル基やベンジロキシエチル基 も用いることができた。本法で合成したデカヒドロキノリン誘導体は酸素官能基化された fawcettimine 型リコポジウムアルカロイド合成への応用が期待できる。

Scheme 21. Summary of this section.



第二章 Lyconesidine B の全合成

第一節 Lyconesidine 類について

Lyconesidine A、B は、2002 年に北海道大学の小林らによってヒカゲノカズラ 科の植物の Lycopodium chinense より単離された (Figure 5)³²。その相対、および 絶対立体配置は、2 次元 NMR を含む各種 NMR スペクトル、X 線結晶構造解析 によって決定された。本天然物は、一般的な fawcettimine 型リコポジウムアルカ ロイドと比較して 13 位の酸化度が低いアミン型に分類される(序論第二節参 照)。また、CD 環がトランス縮環していることから、16 位のメチル基またはヒ



R = H: Lyconesidine A R = OH: Lyconesidine B **Figure 5.** Lyconesidines

ドロキシメチル基がアキシアル位に位置している点も特徴的である。生物活性としては、マウスリン パ腫 L1210 細胞に対する細胞毒性(lyconesidine A: IC₅₀ = 18.0 µg/mL, lyconesidine B: IC₅₀ = 9.5 µg/mL) と、弱いながらもチューブリンの重合阻害作用(lyconesidine A: IC₅₀ = 300 µM, lyconesidine B: IC₅₀ = 250 µM)を有することが報告されている³²。Lyconesidine A、Bのように、基本骨格が酸素官能基化さ れたアミン型の fawcettimine 型リコポジウムアルカロイドは未だ合成例がない。著者は、より酸化度 が高く生物活性の強い lyconesidine B を標的として、その特異な構造の合成経路の開拓を目指し、全 合成研究に着手した。

第二節 ドミノエニンメタセシスについて

本合成では、終盤でアミン化合物のドミノエニンメタセシス反応を利用するので、その背景を概説 する。ドミノエニンメタセシスに用いる触媒は、アミンの塩基性・求核性により失活することがある ため適切な保護が必要な可能性がある。以下に例を挙げて説明する。

ドミノエニンメタセシスは、1994 年に Grubbs らによって 2 つのアルケンと 1 つのアルキンを持つ 化合物からビシクロ[m.n.0]骨格を構築する反応として報告された (Scheme 22)³³。例えば、ジエニン化 合物 99 を CH₂Cl₂中 3 mol%の Ru 触媒 100 存在下室温で攪拌すると、ビシクロ[4.3.0]ノナジエン 101 が 95%収率で得られた。



本反応は、鎖状化合物から一挙に二つの環構造を構築できる点で有用な反応であり、天然物など複 雑骨格の構築にも応用されている³⁴。例えば、2014 年 Prunet らは、シクロヘキセン誘導体 102 をトル エン中、触媒 103 存在下加熱還流すると、タキサン骨格 104 が 70%収率で、副生成物 105 (20%)と共 に得られることを報告している (Scheme 23)^{34r}。 Scheme 23. Synthesis of taxane skeleton using domino enyne metathesis reaction.



窒素原子周辺が嵩高い場合には、アミンを基質としても触媒の失活は大きな問題とならない。例えば、2003 年 Kim らは、ジフェニルメチルアミン 106 を CH₂Cl₂ 中、2 mol%の第一世代 Grubbs 触媒存 在下室温で 1 日攪拌すると、ジヒドロピロール誘導体 107 が 92%収率で得られると報告している (Scheme 24)^{34b}。



一方、窒素原子周辺の立体障害が小さいために基質のアミンが触媒を失活させる場合があり、Lewis 酸や Brønsted 酸の添加による改善が報告されている。

2003 年、森らは、ジエニン化合物 108 を CH₂Cl₂中、第一世代 Grubbs 触媒存在下加熱還流したが、 目的のジエン 109 は得られず、69%の原料が回収された (Table 4, entry 1)^{34a}。また、第二世代 Grubbs 触媒を用いても 109 は得られなかった (entry 2)。そこで、触媒の金属中心へのアミンの配位を防ぐた めに 108 を一度塩酸塩とした後に第一世代 Grubbs 触媒で処理すると、ドミノエニンメタセシスが進 行した。その後、K₂CO₃水溶液で後処理すると、四環性ジエン 109a と 109b を 1:1 のジアステレオマ ー比で定量的に得ることができた (entry 3)。

 Table 4. Domino enyne metathesis reaction of HCI salt of amine 108.



また、2005 年、Xiao、Yu らは、ジアリルアミン 110 の閉環メタセシスにおいて Ti(O'Pr)₄ が効果的 に働くことを報告した ³⁵。まず、ジアリルアミン 110 を CH₂Cl₂ 中、5 mol%の触媒 111 存在下 40 ℃ で 48 時間加熱したが、111 の失活により 24%収率でジヒドロピロール誘導体 112 が得られるのみであっ た (Scheme 25a)。110 を塩酸塩 113 とした後に 111 で処理すると、酸化剤についての言及はないが、 環化後に酸化されてピロール誘導体 114 がジヒドロピロール誘導体の代わりに生成した (Scheme 25b)。 そこで、添加剤として種々の Lewis 酸を検討した (Table 5)。まず、LiI を添加したところ、53%収率で 112 が得られた (entry 1)。また、AlCl₃や La(OTf)₃を用いると、112 の生成は確認できなかった (entries 2,3)。これは、Lewis 酸性が強すぎるために触媒が速やかに失活したと Xiao、Yu らは推測した。一方 で、Ti(O[']Pr)₄を用いると、2 時間、91%収率で 112 を与えた (entry 4)。さらに、Ti(O[']Pr)₄の当量を 50 mol%、20 mol%と低減しても、反応時間の延長で 112 を高い収率で得ることに成功した。



 Table 5. Investigation of Lewis acid for ring closing metathesis of diallylamine 110.

	Ph CO ₂ Me	111 (10 mol%) Lewis acid	Ph	CO ₂ Me
		CH ₂ Cl ₂ , 40 °C	- [
110			1	112
entry	Lewis acid	amount (mol%)	time (h)	yield of 112 (%)
1	Lil	100	36	53
2	AICI ₃	100	2	0 <i>c</i>
3	La(OTf) ₃	100	2	0 <i>°</i>
4	Ti(O ⁱ Pr) ₄	100	2	91
5	Ti(O ⁱ Pr) ₄	50	5	82
6	Ti(O ⁱ Pr) ₄	20	6	93

一方、第四級アンモニウム塩を基質として用いると、触媒は失活することなく反応が進行する。2006 年 Grubbs らは、第四級アンモニウム塩 115 を水溶性の触媒 116 で処理すると、ほとんど定量的に閉 環メタセシス反応が進行することを報告した (Scheme 26)³⁶。しかし、複雑な構造を持つ第四級アンモニウム塩を用いた例はなく、実践的な合成への展開は未検討であった。



第三節 遷移金属触媒によるジアゾ化合物とアルケンの不斉シクロプロパン化について

Lyconesidine B の全合成では、不斉シクロプロパン化による不斉合成研究にも取り組んだ。以下、 遷移金属を用いた不斉シクロプロパン化について、その背景を紹介する。

① これまでに開発されている主要な不斉シクロプロパン化の触媒について

遷移金属触媒を用いたジアゾケトンとアルケンの不斉シクロプロパン化の先駆的な研究は、1966年 に野崎らによって報告された (Scheme 27)³⁷。野崎らは、エチルジアゾ酢酸 (118a) とスチレンを Cu 触 媒 120 存在下、反応させて光学活性なシクロプロパン 121a と 122a を 72%収率、3:1 dr で得た。



野崎らの研究から、Cu や、Rh、Ru、Co などの金属錯体を用いた不斉シクロプロパン化が精力的に 研究されてきた (Scheme 28)³⁸。例えば、1991 年、Evans らは Cu-bisoxazoline 錯体による高エナンチオ 選択的なシクロプロパン化反応を報告した ³⁹。1990 年、Doyle らは Rh 二核錯体による不斉シクロプ ロパン化を報告した ⁴⁰。また、1994 年、西山らは Ru-bis(oxazolinyl)pyridine 錯体、1995 年、香月らは Co-salen 錯体による不斉シクロプロパン化を報告した ^{41,42}。

Scheme 28. Representative Cu, Rh, Ru, Co catalysts for asymmetric cyclopropanation of styrene.



② 窒素原子が置換したアルケンの分子内不斉シクロプロパン化について

以上のような例を代表として、これまでにスチレン誘導体やアルキル置換アルケンの不斉シクロプロパン化は、合わせて 300 以上が報告されている (Scheme 29)⁴³。一方で、窒素原子が置換したアルケンに対する不斉シクロプロパン化の例は、分子間反応が 27 例 ⁴⁴ であり、分子内反応はわずか 2 例 ⁴⁵ にとどまる (2021 年 2 月時点)。





窒素原子が置換したアルケンの分子内不斉シクロプロパン化は、2016年、Guo らにより初めて報告 された。彼らは、プリン誘導体 123 を Ru 錯体 124a で処理することで高収率、高エナンチオ選択的な 分子内不斉シクロプロパン化を達成した (Scheme 30a)^{45a}。また、2017年、Zhou らは、リガンド 127 を 用いた Cu 触媒によるインドール誘導体 126の分子内シクロプロパン化を達成した (Scheme 30b)^{45b}。 しかし、両報告は、基質がジアゾエステルと制約があり、オレフィン部位もプリンやインドールの置 換した二置換、三置換アルケンのみとなっている。

このように窒素原子が置換したアルケンの分子内不斉シクロプロパン化は未だ例が少なく、発展途 上の分野である。



.__

第四節 Lyconesidine B の合成計画

Lyconesidine B の合成上の課題は、(i) その複雑な四環性骨格の構築と(ii) 核間位第四級炭素や(iii) D 環上のアキシアルヒドロキシメチル基を含む連続した 6 つの不斉中心の導入である (Scheme 31)。 著者は、ドミノエニンメタセシスによる AB 環部の合成と第一章で開発した反応を利用した CD 環部 構築を鍵工程とし、本天然物の合成を計画した。すなわち、lyconesidine B は四環性ジエン 53 から立 体選択的なアキシアルヒドロキシメチル基の導入を含む数工程で合成することとした。また、AB 環 部のヒドロアザアズレン骨格はジエニン化合物 129 のドミノエニンメタセシスで合成する。129 の前 駆体となるトランスデカヒドロキノリン 49 は、テトラヒドロピリジン 48 の分子内シクロプロパン化 による核間位第四級炭素の導入と、その開環で生じたイミニウムイオンの立体選択的な還元で合成す る。48 は、既知のエノールトリフラート 131 より合成することとした。



第五節 (±)-Lyconesidine B の全合成

① ワンポットシクロプロパン化-開環-還元反応による核間位第四級炭素を持つデカヒドロキノリン

の合成

まず、シクロプロパン化前駆体 48 の合成から着手した (Scheme 32)。既知のエノールトリフラート 131⁴⁶とボロン酸エステル 132⁴⁷とを鈴木-宮浦クロスカップリングで連結して α,β-不飽和エステル 133 を得た後、1,4-還元 ⁴⁸してエステル 134 を合成した。さらに、ホルミル化でアルデヒド 135 とした。 135 を NaBH₄ で還元し、生じた水酸基をシリル化してシリルエーテル 136 へと変換した。続いて、脱 プロトン化したアセトニトリルを 136 に付加させた後、ジアゾ化 ²⁸してシクロプロパン化前駆体 48 を得た。

Scheme 32. Preparation of cyclopropanation precursor 48.



合成した48を基質として第一章で開発したシクロプロパン化と続く開環・還元反応を試みた(Table 6)。まず、第一章で用いたデカヒドロキノリン合成の条件で処理したところ、目的のデカヒドロキノリン 49 と望まない副生成物 137 が混合物として得られた(entry 1)³¹。137 の生成を抑える目的で更に 還元剤を精査し、NaBH4に対して3当量のTFAを加えて調製した NaBH(OCOCF3)3⁴⁹を NaBH(OAc)3 と TFA の代わりに用いると137 の生成が抑えられた(entry 2)。還元剤の変更により137 の生成が抑 えられた理由は次のように考察している(Scheme 33)。シクロプロパン化体 130 を TFA と NaBH(OAc)3 の組み合わせで処理したとき、これら試薬間で酢酸イオンとトリフルオロ酢酸イオンの交換が起こり、 反応系中には、対アニオンがトリフルオロ酢酸イオンの138aと、酢酸イオンの138bの両方が生成す る。対アニオンの塩基性度の違いから、138aでは還元のみが進行するが、138bでは還元と酢酸イオ ンによる脱プロトン化が競合し望まない生成物 137 を与えた。一方、酢酸イオンが系中に存在しない NaBH(OCOCF₃)₃による還元は、脱プロトン化が進行しないために高い選択性で目的物 **49** を与えた。 続いて、本反応の更なる収率向上を目指してシクロプロパン化の触媒についても再検討した。 Rh₂(esp)₂より電子豊富または電子不足な配位子を持つ Rh₂(esp-OMe)₂⁵⁰ や Rh₂(esp-NO₂)₂⁵⁰ では収率は 向上しなかったが、Rh₂(NHCO*t*Bu)₄⁵¹を用いると収率は 72%まで向上した (entries 3-5)。第一章の検討 において、ラクタムを配位子として持つ Rh₂(cap)₄は Rh₂(esp)₂よりも低い収率でシクロプロパン化体 を与えていたため、Rh₂(NHCO*t*Bu)₄で収率が改善されたことは配位子のアミド水素が重要な役割を果 たしたと推測している。

 Table 6. Optimization of one-pot cyclopropanation-ring-opening-reduction.



^a1M THF solution.



② ドミノエニンメタセシス前駆体 129 の合成

続いて、ドミノエニンメタセシス前駆体を合成することとした。本誘導化では、核間位にアルキン を導入するが、その段階について検討が必要であった。まず、ケトニトリル 49 をアリルビニルエー テル 139 へと変換した (Scheme 34)。その後、Claisen 転位でアリルケトン 140 と 141 を得た。なお、 140 のアリル基の立体化学は、図に示した NOE 相関により決定した。得られた 140 をエノールシリ ルエーテルへと変換した後に Sc(OTf)3 とホルマリンで処理すると向山アルドール反応 ⁵² が進行し、 18%の原料が回収されたものの、ヒドロキシメチル化体 142 を単一のジアステレオマーとして 54%収 率で得た。その立体化学を含む構造については、X 線結晶構造解析によって確認した。本ヒドロキシ メチル化のジアステレオ選択性発現は、シロキシメチル基の立体障害によるものと推測している。続いて、142からリチウムナフタレニド処理によりシアノ基を還元的除去し、ケトン143へと導いた⁵³。



得られた 143 のケトン部位のジアステレオ選択的な還元を検討した。まず、DIBAL-H による還元 では、エクアトリアル側から還元剤が攻撃して望まない立体化学のジオール 145 が 71%収率で生成し た (Table 7, entry 1)。145 は推定構造であるが、得られた化合物の高分解能 MS スペクトルが 145 とー 致することを確認した。また、第二級水酸基の立体化学は、得られた化合物を CH₂Cl₂中 PhCH(OMe)₂、 CSA 存在下室温で 23 時間攪拌してもベンジリデンアセタール化が進行しなかったことから、第二級 水酸基とヒドロキシメチル基がアンチの関係にある 145 の構造と推測した。望みの生成物 144 は、ケ トンの還元で生じる第二級アルコールが、エクアトリアル位にあり、かつ第一級アルコールと水素結 合を形成できるため、145 と比べて熱力学的に安定と推測し、Meerwein-Ponndorf-Verley 還元の条件を 二種類検討したが、反応が進行しない、もしくは複雑な混合物を与えるのみであった (entries 2, 3)⁵⁴。 そこで、β-ヒドロキシケトンとジエチルメトキシボランとのキレートを利用した還元を試みたが、145 が主生成物であった (entry 4)⁵⁵。一方、CeCl₃と NaBH₄で処理すると、望みのジアステレオマー144 が わずかに優先して得られた ⁵⁶。なお、144 の構造は、その後に実施した以下の誘導化が進行したこと から本構造と推定した。 Table 7. Diastereoselective reduction of ketone 143.



上記の条件で得られた 144 と 145 の混合物を分離精製することなく CSA 存在下ベンズアルデヒド ジメチルアセタールで処理するとベンジリデンアセタールの形成と TBS 基の除去が進行し、アルコ ール 146 が得られた (Scheme 35)。さらに、146 の TPAP 酸化によりアルデヒド 147 へと変換し⁵⁷、さ らにアルキン 148 への変換を試みた。しかし、塩基性条件下、Ohira-Bestmann 試薬、あるいは、Seyferth-Gilbert 試薬で処理しても、反応は全く進行しなかった。これは、反応点であるアルデヒドがネオペン チル位にあり、かつアキシアル水素やアリル基が立体障害になっているために試薬が接近できないこ とが原因と推測した (Figure 6)。そこで、基質の変更により、本課題の解決を試みることとした。すな わち、7 位と 8 位が sp²炭素のアリルビニルエーテル 149 であれば、アルデヒド周辺の立体障害が低 減され、アルキン合成反応が進行すると予想した。



Figure 6. Strategy for formation of alkyne.

そこで、アリルビニルエーテル 139 の TBS 基を除去したのち、生じたアルコールを酸化してアル デヒド 149 を合成した (Scheme 36)。これを MeOH 中 K₂CO₃ 存在下、Ohira-Bestmann 試薬で処理する と狙い通り反応が進行しアルキン 150 を 82%収率で得ることに成功した。続いて、Claisen 転位でア リルケトン 151 をジアステレオ混合物として得たのち、シアノ基を Birch 条件で除去してエニン化合 物 152 を得た。なお、向山アルドール反応を実施する目的で 151 や 152 を LDA や LHMDS と TMSCI で処理してエノールシリルエーテルへ変換することを試みたが、複雑な混合物を与えたため 15 位へ のヒドロキシメチル基の導入は四環性骨格構築後に実施することとした。152 の Boc 基の除去と N-ク ロチル化で、ドミノエニンメタセシス前駆体 129 へと変換した。

Scheme 36. Preparation of domino-enyne-metathesis precursor 129.



③ ドミノエニンメタセシス反応の検討

続いて、129を基質としてドミノエニンメタセシス反応を検討した。本反応で望みの四環性化合物 53を得るには、その反応順序が重要である (Scheme 37)。すなわち、129のアリル基から反応すると ヒドロアザアズレン環 (AB 環部)を形成して 53 が得られるが、クロチル基から反応するとヒドロイ ソキノリン環を形成して 153 へと変換される。本反応順序を制御するために、3 位側にはアリル基よ り立体的に嵩高いクロチル基を用いた。

Scheme 37. The role of crotyl group for the construction of hydroazaazulene structure (AB rings).



実際に、ジエニン化合物 129 を 5 mol%の第二世代 Grubbs 触媒で処理すると 5%の収率ながら所望の順序で反応が進行し、目的の 53 が得られた (Table 8, entry 1)。また、第二世代 Grubbs 触媒を 50

mol%用いると収率は 50%となり、触媒の当量依存的に目的物 53 を与えた (entry 2)。これは、基質 129 あるいは生成物 53 の第三級アミンにより触媒が失活したためと推測した。そこで、第三級アミンによる Grubbs 触媒の失活を効率的に抑えることが報告されている Ti(O*i*Pr)4⁵⁸ を添加したが大きな収率の向上は見られず、さらに、129 の塩酸塩 ^{34a} を用いた場合は、複雑な混合物を与えるのみであった (entries 3, 4)。

Table 8. Initial investigation of domino-enyne-metathesis of dienyne 129. O Grubbs 2nd (x mol%) additive CH2Cl2, 40 °C N 129 53			53 53	
entry	Grubbs 2nd (mol%)	additive	time	yield (%)
1	5	-	17 h	5
2	50	-	16.5 h	50
3	30	Ti(O <i>i</i> Pr) ₄ (1 eq.)	5 days	35
4 ^a	10	HCI	2 days	complex mixture

HCI salt of 129 was used as a substrate.

以上の結果を次のように考察した。まず、129を第二世代 Grubbs 触媒のみで処理した場合、生成物 53 が橋頭位に窒素原子をもつ反応性の高いアミンであるために、触媒を失活させたと予想した (Scheme 38, path a)。また、129を塩酸塩としたときは、クロチル基がエクアトリアル位にある熱力学 的に安定な塩酸塩が生成し、二回目の環化反応が進行しなかったと推測した (path b)。これらのこと から、本反応を円滑に進行させるためには、53 による Grubbs 触媒の失活を抑えつつ、クロチル基を アキシアル位に位置させる必要がある。そこで著者は、第四級アンモニウム塩 154 がこれらを満たす と考えた (path c)。すなわち、129を N-アルキル化して第四級アンモニウム塩 154 とすることで、ク ロチル基をアキシアル位に位置させることが可能である。さらに、環化後の生成物 155 はアンモニウ ム塩なので、Grubbs 触媒の失活が抑えられる。最後に置換基 R を除去すれば、望みの四環性ジエン 53 を得られる。なお、置換基 R には、1 つ目のクロチル基との識別の必要がなく、求核剤で容易に除 去可能な、クロチル基を採用することとした。

33

Scheme 38. Strategy for synthesis of tetracyclic diene 53.



実際に、エニン化合物 50 を二段階でクロチル化して第四級アンモニウム塩 51 を合成した (Scheme 39)。129から51への変換では、反応初期に一部生じた分岐型ブテニル化体を熱力学的に安定な直鎖 型クロチル化体に変換するために、塩基 (K₂CO₃)を用いない条件で加熱することが重要であった。 得られた第四級アンモニウム塩 51 を、11 mol%の第二世代 Grubbs 触媒で処理すると、望みの環化反 応が円滑に進行し四環性アンモニウム塩 52 を得た。最後に、Na2S で 52 のクロチル基を除去し四環 性ジエン 53 を 4 工程 67% 収率で得た。本法により、四環性骨格の構築法を確立することができた。



④ Lyconesidine B の全合成

四環性骨格の構築に成功したので、その骨格の修飾と lyconesidine B の全合成を目指した。まず、 四環性ジエン 53 に対する 15 位のヒドロキシメチル化を試みた。本基質に対するヒドロキシメチル化 は convex 面である紙面左側から進行することを期待した (Scheme 40)。しかし、実際のエノールシリ ルエーテル 156 に対する向山アルドール反応は、シリル基が convex 面を遮蔽したためか、β-ヒドロキ シケトン 157 を 2:5 のジアステレオ混合物として与えた。そこで、紙面左右でより立体障害に差のあ る基質に変更してヒドロキシメチル化のジアステレ選択性向上を目指すこととした。
Scheme 40. Hydroxymethylation of tetracyclic diene 53.



53 の5位にβ-水酸基を導入し、これを立体障害として15位にヒドロキシメチル基をジアステレオ 選択的に導入することを計画した (Scheme 41)。53 を L-Selectride®で還元すると、ヒドリドの攻撃は 優先的に convex 面から進行し、第二級アルコール 158 を与えた。この水酸基を足掛かりに 5 位への B 選択的な水酸基の導入を試みた。まず、アミンの酸化を防ぐことを目的として CSA を添加した条件 で、NBS で処理してブロモエーテル 159 を得ることを試みたが、複雑な混合物を与えた。8 位水酸基 と三置換アルケンの距離が遠かったことが原因と考え、8 位水酸基をアセチル化した後 NBS と H₂O で処理したが、2 位に水酸基が導入されたブロモヒドリン 160 が得られ、目的とする 161 は得られな かった。続いて、158をイミダゾール存在下、iPr2SiHCl で処理した。その後、B(C6F5)3で処理して生 じたシリルカチオンとジエンの反応でアリルカチオンが生成し、これが立体的に空いている側からホ ウ素ヒドリド種によって還元されて、アリルシロキサン162が得られることを期待したが、複雑な混 合物と158が回収されるのみであった。以上のような水酸基を足掛かりとした5位へのジアステレオ 選択的な酸素官能基導入は困難であった。一方、ジエン 53 を過剰量の mCPBA で処理して、アミンが 酸化された後も攪拌を続けると18%と低収率ながら、三置換アルケンがエポキシ化されたエポキシド 163が単一のジアステレオマーとして得られることが明らかとなった。そこで、CH₂Cl₂/H₂O中CCl₃CN、 H2O2、KHCO3で処理してより温和な条件で酸化を試みたところ、99%収率でエポキシド164が得られ ることを見出した 59。



酸化された三置換アルケンの両ジアステレオトピック面の嵩高さに大きな差はないため、本ジアス テレオ選択性は予想外であった。そこで、本反応について三置換アルケンの両面がエポキシ化される ときの活性化エネルギーをそれぞれ DFT 計算によって算出すると、実際に得られたエポキシド 163 を与える活性化エネルギーは、164 を与えるそれより 1.4 kcal/mol 安定であることが示唆された (Figure 7)。



Figure 7. DFT calculation of transition state energy for epoxydation calculated by Gaussian 09 at the $\omega B97XD/6-311G(d,p)$ level of theory.

エポキシド163から lyconesidine B への誘導化を検討した。163を水素雰囲気下 Pd/C で処理すると、 N-オキシドが還元された後にエポキシドの開環と還元が進行し、アリルアルコール 165 が 70% 収率で 得られた (Scheme 42)。生じたアリルアルコールを TES 基で保護した後、三置換オレフィンを接触水 素化してシリルエーテル 166 を得た。シリルエーテル 166 について、その塩酸塩 166·HCIの X 線結 晶構造解析により立体化学を確認した。続いて、シリルエーテル166をエノールシリルエーテルとし た後、TES 基を立体障害としたホルムアルデヒドとの向山アルドール反応に付すことで、β-ヒドロキ シケトン167を単一ジアステレオマーとして得た。通常、ランタノイドトリフラートやSc(OTf)3を用 いたエノールシリルエーテルとホルムアルデヒドの向山アルドール反応では、ホルムアルデヒド水溶 液が用いられるが、本基質ではエノールシリルエーテルのプロトン化で166に戻る反応が競合した。 そのため、収率良く本反応を進行させるために、禁水条件でパラホルムアルデヒドを用いた。続いて、 TES 基の脱着でケトアルコール 168 としたのち、5 位の水酸基を配向基としたケトンのジアステレオ 選択的なヒドリド還元により、ジオール169を得た。最後に、5位水酸基の選択的酸化⁶⁰とTES基の 除去を経て lyconesidine B の世界初の全合成を達成した。また、合成品は、天然由来の lyconesidine B と¹H、¹³CNMR および高分解能 MS スペクトルが完全に一致した。本合成経路では、既知のエノール トリフラート 131 から 30 工程、総収率 0.52%であった。合成経路では、官能基化可能な四環性骨格の 供給が数100mgスケールで実施でき、多様な類縁体の合成にも発展が期待できる。

Scheme 42. Total synthesis of lyconesidine B.



第六節 (-)-Lyconesidine B の不斉合成研究

著者が確立した lyconesidine B のラセミ全合成経路おいて、不斉炭素を生じるのは、テトラヒドロ ピリジン 48 のシクロプロパン化の段階である。したがって、本反応を不斉反応へと展開できれば、 本天然物の不斉全合成へと発展できる。そこで、不斉配位子を持った遷移金属触媒を用いて、不斉シ クロプロパン化を検討することとした。なお、シクロプロパン化・開環・還元の後に得られるデカヒ ドロキノリン 49 は、エナンチオマーの分離条件を見出すのが困難であったため、アリルビニルエー テル 139 へと変換して、エナンチオマー比を決定した。

初期検討として、不斉シクロプロパン化に頻用される不斉遷移金属錯体によるシクロプロパン化を 試みた。まず、[CuOTf]₂·C₆H₆と2,2-bis[(4*S*)-(-)-4-isopropyloxazoline]propane から用時調製した触媒 170⁶¹ を用いると、5時間攪拌しても反応は進行しなかった (Table 9, entry 1)。次に、市販の不斉 Rh 二核錯 体 171⁶²、172⁶³、173⁶⁴を検討したが、得られた 49 のエナンチオマー比は、それぞれ 50:50、59:41、 65:35 に留まった (entries 2-4)。不斉 Rh 二核錯体は、この他にも多くの種類が開発されているが、そ のほとんどが触媒 171、172、173 の類縁体なので、同様の配位子でのエナンチオ選択性の大幅な向上 は見込めないと推測した。次に、ビニルプリン誘導体の分子内不斉シクロプロパン化(第二章第三節 page 27)で用いられた不斉カチオン性 Ru 錯体 124a⁶⁵を用いたところ、26:74 と比較的良好なエナン チオ選択性で 49 を与えた (entry 5)。さらに、124a を用いて溶媒を検討した。EtOAc を用いると、エ ナンチオ選択性がわずかに向上し、25:75 er で 49 が得られた (entry 6)。次に、toluene を用いると、 23:77 er で 49 が得られ、THF 中では 21:79 er まで向上した (entries 7, 8)。なお、CH₃CN 中ではほとん ど原料が消費しなかったが、これはおそらく Ru 金属中心からの CH₃CN の解離が不利になり、Ru カ ルベン錯体の形成が遅くなったことが原因と推測される (entry 9)。 Table 9. Initial screening of catalysts and solvents for asymmetric cyclopropanaiton of 48.

OTE	$\frac{N_2}{CN} = \frac{1}{1}$	catalyst ({ solvent the M NaBH(OCOC	5 mol%) , time n CF ₃) ₃ in CH ₂ Cl ₂		$\begin{array}{c} \text{allyl bomide} \\ Cs_2CO_3 \\ \hline acetone \end{array}$	NC O OTBS N Boc (-)-139
entry	catalyst	solvent	time	yield (%)	er (−)- 49 :(+)- 49	
1	170	toluene	5 h	no reaction	() ()	_
2	171	CH ₂ Cl ₂	20 min	45	50:50	
3	172	CH ₂ Cl ₂	20 min	22	59:41	
4	173	CH ₂ Cl ₂	3 h	29	65:35	
5	124a	CH ₂ Cl ₂	1 h	29	26:74	
6	124a	EtOAc	1 h	26	25:75	
7	124a	toluene	4 h	<20 ^a	23:77	
8	124a	THF	40 min	28	21:79	
9	124a	CH ₃ CN	1.5 h	_b		

^aincluding small amount of impurity. ^bAlthough small amount of 48 was consumed, 49 was not detected.



得られたデカヒドロキノリン **49** の主エナンチオマーの絶対立体配置を決定する目的で、第二章第 五節② (page 29) の方法に従い、4 工程で β-ヒドロキシケトン **142** へと誘導化し、その結晶を得た (Scheme 43)。この X 線結晶構造解析から、主エナンチオマーは、望みと逆の絶対立体配置であること が明らかとなった。

Scheme 43. Determination of absolute stereochemistry of 142.



触媒 124a は、豊橋技術科学大学の岩佐らが開発したものであるが、市販のアミノアルコールから 数工程(通常3工程)で合成可能であり、その構造最適化が比較的容易である。そこで、更なるエナ ンチオ選択性の向上を目指し、触媒構造の改変に着手した。触媒は、岩佐らの報告に従い合成した。 まず、オキサゾリン環上に*t*Bu 基を持つ触媒 124b⁶⁶を用いたが、その嵩高さのためか反応は進行せず 原料が回収された (Table 11, entry 1)。続いて、金属中心と結合したベンゼン環上の置換基 R¹がそれぞ れメトキシ基、ニトロ基の 124c⁶⁷ と 124d⁶⁸ を検討したが、いずれも 124a より低いエナンチオ選択性 を与えたため、R¹は H に固定することとした (entries 2, 3)。続いて、オキサゾリン環上の置換基 R²が フェニル基の 124e⁶⁹ を用いたところ、16:84 er とエナンチオ選択性が向上した (entry 4)。一方で R¹、 R² 共にフェニル基の 124f⁷⁰では、エナンチオ選択性が低下した (entry 5)。このことからオキサゾリン 環上の置換基は、124e のように二つのフェニル基がトランス置換した構造を採用した。次に、Ru 周 辺の立体障害によるエナンチオ選択性への影響を調査する目的で、Ru に直接結合したベンゼン環に メチル基を導入した 124g を合成した。なお、望みの(-)-49 を主生成物として得るために、触媒は 1R, 2R 体とした。124g を用いると 63:37 er と顕著な反応時間の延長とエナンチオ選択性の低下が確認さ れた (entry 6)。そこで、立体的に嵩が低い 55 によるシクロプロパン化を試みたところ、88:12 er まで 向上した (entry 7)。

 Table 11. Optimization of the structure of catalyst.



^acontaining a small amount of unidentified impurity.

本反応の反応機構について、中間体を観測するなど直接的な証拠は得られていないが過去の報告を 参考に考察した。触媒 124a を用いた分子内不斉シクロプロパン化について 2018 年、岩佐らは計算化 学を用いて次のようにエナンチオ選択性が発現すると提唱した (Scheme 44)⁷¹。ジアゾエステル 174 と 触媒 124a から Ru カルベン錯体 175 が生成した後、メタラシクロブタン 176 を経て、還元的脱離で主 エナンチオマーを与える (Scheme 44a)。一方、177 ように、主エナンチオマーを与えた 175 と逆のエ ナンチオトピック面でオレフィンが反応すると、メタラシクロブタン 178 を経てもう一方のエナンチ オマーが生成する (Scheme 44b)。

39

Scheme 44. Reported mechanism of asymmetric cyclopropanation using catalyst 124a



しかし、岩佐らが報告した本モデルを著者の基質 48 に適用すると主エナンチオマーが実際の実験 結果と逆転する。これは、岩佐らの基質がジアゾエステルであることに対して、著者の基質 48 がジ アゾケトニトリルであることに起因すると考えた。一般に、2 つの電子求引基が置換した金属カルベ ン錯体では、カルベンの不安定化を避けるために基底状態でカルベンと両電子求引基が直交している (Scheme 45, out-out)。しかし、立体的な要因から、シクロプロパン化等の反応は 1 つの電子求引基が カルベンと平面構造をとって進行する (in-out)。一方、両電子求引基とカルベンが平面構造をとると 大きく不安定化されるため、この状態からは反応しないとされている(in-in)⁷²。





岩佐らの報告では、エステルがカルベンと平面構造をとることが想定されているが、著者の基質は ニトリルが常にカルベンと共役しており、ケトンはカルベンと直交した状態で反応することが予想さ れる (Scheme 46)。この状態で Ru カルベン錯体 179 からメタラシクロブタン 180 への変換には大き なひずみを伴う。したがって Ru カルベン錯体 181 からメタラシクロブタン 182 を経て、大きなひず みを伴わずシクロプロパン化が進行しているものと予想した。



即ち、最も良いエナンチオ選択性を与えた触媒 55 を用いたとき、Ru カルベン錯体 A からメタラシ クロブタン B を形成し、続く還元的脱離で主エナンチオマーとしてシクロプロパン 130 を与えたと推 察した (Scheme 47a)。一方、Ru カルベン錯体 C からは、メタラシクロブタン D を経てシクロシクロ プロパン *ent*-130 を与える (47b)。



Scheme 47. Proposed mechanism of asymmetric cyclopropanation.

触媒を 124e から 55 に変更したときエナンチオ選択性が向上した。これは、ルテニウムに直接結合 したベンゼン環をメチルビニル基に変更したことで、A において基質のテトラヒドロピリジン環と触 媒との立体反発が低減されたためと推測した。また、触媒を 124a から 124e に変更したときエナンチ オ選択性が向上した。フェニル基②が触媒のオキサゾリン環上に導入されるとオキサゾリン環の配座 が変化し、フェニル基①が擬アキシアル位に位置することが DFT 計算から示唆された (Figure 8)。こ れにより、C において基質のシアノ基と触媒のフェニル基①の立体反発が大きくなり *ent*-130 の生成 が抑制されため、エナンチオ選択性が向上したと推察した (Scheme 47)。以上の理由から、触媒 55 が 最も良いエナンチオ選択性を与えたと考えた。



Calculated by Gausian 09 ω B97X-D/(LANL2DZ: Ru; 6-31G(d): others)

第七節 結論

著者は、(i) シクロプロパン化による第四級炭素の構築とその開環・還元によるD環部の構築、(ii) ドミノエニンメタセシス反応によるAB環部の一挙構築を鍵として、(±)-lyconesidine Bの初の全合成 を達成した。酸素官能基化されたアミン型の fawcettimine 型リコポジウムアルカロイドの全合成は、 本報告が初であり、シクロプロパン化を利用したオクタヒドロキノリン合成法の有用性が示された。 また、Ru 触媒による不斉シクロプロパン化により、合成中間体のデカヒドロキノリン 49 を 88:12 er で得ることに成功した。これにより、本法での fawcettimine 型リコポジウムアルカロイドの不斉全合 成への発展も期待できる。

第三章 結論

以上のように、著者は、Fawcettimine グループの中でもエナミン型やアミン型の天然物に注目して、 新たな合成戦略を検討した。これまで多くの合成で用いられてきた犬伏・Heathcock らの合成戦略と は別の CD 環部から構築する戦略を開発し、合成戦略におけるアミン型の合成法へ1つの解決策を提 示した。原料もキラルシントンを用いないため、幅広い酸化された天然物合成へ対応可能である。そ の要点は下記の通りである。

第一章では、テトラヒドロピリジンの分子内シクロプロパン化による第四級炭素の構築と生じたシ クロプロパンの開裂によって核間位に第四級炭素を有するオクタおよびデカヒドロキノリン骨格の 新規合成法を開発した (Scheme 48)。さらに、分子内に水酸基を有する基質を用いて、三環性化合物 98 の合成にも発展させた。本法で合成したヒドロキノリン誘導体は、シクロヘキサン、または、シク ロヘキセン環上にケトンやニトリルを有しており、これら官能基を更なる誘導化や置換基導入の足掛 かりとして利用できる点で有用な合成中間体である。



第二章では、第一章のデカヒドロキノリン合成法とドミノエニンメタセシス反応による骨格構築を 鍵として (±)-lyconesidine B の初の全合成を達成した (Scheme 49)。酸素官能基化されたアミン型の fawcettimine 型リコポジウムアルカロイドの全合成は、本報告が初であり、シクロプロパン化を利用 したオクタヒドロキノリン合成法の有用性が示された。また、Ru 触媒 55 による不斉シクロプロパン 化で合成中間体 49 を 88:12 er で得ることにも成功した。これにより、本法での fawcettimine 型リコポ ジウムアルカロイド類の不斉全合成への展開も期待できる。ドミノエニンメタセシス反応による AB 環部合成では、第四級アンモニウム塩を経由することが鍵であった。本研究により Grubbs 触媒の失 活を抑え、かつ反応点を接近させる合成戦略の有用性を示せたことから、エニンメタセシスを用いた アミン化合物合成における1つの課題の解決策を提示した。

Scheme 49. Summary of chapter 2.





General Information

All non-aqueous reactions were carried out under argon in dried glassware. Analytical thin-layer chromatography was performed using Silica gel 60 plates (Merck, Darmstadt, Germany). Silica gel column chromatography was performed using Kanto silica gel 60 (particle size 63–210 µm, Kanto, Tokyo, Japan), Chromatorex BW-300 (Fuji silysia, Aichi, Japan), DualPore OPEN (DPS Inc., Kyoto, Japan), Chromatorex DIOL SMB10020/45 (Fuji silysia) and Chromatorex NH-DU3050 (Fuji silysia). Proton nuclear magnetic resonance (¹H NMR) spectra were recorded on a JNM-AL 400 (JEOL) at 400 MHz, a JNM-ECA 500 (JEOL, Tokyo, Japan) at 500 MHz, Avance I 600 (Bruker Biospin AG, Switzerland) at 600 MHz or a JNM-ECZ 600 (JEOL) at 600 MHz. Chemical shifts were reported relative to Me4Si (δ 0.00) in CDCl₃ or the residual solvent peak in C₆D₆ (δ 7.16) or CD₃OD (8 3.31). Multiplicity was indicated by one or more of the following: s (singlet); d (doublet); t (triplet); q (quartet); m (multiplet); br (broad). Carbon nuclear magnetic resonance (13C NMR) spectra were recorded on a JNM-AL 400 (JEOL) at 100 MHz, a JNM-ECA 500 at 126 MHz, an Avance I 600 (Bruker Biospin AG, Switzerland) at 151 MHz or a JNM-ECZ 600 at 151 MHz. Chemical shifts were reported relative to $CDCl_3$ (δ 77.0), C_6D_6 (δ 128.0) or CD_3OD (δ 49.0). Infrared spectra were recorded on a FT/IR-4100 Fourier-transform infrared spectrometer (JASCO, Tokyo, Japan) ATR (attenuated total reflectance). Low and High resolution mass spectra were recorded on JMS-700 mass spectrometer (JEOL) for FAB-MS and a LCMS-IT-TOF (Shimadzu, Kyoto, Japan) for ESI-MS. X-ray crystallography was recorded on XtaLAB P200 deffractometer (Rigaku, Tokyo, Japan).

Materials

Anhydrous acetone, CH₂Cl₂, THF, DMF, toluene, methanol and CH₃CN, were purchased from KANTO Chemical Co., Aldrich and Wako chemicals. Materials were obtained from Tokyo Chemical Industry Co., Ltd. Aldrich Inc., and other commercial suppliers, and used without further purification.

第一章 四置換エンカーバメートのシクロプロパン化とその開環を利用したオクタ-お よびデカヒドロキノリンの合成

1. Experimental Procedure

Compound **91a** was prepared by following Waser's procedure.²⁷ Compound **91b-d**, **91f** and **91h** was synthesized by modifying this procedure as follows.



Compound 91b: To a solution of 2-piperidone (4.00 g, 40.4 mmol) in THF (80 mL) was added *n*BuLi (1.6 M hexane solution, 55.5 mL, 88.8 mmol) dropwise at 0 °C, and the solution was stirred at the same temperature for

30 min. EtI (4.90 mL, 60.6 mmol) was then added dropwise, and the resultant solution was stirred at the same temperature for 0.5 h. ClCO₂Me (3.30 mL, 42.4 mmol) was then added at 0 °C, and the resultant solution was warmed to room temperature. After stirring at room temperature for 1 h, aq. NH₄Cl was added to the reaction mixture. The resultant mixture was extracted with EtOAc. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **91b** (5.10 g, 27.5 mmol, 68%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 3.86 (s, 3H), 3.81 (m, 1H), 3.69 (m, 1H), 2.36 (m, 1H), 2.03 (m, 1H), 1.95-1.87 (m, 2H), 1.82 (m, 1H), 1.54-1.49 (m, 2H), 0.97 (t, 3H, *J* = 7.4 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 172.8, 153.6, 52.3, 44.8, 43.9, 24.3, 22.9, 20.4, 10.3; IR (ATR) 2957, 2876, 1774, 1715, 1283, 1257, 1089 cm⁻¹; HRMS (FAB) *m*/*z*: [M+H]⁺ Calcd for C₉H₁₆NO₃ 186.1130; Found 186.1127.



Compound 91c: To a solution of 2-piperidone (1.00 g, 10.1 mmol) in THF (20 mL) was added *n*BuLi (1.6 M hexane solution, 13.9 mL, 22.0 mmol) dropwise at 0 °C, and the solution was stirred at the same temperature for 30 min. EtI (1.23 mL, 15.1 mmol) was then added dropwise, and the resultant solution was stirred at the same temperature for 0.5 h. Boc₂O (2.31 g, 10.6 mmol) was then added at 0 °C, and the resultant solution was warmed to room temperature. After stirring at room temperature for 40 min, aq. NH₄Cl was added to the reaction mixture. The resultant mixture was extracted with EtOAc. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **91c** (1.89 g, 8.32 mmol, 83%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 3.77-3.72 (m, 1H), 3.63-3.58 (m, 1H), 2.34-2.29 (m, 1H), 2.04-1.79 (m, 4H), 1.58-1.50 (m, 2H), 1.52 (s, 9H), 0.96 (t, 3H, *J* = 7.3 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 173.9, 152.6, 82.1, 45.3, 44.7, 27.6, 25.1, 23.7, 21.3, 11.1; IR (ATR) 2967, 2875, 1768, 1712, 1296, 1150 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₂H₂₂NO₃ 228.1600; Found: 228.1602.



Compound 91d: To a solution of 2-piperidone (500 mg, 5.04 mmol) in THF (10 mL) was added *n*BuLi (1.6 M hexane solution, 6.95 mL, 11.1 mmol) dropwise at 0 °C, and the solution was stirred at the same temperature for 30 min. EtI (0.615 mL, 7.65 mmol) was then added dropwise, and the resultant solution was stirred at the same temperature for 0.5 h. A solution of TsCl (1.01 g, 5.29 mmol) in THF (5.0 mL) was then added at 0 °C, and the resultant solution was warmed to room temperature. After stirring at room temperature for 0.5 h, aq. NH₄Cl was added to the reaction mixture. The resultant mixture was extracted with EtOAc. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column

chromatography (hexane/EtOAc = 10:1) to afford **91d** (1.00 g, 3.57 mmol, 71%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ 7.89 (d, 2H, *J* = 8.0 Hz), 7.31 (d, 2H, *J* = 8.0 Hz), 3.95 (m, 1H), 3.87 (m, 1H), 2.42 (s, 3H), 2.25 (m, 1H), 2.03-1.93 (m, 2H), 1.84-1.77 (m, 2H), 1.50-1.42 (m, 2H), 0.85 (t, 3H, *J* = 7.4 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 173.2, 144.5, 136.3, 129.3, 128.6, 128.5, 46.7, 44.8, 25.1, 23.9, 22.3, 21.6, 11.1; IR (ATR) 2962, 2875, 1693, 1349, 1167 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₄H₂₀NO₃S 282.1164; Found: 282.1169.



Compound 91g: To a solution of 2-piperidone (2.97 g, 30.0 mmol) in THF (60 mL) was added *n*BuLi (1.6 M hexane solution, 41.0 ml, 66.0 mmol) dropwise at 0 °C, and the solution was stirred at the same temperature for 30 min. Ethylene oxide (1.2 M THF solution, 25.0 ml, 30.0 mmol) was then added dropwise, and the resultant solution was stirred at the same temperature for 3 h. TBSCl (7.05 g, 45.0 mmol) was then added at 0 °C, and the resultant solution was warmed to room temperature. After stirring at room temperature for 10 h, aq. NH4Cl was added to the reaction mixture. The resultant mixture was extracted with EtOAc. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:2) to afford 3-(2-tert-butyldimethylsilyloxyethyl)-piperidin-2-one (5.30 g, 20.6 mmol, 69%) as a colorless solid: ¹H NMR (500 MHz, CDCl₃) δ 5.71 (brs, 1H), 3.75 (t, 2H, *J* = 6.2 Hz), 3.30 (brs, 2H), 2.43 (m, 1H), 2.21 (m, 1H), 2.00 (m, 1H), 1.88 (m, 1H), 1.74 (m, 1H), 1.64-1.52 (m, 2H), 0.89 (s, 9H), 0.05 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 175.3, 60.8, 41.8, 37.7, 34.2, 27.0, 26.2, 25.7, 21.2, 18.0, -5.58, -5.64; IR (ATR) 3284, 3191, 3070, 2951, 2856, 1645, 1491, 1249 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₃H₂₈NO₄Si [M+H]⁺ 258.1889; Found: 258.1887.

To a solution of 3-(2-tert-butyldimethylsilyloxyethyl)piperidin-2-one (5.30 g, 20.6 mmol) in dry THF (80 mL) was added *n*BuLi (1.6 M hexane solution, 12.9 ml, 20.6 mmol) dropwise at -78 °C. The solution was stirred at the same temperature for 30 min. CbzCl (2.90 ml, 20.6 mmol) was then added dropwise. After stirring at -78 °C for 1.5 h, water was added to the reaction mixture. The resultant solution was extracted with Et₂O. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **91g** (7.30 g, 16.8 mmol, 90%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.44-7.43 (m, 2H), 7.38-30 (m, 3H), 5.28 (s, 2H), 3.88 (m, 1H), 3.77-3.64 (m, 3H), 2.63 (m, 1H), 2.19 (m, 1H), 2.05 (m, 1H), 1.91-1.80 (m, 2H), 1.60-1.49 (m, 2H), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 174.4, 154.2, 135.5, 128.5, 128.2, 128.0, 68.4, 60.6, 45.7, 40.3, 33.8, 26.0, 25.9, 21.7, 18.3, -5.3, -5.4; IR (ATR) 2953, 2857, 1772, 1714, 1253, 1169 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₁H₃₄NO₄Si 392.2257; Found: 392.2266.



Compound 91h: To a solution of 2-piperidone (20.0 g, 202 mmol) in THF (500 mL) was added nBuLi (1.6 M

hexane solution, 152 mL, 244 mmol) dropwise at 0 °C, and the solution was stirred at the same temperature for 30 min. ClCO₂Et (20.0 mL, 212 mmol) was then added at -78 °C, and the resultant solution was warmed to room temperature. After stirring at room temperature for 50 min, aq. NH₄Cl was added to the reaction mixture. The resultant mixture was extracted with EtOAc. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:1) to afford **91h** (17.7 g, 103 mmol, 51%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 4.31 (q, 2H, *J* = 7.1 Hz), 3.72 (m, 2H), 2.54 (t, 2H, *J* = 6.2 Hz), 1.84 (m, 4H), 1.35 (t, 3H, *J* = 7.2 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 170.9, 153.8, 62.6, 46.1, 34.5, 22.3, 20.0, 13.9; IR (ATR) 2958, 1770, 1712, 1235, 1090 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₈H₁₄NO₃Na 172.0974; Found: 172.0976.



Compound 92a: To a solution of KHMDS (0.5 M toluene solution, 47.0 mL, 23.5 mmol) in THF (75 mL) was added a solution of **91a** (4.90 g, 18.8. mmol) in THF (15 mL) dropwise at -78 °C. The solution was stirred at the same temperature for 2 h. A solution of PhNTf₂ (5.10 g, 23.5 mmol) in THF (25 mL) was then added dropwise via cannula and the resultant solution was warmed to room temperature. After stirring at room temperature for 5 h, the solution was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 15:1) to afford **92a** (4.86 g, 12.4 mmol, 66%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.40-7.28 (m, 5H), 5.22 (s, 2H), 3.65 (t, 2H, *J* = 5.3 Hz), 2.28-2.24 (m, 4H), 1.82 (tt, 2H, *J* = 6.5, 5.5 Hz), 1.10 (t, 3H, *J* = 7.6 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 154.3, 135.3, 134.0, 128.4, 128.2, 128.0, 123.2, 118.2 (q, *J* = 318 Hz), 68.2, 46.1, 25.2, 23.14, 23.09, 11.9; IR (ATR) 2976, 2920, 1725, 1414, 1390 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₆H₁₈NO₅F₃Na 416.0750; Found: 416.0737.



Compound 92b: To a solution of KHMDS (0.5 M toluene solution, 67.0 mL, 33.5 mmol) in THF (100 mL) was added a solution of **91b** (4.96 g, 26.8. mmol) in THF (20 mL) dropwise at -78 °C. The solution was stirred at the same temperature for 2 h. A solution of PhNTf₂ (7.31 g, 33.5 mmol) in THF (20 mL) was then added dropwise via cannula and the resultant solution was warmed to room temperature. After stirring at room temperature for 13.5 h, the solution was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **92b** (5.40 g, 17.0 mmol, 64%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 3.77 (s, 3H), 3.61 (t, 2H, *J* = 5.6 Hz), 2.26-2.21 (m, 4H), 1.83-1.78 (m, 2H), 1.08 (t, 3H, *J* = 7.6 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 154.8, 133.9, 122.8, 118.2 (q, *J* = 320 Hz), 53.2, 45.9, 25.2, 23.1, 23.0, 11.8; IR (ATR) 2957, 1730, 1692, 1414, 1208, 1088

cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₀H₁₅F₃NO₅S 318.0623; Found: 318.0630.



Compound 92c: To a solution of KHMDS (0.5 M toluene solution, 18.7 mL, 9.36 mmol) in THF (75 mL) was added a solution of **91c** (1.70 g, 7.49 mmol) in THF (10 mL) dropwise at -78 °C. The solution was stirred at the same temperature for 2 h. A solution of PhNTf₂ (3.34 g, 9.36 mmol) in THF (10 mL) was then added dropwise via cannula and the resultant solution was warmed to room temperature. After stirring at room temperature for 15 min, the solution was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 20:1) to afford **92c** (2.11 g, 5.88 mmol, 78%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 3.53 (br, 2H), 2.24-2.20 (m, 4H), 1.79-1.75 (m, 2H), 1.47 (s, 9H), 1.08 (t, 3H, *J* = 7.8 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 153.5, 134.9, 122.2, 118.25 (q, *J* = 318 Hz), 82.3, 45.8, 27.9, 25.5, 23.22, 23.19, 12.1; IR (ATR) 2942, 2879, 1717, 1415, 1362, 1205, 1156, 1138 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for Cl₃H₂IF₃NO₅S 360.1093; Found: 360.1091.



Compound 92d: To a solution of KHMDS (0.5 M toluene solution, 12.8 mL, 6.40 mmol) in THF (30 mL) was added a solution of **91d** (1.52 g, 5.10. mmol) in THF (10 mL) dropwise at -78 °C. The solution was stirred at the same temperature for 2 h. PhNTf₂ (2.29 g, 6.40 mmol) in THF (10 mL) was then added dropwise via cannula and the resultant solution was warmed to room temperature. After stirring at room temperature for 1 h, the solution was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **92d** (1.04 g, 2.39 mmol, 47%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.75 (d, 2H, *J* = 7.7 Hz), 7.33 (d, 2H, *J* = 8.0 Hz), 3.56 (t, 2H, *J* = 5.9 Hz), 2.45 (s, 3H), 2.23 (q, 2H, *J* = 7.4 Hz), 1.93 (t, 2H, *J* = 6.7 Hz), 1.39-1.34 (m, 2H), 1.03 (t, 3H, *J* = 7.4 Hz), 0.88 (t, 2H, *J* = 6.4 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 144.8, 135.0, 133.5, 129.8, 129.3, 128.0, 118.2 (*J* = 320 Hz), 48.0, 24.7, 24.0, 21.6, 19.9, 12.0; IR (ATR) 2943, 2879, 1711, 1691, 1412, 1367, 1203, 1167 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₅H₁₉F₃NO₅S₂ 414.0657; Found: 414.0663.



Compound 92g: To a solution of KHMDS (0.5 M toluene solution, 46.6 mL, 23.3 mmol) in THF (93 mL) was added a solution of **91g** (7.30 g, 18.6. mmol) in THF (30 mL) dropwise at -78 °C. The solution was stirred at the same temperature for 2 h. PhNTf₂ (5.10 g, 23.4 mmol) in THF (30 mL) was then added dropwise via cannula and

the resultant solution was warmed to room temperature. After stirring at room temperature for 2.5 h, the solution was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 20:1) to afford **92g** (7.40 g, 14.1 mmol, 76%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.38-7.32 (m, 5H), 5.18 (s, 2H), 3.73 (t, 2H, *J* = 6.3 Hz), 3.62 (t, 2H, *J* = 5.7 Hz), 2.40 (t, 2H, *J* = 6.6 Hz), 2.31 (t, 2H, *J* = 6.9 Hz), 1.80-1.75 (m, 2H), 0.86 (s, 9H), 0.02 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 154.4, 135.3, 128.5, 128.3, 128.1, 120.1, 118.2 (q, *J* = 320 Hz), 68.4, 61.2, 46.1, 33.6, 27.0, 25.8, 23.3, 18.2, -5.5; IR (ATR) 2954, 2858, 1729, 1695, 1415, 1252, 1208 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₃₃F₃NO₆SSi 524.1750; Found: 524.1755.



Compound 92h: To a solution of KHMDS (0.5 M toluene solution, 73.0 mL, 36.5 mmol) in THF (90 mL) was added a solution of **91h** (5.00 g, 29.2 mmol) in THF (20 mL) dropwise at -78 °C. The solution was stirred at the same temperature. for 2 h A solution of PhNTf₂ (8.00 g, 36.5 mmol) in THF (20 mL) was then added dropwise via cannula and the resultant solution was warmed to room temperature. After stirring at room temperature for 20 min, the solution was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 20:1) to afford **92h** (5.80 g, 19.1 mmol, 65%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 5.33 (t, 1H, *J* = 3.9 Hz), 4.25 (q, 2H, *J* = 7.0 Hz), 3.67 (t, 2H, *J* = 5.4 Hz), 2.28 (td, 2H, *J* = 6.7, 3.9 Hz), 1.81-1.77 (m, 2H), 1.31 (t, 3H, *J* = 7.0 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 153.6, 139.7, 118.3 (*J* = 320 Hz), 107.1, 62.8, 45., 22.2, 21.9, 14.0; IR (ATR) 2941, 1727, 1682, 1420, 1375, 1205, 1138 cm⁻¹; HRMS (FAB) *m*/*z*: [M+H]⁺ Calcd for C₉H₁₃F₃NO₅S 304.0467; Found: 304.0463.



Compound 94a: To a solution of **92a** (1.82 g, 4.63 mmol) in DMF (14 mL) was added methyl acrylate (1.24 mL, 13.9 mmol), Et₃N (1.90 mL, 13.9 mmol) and Pd(PPh₃)₄ (104 mg, 0.0926 mmol). The solution was stirred at 80 °C for 20 h. The reaction mixture was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 8:1) to afford **93a** as a colorless oil (1.26 g, 3.83 mmol, 83%): ¹H NMR (500 MHz, CDCl₃) δ 7.57 (d, 1H *J* = 15.5 Hz), 7.30 (m, 5H), 5.77 (d, 1H, *J* = 15.5 Hz), 5.10 (s, 2H), 3.71 (s, 3H), 3.53 (t, 2H, *J* = 5.7 Hz), 2.30-2.22 (m, 4H), 1.83 (tt, 2H, *J* = 6.5, 5.5 Hz), 1.06 (t, 3H, 7.4 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 167.7, 154.9, 141.2, 137.3,

136.0, 131.4, 128.2, 127.9, 127.8, 117.1, 67.3, 51.2, 44.3, 27.6, 25.7, 23.5, 13.5; IR (ATR) 2949, 2879, 1708, 1630, 1393, 1308, 1252, 1170 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Ccalcd for C₁₉H₂₄NO₄ 330.1700; Found: 390.1690. To a solution of the above **93a** (1.08 g, 3.29 mmol) in MeOH (30 mL) was added NaBH₄ (1.24 g, 32.9 mmol) at -50 °C. The resultant solution was stirred at the same temperature for 15 min. CoCl₂ (85.0 mg, 0.670 mmol) was added, and the resultant solution was then stirred at -50 °C for 10 min. At the same temperature, aq. NH₄Cl was added to the reaction mixture. The resultant solution was extracted with EtOAc. The combined organic layers were washed with brine, and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **94b** (843 mg, 2.60 mmol, 64% for 2 steps) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.35-7.30 (m, 5H), 5.14 (s, 2H), 3.61 (s, 3H), 3.48 (t, 2H, *J* = 5.7 Hz), 2.34 (br, 2H), 2.37 (t, 2H, *J* = 6.9 Hz), 2.08-2.04 (m, 4H), 1.76 (tt, 2H, *J* = 6.5, 6.0 Hz), 1.00 (t, 3H, 7.7 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 173.5, 154.5, 136.3, 131.9, 128.3, 128.2, 127.9, 127.8, 67.0, 51.2, 44.9, 32.4, 25.4, 23.8, 13.9; IR (ATR) 2949, 2876, 1737, 1698, 1397, 1254, 1185 cm⁻¹; HRMS (ESI) *m*/z; [M+H]⁺ Calcd for C₁₉H₂₅NO₄Na 354.1676; Found: 354.1659.



Compound 94b: To a solution of 92b (4.83 g, 15.2 mmol) in DMF (45 mL) was added methyl acrylate (6.80 mL, 76.1 mmol), Et₃N (6.30 mL, 45.6 mmol) and Pd(PPh₃)₄ (351 mg, 0.300 mmol). The solution was stirred at 80 °C for 13.5 h. The reaction mixture was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by a short pad of silica gel (hexane/EtOAc = 5:1) to give crude **93b** (2.20 g) as a colorless oil. To a solution of the above crude 93b (2.20 g) in MeOH (23 mL) was added NaBH₄ (1.46 g, 38.7 mmol) at -50 °C. The resultant solution was stirred at the same temperature for 15 min. CoCl₂ (50.0 mg, 0.387 mmol) was added, and the resultant solution was then stirred at -50 °C for 10 min. At the same temperature, aq. NH₄Cl was added to the reaction mixture. The resultant solution was extracted with EtOAc. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **94b** (1.66 g, 6.50 mmol, 51% for 2 steps) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 3.71 (s, 3H), 3.65 (s, 3H), 3.44 (t, 2H, J = 5.6 Hz), 2.83 (t, 2H, J = 7.3 Hz), 2.41 (t, 2H, J = 7.6 Hz), 2.08-2.04 (m, 4H), 1.79-1.74 (m, 2H), 1.01 (t, 3H, J = 7.6 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 173.6, 155.2, 132.0, 127.8, 52.4, 51.3, 44.9, 32.5, 26.4, 25.3, 25.1, 23.8, 13.1; IR (ATR) 2952, 2875, 1737, 1701, 1440, 1376, 1255, 1191 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₃H₂₂NO₄ 256.1549; Found: 256.1551.



Compound 94c: A solution of Pd(OAc)₂ (26.5 mg, 0.118 mmol) and 2-(di-tert-butylphosphino)biphenyl A (70.4 mg, 0.236 mmol) in THF (8.0 mL) was stirred at room temperature for 10 min. A solution of 92c (426 mg, 1.18 mmol) and methyl (E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate (3.55 mmol, prepared from methyl propionate and bis(pinacolato)diboron by following Yun's procedure⁷⁷) in THF (4.0 mL), and KF (206 mg, 3.55 mmol) were added to the pre-mixed solution. The solution was refluxed for 41 h. The reaction mixture was diluted with Et2O. The organic layer was washed with water and brine and dried over Mg2SO4. After filtration, the solution was concentrated under reduced pressure. The residue was purified by a short pad of silica gel (hexane/EtOAc = 10:1) to give crude 93c (350 mg) as a yellow oil. To a solution of the above crude 93c (350 mg) in MeOH (30 mL) was added NaBH₄ (449 mg, 11.9 mmol) at -50 °C. The resultant solution was stirred for 5 min at the same temperature. CoCl₂ (30.9 mg, 0.238 mmol) was added, and the resultant solution was then stirred at -50 °C for 30 min. At the same temperature, aq. NH₄Cl was added to the reaction mixture. The resultant solution was extracted with CHCl₃. The combined organic layers were washed with brine, and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford 94c (215 mg, 0.723 mmol, 61% for 2 steps) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) & 3.65 (s, 3H), 3.39 (t, 2H, J = 5.8 Hz), 2.84 (t, 2H, J = 7.8 Hz), 2.39 $(t, 2H, J = 7.8 \text{ Hz}), 2.10-2.02 \text{ (m, 4H)}, 1.81-1.73 \text{ (m, 2H)}, 1.48 \text{ (s, 9H)}, 1.01 \text{ (t, 3H, } J = 7.5 \text{ Hz}); {}^{13}\text{C NMR}$ (126) MHz, CDCl₃) δ 173.6, 153.9, 132.2, 127.0, 79.9, 51.2, 44.7, 32.2, 28.1, 26.6, 25.4, 25.1, 23.9, 13.1; IR (ATR) 2937, 2874, 1740, 1697, 1366, 1156 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₆H₂₈NO₄ 298.2013; Found: 298.2018.



Compound 94d: A solution of Pd(OAc)₂ (17.2 mg, 0.0768 mmol) and 2-(di-*tert*-butylphosphino)biphenyl (45.8 mg, 0.154 mmol) in THF (4.0 mL) was stirred at room temperature for 10 min. A solution of **92d** (317 mg, 0.768 mmol) and methyl (*E*)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate (2.30 mmol, prepared from methyl propionate and bis(pinacolato)diboron by following Yun's procedure⁷⁷) in THF (2.0 mL), and KF (134 mg, 2.30 mmol) were added to the pre-mixed solution. The solution was refluxed for 60 h. The reaction mixture was diluted with Et₂O. The organic layer was washed with water and brine and dried over Mg₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by a short pad of silica gel (hexane/EtOAc = 10:1) to give crude **93d** (159 mg) as a yellow oil. To a solution of the above crude **93d** (159 mg) in MeOH (10 mL) was added NaBH₄ (175 mg, 4.62 mmol) at -50 °C. The resultant solution was stirred at

the same temperature for 10 min. CoCl₂ (12.0 mg, 0.0924 mmol) was added, and the resultant solution was then stirred at -50 °C for 30 min. Then aq. NH₄Cl was added to the reaction mixture. The resultant solution was extracted with CHCl₃. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **94d** (53.3 mg, 0.152 mmol, 20% for 2 steps) as a colorless oil:¹H NMR (500 MHz, CDCl₃) δ 7.66 (d, 2H, *J* = 8.0 Hz), 7.27 (d, 2H, *J* = 8.0 Hz), 3.65 (s, 3H), 3.45 (t, 2H, *J* = 6.0 Hz), 2.95 (t, 2H, *J* = 7.4 Hz), 2.57 (t, 2H, *J* = 7.4 Hz), 2.42 (s, 3H), 2.05 (d, 2H, *J* = 7.4 Hz), 1.69 (t, 2H, *J* = 7.0 Hz), 1.39-1.34 (m, 2H), 0.95 (t, 3H, *J* = 7.4 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 173.7, 143.2, 137.1, 132.2, 130.9, 129.3, 127.1, 51.4, 46.7, 32.4, 26.4, 26.3, 25.8, 21.4, 21.0, 13.2; IR (ATR) 2961, 1736, 1337, 1236, 1160 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₈H₂₆NO4S 352.1583; Found: 352.1588.



Compound 94g: To a solution of 92g (7.40 g, 14.1 mmol) in DMF (47 mL) was added methyl acrylate (12.7 mL, 141 mmol), Et₃N (5.90 mL, 42.3 mmol) and Pd(PPh₃)₄ (326 mg, 0.282 mmol). The solution was stirred at 80 °C for 16 h. The reaction mixture was diluted with Et₂O, and water was added for quenching the reaction. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by a short pad of silica gel (hexane/EtOAc = 10:1) to give crude 93g (6.30 g) as a colorless oil. To a solution of the above crude 93g (6.30 g) in MeOH (137 mL) was added NaBH4 (5.20 g, 137 mmol) at -50 °C. The resultant solution was stirred for at the same temperature 15 min. CoCl₂ (356 mg, 2.74 mmol) was added, and the resultant solution was then stirred at -50 °C for 10 min. At the same temperature, aq. NH₄Cl was added to the reaction mixture. The resultant solution was extracted with EtOAc. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford 94g (2.76 g, 6.00 mmol, 42% for 2 steps) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.32-7.24 (m, 5H), 5.11 (s, 2H), 3.62-3.59 (m, 2H), 3.58 (s, 3H), 3.44 (t, 2H, *J* = 5.2 Hz), 2.81 (t, 2H, *J* = 6.6 Hz), 2.33 (t, 2H, *J* = 7.2 Hz), 2.24 (t, 2H, *J* = 6.9 Hz), 2.04 (t, 2H, *J* = 6.6 Hz), 1.72 (t, 2H, *J* = 5.6 Hz), 0.84 (s, 9H), 0.00 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) & 173.5, 154.6, 136.5, 134.2, 128.4, 128.4, 128.03, 128.00, 123.3, 67.3, 62.0, 51.4, 45.0, 36.1, 32.5, 28.0, 25.9, 24.0, 18.3, 14.1, -5.4; IR (ATR) 2951, 2857, 1738, 1703, 1398, 1254, 1088 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₅H₄₀NO₅Si 462.2676; Found: 462.2680.



Compound 94f: To a solution of **94g** (129.4 mg, 0.280 mmol) in MeOH (2.8 mL) was added (–)-10-camphorsulfonic acid (6.5 mg, 0.0280 mmol) at room temperature. After the solution was stirred for 1.5 h, Et₃N

was added for quenching the reaction. The resultant mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:2) to afford an alcohol (79.3 mg, 0.228 mmol, 81%) as a colorless oil. To a solution of the above alcohol (21.4 mg, 0.0616 mmol) in DME (1.0 mL) were added 4-(4,6- diphenoxy-1,3,5-triazin-2-yl)-4-benzylmorholinium trifluoromethanesulfonate (DPT-BM)²¹ (107 mg, 0.246 mmol) and MgO (10.0 mg, 0.246 mmol) at room temperature. The solution was stirred for 17 h. The solution was diluted with EtOAc and washed with aq. NaHCO₃. The organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) and GPC to afford **94f** (21.4 mg, 0.0489 mmol, 79%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.36-7.25 (m, 10H), 5.14 (s, 2H), 4.50 (s, 2H), 3.60 (s, 3H), 3.50 (t, 2H, *J* = 7.0 Hz), 3.47 (t, 2H, *J* = 6.0 Hz), 2.86 (t, 2H, *J* = 7.3 Hz), 2.38 (d, 2H, *J* = 7.5 Hz), 2.36 (d, 2H, *J* = 7.5 Hz), 2.07 (t, 2H, *J* = 6.9 Hz), 1.77-1.72 (m, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 173.6, 154.6, 138.3, 136.4, 134.3, 128.5, 128.4, 128.0, 127.7, 127.6, 127.4, 123.1, 72.9, 69.0, 67.3, 51.4, 45.1, 33.1, 32.4, 27.8, 25.3, 24.0; IR (ATR) 2921, 1730, 1420, 1257, 1210, 1089 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₆H₃₂NO₅ 438.2280; Found: 438.2275.



Compound 94h: A solution of Pd(OAc)₂ (57.3 mg, 0.255 mmol) and 2-(di-tert-butylphosphino)biphenyl (152 mg, 0.510 mmol) in THF (8.0 mL) was stirred at room temperature for 10 min. A solution of 92h (773 mg, 2.55 mmol) and methyl (E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate (7.65 mmol, prepared from methyl propionate and bis(pinacolato)diboron by following Yun's procedure) in THF (4.0 mL), and KF (444 mg, 7.65 mmol) were added to the pre-mixed solution. The solution was refluxed for 21 h. The reaction mixture was diluted with Et₂O. The organic layer was washed with water and brine and dried over Mg₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by a short pad of silica gel (hexane/EtOAc = 5:1) to give crude **93f** (638 mg) as a yellow oil. To a solution of the above crude **93h** (638 mg) in MeOH (26 mL) was added NaBH₄ (1.01 g, 26.7 mmol) at -50 °C. The resultant solution was stirred at the same temperature for 10 min. CoCl₂ (69.3 mg, 0.534 mmol) was added, and the resultant solution was then stirred at -50 °C for 20 min. At the same temperature, aq. NH₄Cl was added to the reaction mixture. The resultant solution was extracted with CHCl₃. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **94f** (274 mg, 1.13 mmol, 44% for 2 steps) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 5.05 (t, 1H, J = 3.3 Hz), 4.17 (q, 2H, J = 7.1 Hz), 3.66 (s, 3H), 3.56-3.54 (m, 2H), 2.84-2.81 (m, 2H), 2.43 (t, 2H, J = 7.6 Hz), 2.09-2.05 (m, 2H), 1.78-1.75 (m, 2H), 1.29 (t, 2H, J = 7.0 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 173.5, 154.3, 138.1, 113.4, 61.5, 51.4, 44.9, 32.8, 30.7, 23.1, 22.8, 14.4; IR (ATR) 2950, 1738, 1703, 1402, 1378, 1339, 1090 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₂H₂₀NO₄ 242.1392; Found: 242.1395.



Compound 95a: To a THF solution of LDA (4.31 mmol in THF (7.0 mL)), prepared from *i*Pr₂NH (0.634 mL, 4.51 mmol and *n*BuLi (1.6 M hexane solution, 2.70 mL, 4.31 mmol at -78 °C, was added CH₃CN (0.229 mL, 0.4.31 mmol) dropwise at -78 °C. After the solution was stirred at the same temperature for 30 min, **95a** (650 mg, 1.96 mmol) in THF (3.0 mL) was added dropwise via cannula. The solution was stirred for 15 min, then aq. NH₄Cl was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **95a** (497 mg, 1.46 mmol, 74%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.36-7.33 (m, 5H), 5.12 (s, 2H), 3.47 (t, 2H, *J* = 5.4 Hz), 3.26 (br, 2H), 2.74 (br, 2H), 2.58 (br, 2H), 2.06-1.99 (m, 4H), 1.76 (tt, 2H, *J* = 7.0, 5.5 Hz), 0.99 (t, 3H, *J* = 7.4 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 197.1, 154.4, 136.2, 130.9, 128.4, 128.1, 127.8, 113.8, 67.1, 44.9, 40.5, 31.4, 26.4, 25.3, 23.9, 23.7, 13.0; IR (ATR) 2961, 2872, 2257, 1731, 1695, 1399, 1189 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₂₄N₂O₃Na 363.1679; Found: 363.1665.



Compound 95b: To a solution of LHMDS (10.4 mL, 13.5 mmol, 1.3 M THF solution) in THF (20 mL) was added CH₃CN (0.718 mL, 13.5 mmol) dropwise at -78 °C. After the solution was stirred at the same temperature for 0.5 h, a solution of **94b** (1.38 g, 5.40 mmol) in THF (7.0 mL) was added dropwise via cannula. The solution was stirred for 0.5 h, then aq. NH₄Cl was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **95b** (745 mg, 2.82 mmol, 52%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 3.71 (s, 3H), 3.48 (s, 2H), 3.43 (t, *J* = 5.7 Hz, 2H), 2.82-2.79 (m, 2H), 2.76-2.73 (m, 2H), 2.08-2.01 (m, 4H), 1.79-1.74 (m, 2H), 1.01 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 197.3, 155.2, 131.2, 127.9, 113.8, 52.6, 45.0, 40.7, 31.8, 26.4, 25.4, 23.9, 23.7, 13.1; IR (ATR) 2956, 2259, 1731, 1693, 1442, 1375, 1193 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₄H₂₁N₂O₃ 265.1552; Found: 265.1552.



Compound 95c: To a solution of LHMDS (1.00 mL, 1.30 mmol, 1.3 M THF solution) in THF (2.5 mL) was added CH_3CN (0.070 mL, 1.32 mmol) dropwise at -78 °C. After the solution was stirred at the same temperature for 1.5 h, a solution of **94c** (157 mg, 0.528 mmol) in THF (2.0 mL) was added dropwise via cannula. The solution was stirred for 1 h, then aq. NH₄Cl was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated

under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **95c** (98.2 mg, 0.320 mmol, 61%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 3.52 (s, 2H), 3.36 (t, 2H, *J* = 5.5 Hz), 2.81 (t, 2H, *J* = 7.0 Hz), 2.70 (t, 2H, *J* = 7.3 Hz), 2.07-2.01 (m, 4H), 1.77-1.72 (m, 2H), 1.47 (s, 9H), 1.01 (t, 3H, *J* = 7.5 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 197.3, 154.1, 131.4, 127.4, 113.8, 80.2, 45.0, 40.5, 31.8, 28.2, 26.6, 25.5, 24.0, 23.8, 13.1; IR (ATR) 2969, 2259, 1695, 1367, 1088 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₇H₂₇N₂O₃ 307.2022; Found: 307.2021.



Compound 95d: To a solution of LHMDS (0.439 mL, 0.571 mmol, 1.3 M THF solution) in THF (1.0 mL) was added CH₃CN (0.030 mL, 0.571 mmol) dropwise at -78 °C. After the solution was stirred at the same temperature for 0.5 h, a solution of **94d** (80.3 mg, 0.228 mmol) in THF (2.0 mL) was added dropwise via cannula. The solution was stirred for 10 min, then aq. NH₄Cl was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **95d** (59.6 mg, 0.165 mmol, 73%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.63 (d, 2H, *J* = 8.0 Hz), 7.28 (d, 2H, *J* = 8.0 Hz), 3.59 (s, 2H), 3.43 (t, 2H, *J* = 5.9 Hz), 2.94 (t, 2H, *J* = 6.7 Hz), 2.88 (t, 2H, *J* = 6.7 Hz), 2.43 (s, 3H), 2.04 (q, 2H, *J* = 7.4 Hz), 1.69 (t, 2H, *J* = 6.9 Hz), 1.31-1.26 (m, 2H), 0.95 (t, 3H, *J* = 7.4 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 197.5, 143.6, 136.5, 132.5, 129.9, 129.5, 127.2, 113.8, 46.8, 40.5, 32.0, 26.5, 26.0, 25.2, 21.5, 20.5, 13.2; IR (ATR) 2959, 2873, 2260, 1730, 1335, 1158 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₅N₂O₃S 361.1586; Found: 361.1588.



Compound 95e: To a solution of **94e** (300 mg, 0.905 mmol) in THF-H₂O (3:1, 10 mL) was added LiOH·H₂O (57.0 mg, 1.36 mmol) at room temperature. After stirring for 24 h, additional LiOH·H₂O (28.5 mg, 0.679 mmol) was added and the solution was stirred for 17 h. After addition of aq. HCl, the mixture was extracted with CHCl₃, dried over Na₂SO₄ filtered and concentrated under reduced pressure. The residue was dissolved in THF (3 ml). To the solution was added 1,1'-carbonyldiimidazole (152 mg, 0.941 mmol) at room temperature. The solution was stirred at the same temperature for 1 h. MgCl₂ (83.0 mg, 0.869 mmol) and monomethyl potassium malonate (202 mg, 1.36 mmol) were then added at room temperature. After the solution was stirred at the same temperature for 28 h, the solution was diluted with EtOAc and washed with aq. NaHSO₄ and brine. The organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **95e** (220 mg, 0.589 mmol, 65%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.36-7.31 (m, 5H), 5.14 (s, 2H), 3.71 (s, 3H), 3.47 (t, 2H, *J* = 5.7 Hz), 3.32 (brs, 2H), 2.76 (br, 2H) 2.57 (br, 2H), 2.06-2.01 (m, 4H), 1.79-1.74 (m, 2H), 0.99 (t, 3H, *J* = 7.4 Hz); ¹³C NMR (126 MHz,

CDCl₃) δ 202.1, 167.5, 154.5, 136.3, 131.6, 128.42, 128.36, 128.0, 127.7, 67.1, 52.1, 48.6, 45.0, 41.3, 26.5, 25.4, 23.9, 23.8, 13.1; IR (ATR) 2952, 2873, 1747, 1699, 1398, 1254 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₁H₂₈NO₅ 374.1967; Found: 374.1972.



Compound **95f**: To a solution of LHMDS (1.38 mL, 1.79 mmol, 1.3 M THF solution) in THF (5.0 mL) was added CH₃CN (0.095 mL, 1.79 mmol) dropwise at -78 °C. After the solution was stirred at the same temperature for 0.5 h, a solution of **94f** (313 mg, 0.715 mmol) in THF (2.0 mL) was added dropwise via cannula. The solution was stirred for 20 min, then aq. NH₄Cl was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford **95f** (173 mg, 0.387 mmol, 54%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.37-7.28 (m, 10H), 5.11 (s, 2H), 4.46 (s, 2H), 3.52 (t, 2H, *J* = 6.6 Hz), 3.48 (m, 2H), 3.03 (brs, 2H), 2.75 (t, 2H, *J* = 7.0 Hz), 2.51 (br, 2H), 2.33 (t, 2H, *J* = 6.6 Hz), 2.05 (t, 2H, *J* = 6.9 Hz), 1.78-1.73 (m, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 197.0, 154.3, 138.1, 136.1, 133.4, 128.5, 128.24, 128.16, 128.1, 127.6, 127.5, 123.0, 113.7, 72.8, 68.4, 67.2, 44.9, 40.5, 32.9, 31.3, 27.2, 23.9, 23.6; IR (ATR) 2944, 2259, 1729, 1693, 1397, 1357, 1188, 1083 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₇H₃₁N₂O₄ 447.2284; Found: 447.2282.



Compound 95g: To a solution of LHMDS (3.50 mL, 4.58 mmol, 1.3 M THF solution) in THF (15 mL) was added CH₃CN (0.244 mL, 4.58 mmol) dropwise at -78 °C. After the solution was stirred at the same temperature for 1 h, a solution of **94g** (845 mg, 1.83 mmol) in THF (6.0 mL) was added dropwise via cannula. The solution was stirred for 30 min, then aq. NH₄Cl was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford **95g** (366 mg, 0.778 mmol, 43%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 7.40-7.33 (m, 5H), 5.13 (s, 2H), 3.65 (t, 2H, *J* = 6.9 Hz), 3.48 (t, 2H, *J* = 5.4 Hz), 3.21 (s, 2H), 2.77 (t, 2H, *J* = 6.9 Hz), 2.59 (br, 2H), 2.24 (t, 2H, *J* = 6.9 Hz), 2.08 (t, 2H, *J* = 6.6 Hz), 1.79-1.74 (m, 2H), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 196.9, 154.5, 136.3, 133.2, 128.7, 128.33, 123.29, 113.6, 67.4, 61.7, 45.5, 40.6, 36.0, 31.6, 27.8, 25.9, 24.3, 23.8, 18.3, -5.4; IR (ATR) 2952, 2857, 2257, 1733, 1698, 1398, 1253, 1081 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₆H₃₉N₂O₄Si 471.2679; Found: 471.2682.



Compound 95h: To a solution of LHMDS (0.549 mL, 0.714 mmol, 1.3 M THF solution) in THF (3.0 mL) was added CH₃CN (0.038 mL, 0.714 mmol) dropwise at -78 °C. After the solution was stirred at the same temperature for 0.5 h, a solution of **94h** (119 mg, 0.286 mmol) in THF (2.0 mL) was added dropwise via cannula. The solution was stirred for 20 min, then aq. NH₄Cl was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 2:1) to afford **95h** (64.5 mg, 0.258 mmol, 90%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 5.05 (t, 1H, *J* = 3.6 Hz), 4.15 (q, 2H, *J* = 7.1 Hz), 3.54-3.56 (m, 2H), 3.52 (s, 2H), 2.82 (t, 2H, *J* = 7.2 Hz), 2.73 (t, 2H, *J* = 7.0 Hz), 2.09-2.06 (m, 2H), 1.78-1.74 (m, 2H), 1.28 (t, 3H, *J* = 7.1 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 197.1, 154.1, 137.3, 113.8, 113.7, 61.6, 44.9, 41.0, 31.8, 29.2, 22.9, 22.7, 14.4; IR (ATR) 2940, 2259, 1727, 1693, 1403, 1377, 1252, 1194 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₃H₁₉N₂O₃ 251.1396; Found: 251.1393.



Compound 95i: To a solution of **95g** (29.5 mg, 0.0827 mmol) in MeOH (1 mL) was added (-)-10camphorsulfonic acid (1.5 mg, 0.0063 mmol) at room temperature. After the solution was stirred for 30 min, Et₃N was added for quenching the reaction. The resultant mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:2) to afford **95i** (16.9 mg, 76%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.40-7.34 (m, 5H), 5.14 (s, 2H), 3.71 (t, 2H, *J* = 6.3 Hz), 3.46 (t, 2H, *J* = 5.7 Hz), 3.26 (s, 2H), 2.86 (br, 2H), 2.61 (br, 2H), 2.32 (t, 2H, *J* = 6.3 Hz), 2.09 (d, 2H, *J* = 7.0 Hz), 1.81-1.76 (m, 2H), 1.71 (br, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 197.6, 154.6, 136.2, 133.8, 128.7, 128.4, 123.1, 113.6, 67.5, 60.8, 45.1, 39.9, 35.7, 31.8, 29.7, 27.2, 24.2, 23.7; IR (ATR) 3453, 2921, 2260, 1696, 1402, 1236, 1089 cm⁻¹; HRMS (FAB) *m*/*z*: [M+H]⁺ Calcd for C₂₀H₂₅N₂O₄ 357.1814; Found: 357.1809.



Compound **43a**: To a solution of **95a** (1.07 g, 3.14 mmol) in THF (31 mL) were added 4-methylmorpholine (0.414 mL, 3.77 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (1.06 g, 3.77 mmol) at room temperature. After the solution was stirred for 30 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **43a** (944 mg, 2.58 mmol, 82%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.37-7.30 (m, 5H), 5.14 (s, 2H), 3.49 (t, 2H, *J* = 6.0 Hz), 2.87 (t, 2H, *J* = 7.5

Hz), 2.68 (t, 2H, J = 7.0 Hz), 2.08-2.00 (m, 4H), 1.77 (tt, 2H, J = 6.5, 6.0 Hz), 1.00 (t, 3H, J = 7.5 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 189.5, 154.6, 136.3, 131.2, 128.5, 128.2, 128.1, 128.0, 108.3, 67.3, 56.9, 45.1, 37.9, 26.6, 25.5, 24.5, 23.8, 13.2; IR (ATR) 3032, 2937, 2874, 2221, 2125, 1696, 1497, 1455, 1397, 1356, 1337, 1254, 1183, 1120, 1023 cm⁻¹; HRMS (ESI) *m*/*z*: [M+Na]⁺ Calcd for C₂₀H₂₂N₄O₃Na 389.1584; Found: 389.1598;



Compound 43b: To a solution of **95b** (122 mg, 0.463 mmol) in THF (4.6 mL) were added 4-methylmorpholine (0.061 mL, 0.555 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (158 mg, 0.555 mmol) at room temperature. After the solution was stirred for 15 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **43b** (106.3 mg, 0.366 mmol, 79%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 3.72 (s, 3H), 3.46 (t, 2H, *J* = 5.5 Hz), 2.90 (t, 2H, *J* = 7.5 Hz), 2.72 (t, 2H, *J* = 7.3 Hz), 2.08-2.03 (m, 4H), 1.77 (tt, 2H, *J* = 7.0, 6.0 Hz), 1.01 (t, 3H, *J* = 7.5 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 189.7, 155.2, 131.2, 128.1, 108.3, 57.0, 52.6, 45.0, 37.9, 26.5, 25.4, 24.5, 23.7, 13.2; IR (ATR) 2956, 2221, 2127, 1698, 1440, 1276, 1292, 1256, 1236, 1186, 1088 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₄H₁₈N₄O₃Na 313.1271; Found: 313.1264.



Compound 43c: To a solution of **95c** (19.4 mg, 0.0633 mmol) in THF (1 mL) were added 4-methylmorpholine (8.4 μ L, 0.076 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (1.06 g, 3.77 mmol) at room temperature. After the solution was stirred for 15 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **43c** (18.8 mg, 0.0566 mmol, 90%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 3.39 (t, 2H, *J* = 5.8 Hz), 2.89 (t, 2H, *J* = 7.3 Hz), 2.72 (t, 2H, *J* = 7.5 Hz), 2.07-2.03 (m, 4H), 1.75 (tt, 2H, *J* = 6.0, 5.8 Hz), 1.48 (s, 9H), 1.01 (t, 3H, *J* = 7.5 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 189.8, 154.2, 131.9, 127.6, 108.4, 80.4, 45.1, 37.1, 28.3, 26.8, 25.6, 24.7, 24.0 13.3; IR (ATR) 2979, 2920, 1729, 1469, 1382, 1236, 1089, 889 cm⁻¹; HRMS (ESI) *m*/*z*: [M+H]⁺ Calcd for C₁₇H₂₅N₄O₃ 333.1921; Found: 333.1910.



Compound 43d: To a solution of **95d** (15.4 mg, 0.0427 mmol) in THF (1 mL) were added 4-methylmorpholine (5.6 μ L, 0.051 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (14.6 mg, 0.0512 mmol) at room temperature. After the solution was stirred for 10 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **43d** (13.9 mg, 0.0360 mmol, 84%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, 2H, *J* = 8.5 Hz), 7.27 (d, 2H, *J* = 7.5 Hz), 3.47 (t, 2H, *J* = 6.0 Hz), 3.01 (t, 2H, *J* = 7.3 Hz), 2.88 (t, 2H, *J* = 7.8 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 189.8, 143.4, 136.9, 132.4,130.2, 129.5, 127.3, 108.4, 57.1, 46.7, 37.9, 26.5, 26.0, 25.5, 21.5, 20.8, 13.3; IR (ATR) 2962, 2930, 2873, 2222, 2127, 1673, 1592, 1455, 1336, 1301, 1184, 1159, 1088, 881, 815 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₃N₄O₃S 388.1564; Found: 388.1548.



Compound 43e: To a solution of **95e** (95.5 mg, 0.266 mmol) in THF (2.7 mL) were added 4-methylmorpholine (0.0725 mL, 0.659 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (190 mg, 0.659 mmol) at room temperature. After the solution was stirred for 75 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **43e** (104.4 mg, 0.261 mmol, 98%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.35-7.23 (m, 5H), 5.13 (s, 2H), 3.80 (s, 3H), 3.49 (t, 2H, *J* = 5.5 Hz), 2.91 (br, 2H), 2.82 (br, 2H), 2.06-2.01 (m, 4H), 1.77 (tt, 2H, *J* = 6.8, 5.5 Hz), 1.00 (t, 3H, *J* = 7.5 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 191.9, 161.5, 154.6, 136.4, 132.0, 128.3, 128.0, 127.8, 127.7, 75.4, 67.1, 52.0, 45.0, 38.7, 26.5, 25.4, 24.4, 23.9, 13.2; IR (ATR) 2960, 2929, 2134, 1702, 1655, 1437, 1398, 1318, 1253, 1192, 1088 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₂₅N₃O₅Na 422.1686; Found: 422.1690.



Compound 43f: To a solution of **95f** (23.8 mg, 0.0533 mmol) in THF (1 mL) were added 4-methylmorpholine (5.9 μ L, 0.053 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (15.2 g, 0.0533

mmol) at room temperature. After the solution was stirred for 10 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford **43f** (23.1 mg, 0.0679 mmol, 92%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.36-7.23 (m, 10H), 5.14 (s, 2H), 4.50 (s, 2H), 3.52-3.49 (m, 4H), 2.89 (br, 2H), 2.66 (br, 2H), 2.35 (t, 2H, *J* = 6.5 Hz), 2.07 (t, 2H, *J* = 6.5 Hz), 1.76 (t, 2H, *J* = 5.3 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 189.4, 154.5, 138.2, 136.2, 133.6, 128.5, 128.3, 128.2, 128.1, 127.6, 127.5, 123.3, 108.3, 72.9, 68.6, 67.4, 56.1, 45.1, 37.9, 33.1, 27.6, 24.6, 23.8; IR (ATR) 2919, 2856, 2222, 2125, 1698, 1455, 1397, 1356, 1256, 1186, 1087, 4154, 890 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₇H₂₉N4O4 473.2183; Found: 473.2190.



Compound 43g: To a solution of **95g** (37.8 mg, 0.0803 mmol) in THF (1 mL) were added 4-methylmorpholine (8.8 μ L, 0.080 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (22.9 mg, 0.0803 mmol) at room temperature. After the solution was stirred for 15 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **43g** (30.2 mg, 0.0608 mmol, 76%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.37-7.33 (m, 5H), 5.14 (s, 2H), 3.64 (t, 2H, *J* = 7 Hz), 3.50 (t, 2H, *J* = 5.5 Hz), 2.90 (br, 2H), 2.67 (br, 2H), 2.26 (t, 2H, *J* = 7.0 Hz), 2.09 (t, 2H, *J* = 6.8 Hz), 1.77 (t, 2H, *J* = 5.5 Hz), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 189.4, 154.5, 136.2, 133.3, 128.5, 128.2, 128.1, 123.4, 108.3, 67.4, 61.9, 56.9, 45.1, 37.8, 36.1, 27.9, 25.9, 24.7, 23.9, 18.3, -5.4; IR (ATR) 2948, 2928, 2860, 2222, 2126, 1701, 1466, 1397, 1357, 1254, 1186, 1089, 892 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₆H₃₆N₄O₄SiNa 519.2398; Found: 519.2386.



Compound 43h: To a solution of **95h** (25.9 mg, 0.103 mmol) in THF (1 mL) were added 4-methylmorpholine (0.011 mL, 0.10 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (29.5 mg, 0.103 mmol) at room temperature. After the solution was stirred for 10 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford **43h** (18.8 mg, 0.0680 mmol, 66%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 5.05 (t, 1H, *J* = 3.5 Hz), 4.17 (q, 2H, *J* = 4.2 Hz), 3.57 (t, 2H, *J* = 5.8 Hz), 2.90 (t, 2H, *J* = 7.0 Hz), 2.75 (t, 2H, *J* = 7.5 Hz), 2.08 (t, 2H, *J* = 1.8 Hz), 1.76 (tt, 2H, *J* = 6.5, 5.3 Hz), 1.29 (t, 3H, *J* = 7.3 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 189.6, 154.2, 137.4, 113.9, 108.4, 61.7, 57.2, 45.0, 38.2, 30.0,

23.0, 22.9, 14.5; IR (ATR) 2981, 2921, 2223, 2129, 1699, 1402, 1380, 1339, 1236, 1194, 1089, 893 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₃H₁₇N₄O₃ 277.1295; Found: 277.1285.



Compound 43i: To a solution of **95i** (25.2 mg, 0.0707 mmol) in THF (1 mL) were added 4-methylmorpholine (9.3 μ L, 0.085 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (24.2 mg, 0.0848 mmol) at room temperature. After the solution was stirred for 20 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:2) to afford **43i** (56.1 mg, 0.147 mmol, 66%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 7.39-7.34 (m, 5H), 5.17 (s, 2H), 3.71 (t, 2H, *J* = 6.0 Hz), 3.49 (t, 2H, *J* = 5.8 Hz), 2.98 (br, 2H), 2.77 (br, 2H), 2.35 (m, 3H), 2.11 (t, 2H, *J* = 6.9 Hz), 1.80 (tt, 2H, *J* = 6.9, 5.4 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 190.1, 154.6, 136.3, 134.0, 128.6, 128.2, 123.3, 108.3, 67.6, 60.9, 57.3, 45.2, 37.2, 35.8, 27.3, 24.7, 23.8; IR (ATR) 3485, 2919, 2223, 2129, 1697, 1400, 1357, 1258, 1187, 1089, 1042, 890 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₂₂N₄O₄Na 405.1533; Found: 405.1531.



Compound 44a: To a solution of **43a** (405 mg, 1.11 mmol) in CH₂Cl₂ (22 mL) was added Rh₂(esp)₂ (0.8 mg, 0.0011 mmol) at room temperature. After 15 min, the reaction was quenched with Et₃N. The solution was purified directly by silica gel column chromatography without concentration (hexane/EtOAc = 2:1, 1% Et₃N) to afford **44a** (213 mg, 0.629 mmol, 57%, mixture of rotamers) as a colorless oil; ¹H NMR (500 MHz, CDCl₃) δ 7.37 (br, 5H), 5.27-5.06 (m, 2H), 4.02-3.99 (m, 0.7H), 3.83 (t, 0.3H, *J* = 6.0 Hz), 2.99 (t, 0.3H, *J* = 10.7 Hz), 2.88-2.84 (m, 1.4H), 2.72 (t, 0.3H, *J* = 11.6 Hz), 2.39-2.33 (m, 0.7H), 2.25-2.10 (m, 1.6H), 2.05-2.00 (m, 2.7H), 1.85-1.82 (m, 1H), 1.73-1.55 (m, 2H), 1.46-1.32 (m, 1H), 1.07-1.03 (m, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 203.1, 155.5, 1351, 128.85, 128.79, 128.0, 114.4, 69.0, 61.9, 44.6, 42.0, 38.4, 29.7, 26.2, 25.8, 24.8, 22.0, 10.1; IR (ATR) 2960, 2939, 2232, 1712, 1456, 1395, 1299, 1195, 1129, 1089, 892 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₂₂N₂O₃Na 361.1523; Found: 361.1513.



Compound 44b: To a solution of **43b** (17.7 mg, 0.0610 mmol) in CH₂Cl₂ (1 mL) was added Rh₂(esp)₂ (0.5 mg, 0.0006 mmol) at room temperature. After 15 min, the reaction was quenched with Et₃N. The solution was purified directly by silica gel column chromatography without concentration (hexane/EtOAc = 2:1, 1% Et₃N) to afford **44b** (9.7 mg, 0.037 mmol, 60%, mixture of rotamers) as a yellow oil; ¹H NMR (500 MHz, CDCl₃) δ 3.97 (t, 0.5H, J = 6.5 Hz), 3.82-3.78 (m, 3.5H), 3.00 (t, 0.5H, J = 9.8 Hz), 2.87 (t, 1H, J = 9.5 Hz), 2.77-2.67 (m, 1H), 2.54-2.48 (m, 0.5H), 2.31-2.13 (m, 2H), 2.01 (t, 2H, J = 7.0 Hz), 1.86-1.80 (m, 1H), 1.79-1.60 (m, 2H), 1.47-1.38 (m, 1H), 1.07 (t, 3H, J = 7.3 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 203.3, 156.2, 53.7, 44.7, 42.1, 38.4, 29.7, 26.4, 26.2, 25.7, 24.7, 24.3, 21.9, 10.1; IR (ATR) 2979, 2920, 2232, 1716, 1469, 1381, 1236, 1089, 891, 785 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₄H₁₈N₂O₃Na 285.1210; Found: 285.1217.



Compound 44c: To a solution of **43c** (20.0 mg, 0.0602 mmol) in CH₂Cl₂ (1 mL) was added Rh₂(esp)₂ (0.5 mg, 0.0006 mmol) at room temperature. After 20 min, the reaction was quenched with Et₃N. The solution was purified directly by silica gel column chromatography without concentration (hexane/EtOAc = 3:1, 1% Et₃N) to afford **44c** (9.2 mg, 0.030 mmol, 50%, mixture of rotamers) as a yellow oil: ¹H NMR (500 MHz, C₆D₆) δ 3.92-3.89 (m, 0.75H), 3.49 (br, 0.25H), 2.61-2.56 (m, 0.25H), 2.44-2.39 (m, 0.5H), 2.28-2.22 (m, 1.5H), 2.10-2.04 (m, 0.75H), 1.65-1.15 (m, 14H), 0.95-0.92 (m, 1H), 0.87-0.67 (m, 2H), 0.58 (t, 3H, *J* = 7.2 Hz); ¹³C NMR (126 MHz, C₆D₆) δ 202.9, 154.7, 115.4, 81.8, 62.4, 44.6, 42.0, 21.8, 38.6, 30.6, 28.6, 28.4, 26.7, 26.2, 25.0, 22.4, 10.2; IR (ATR) 3370, 2968, 2938, 2877, 2232, 1706, 1457, 1368, 1301, 1254, 1159 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₇H₂₄N₂O₃Na 327.1679; Found: 327.1679.



Compound 44f: To a solution of **43f** (19.4 mg, 0.0411 mmol) in CH₂Cl₂ (1 mL) was added Rh₂(esp)₂ (0.3 mg, 0.0004 mmol) at room temperature. After 10 min, the reaction was quenched with Et₃N. The solution was purified directly by silica gel column chromatography without concentration (hexane/EtOAc = 2:1, 1% Et₃N) to afford **44f** (8.9 mg, 0.020 mmol, 49%, mixture of rotamers) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.30 (m, 10H), 5.26 (d, 0.6H, *J* = 11.6 Hz), 5.20 (s, 0.8H), 5.07 (d, 0.6H, *J* = 11.6 Hz), 4.47 (s, 2H), 3.96-3.93 (m, 0.6H), 3.78 (m, 0.4H), 3.64-3.62 (m, 1H), 3.53 (m, 1H), 2.99 (m, 0.4H), 2.86 (m, 1.2H), 2.70 (m, 0.4H), 2.35-2.23 (m, 2H), 2.15-2.06 (m, 2H), 1.95-1.89 (m, 1H), 1.85-1.82 (m, 2H), 1.68-1.65 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 202.8, 155.5, 137.5, 135.1, 128.84, 128.75, 128.5, 128.0, 127.8, 127.7, 114.3, 73.4, 69.0, 66.1, 61.2, 41.7, 41.6, 38.1, 31.6, 30.0, 26.5, 25.9, 21.8; IR (ATR) 3032, 2957, 2918, 2873, 2232, 1711, 1588, 1497, 1454, 1396, 1362, 1345, 1212, 1192, 1088, 1025, 967, 891, 740 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₇H₂₈N₂O₄Na 467.1941; Found: 467.1954.



Compound 44g: To a solution of **43g** (25.9 mg, 0.0521 mmol) in CH₂Cl₂ (1 mL) was added Rh₂(esp)₂ (0.4 mg, 0.0005 mmol) at room temperature. After 7 min, the reaction was quenched with Et₃N. The solution was purified directly by silica gel column chromatography without concentration (hexane/EtOAc = 2:1, 1% Et₃N) to afford **44g** (12.7 mg, 0.0271 mmol, 52%, mixture of rotamers) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.37 (s, 5H), 5.25 (d, 0.7H, *J* = 11.5 Hz), 5.08 (s, 0.6H), 5.07 (d, 0.7H, *J* = 11.5 Hz), 3.97-3.95 (m, 0.7H), 3.81-3.78 (m, 1.3H), 3.72 (t, 1H, *J* = 5.5 Hz), 3.03 (m, 0.3H), 2.92-2.82 (m, 1.4H), 2.70 (m, 0.3H), 2.34-1.95 (m, 5H), 1.82-1.56 (m, 4H), 0.88 (s, 9H), 0.06 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 202.9, 155.5, 135.1, 128.9, 128.8, 128.0, 114.3, 69.0, 61.2, 59.4, 41.8, 41.6, 38.1, 33.9, 29.7, 26.4, 25.94, 25.91, 21.9, 18.2, -5.5; IR (ATR) 2952, 2930, 2855, 2233, 1711, 1457, 1395, 1340, 1082, 930, 835, 782, 735 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₆H₃₇N₂O₄Si 469.2517; Found: 469.2511.



Compound 47a: To a solution of 44a (356.9 mg, 1.05 mmol) in CH₂Cl₂ (10.5 ml) was added BF₃·OEt₂ (0.125 mL, 1.05 mmol) at room temperature. After 30 min, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over MgSO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:1) to afford 47a (337 mg, 0.996 mmol, 95%, mixture of tautomers) as yellow viscous foam: ¹H NMR (500 MHz, CDCl₃) δ 7.34-7.33 (m, 5H), 6.09 (br, 0.4H), 5.76 (br, 0.6H), 5.61 (br, 0.4H), 5.14 (s, 2H), 4.36-4.24 (m, 1H), 3.65 (s, 0.6H), 3.13-2.93 (m, 2.6H), 2.81 (t, 0.4H, J = 12.3 Hz), 2.06-2.00 (m, 1H), 1.95-1.79 (m, 1.6H), 1.78-1.68 (m, 1H), 1.64-1.56 (m, 1.4H), 1.33-1.23 (m, 1H), 0.89-0.78 (m, 3H); ¹³C NMR (126 MHz, CDCl₃) & 197.8, 163.5, 154.9, 136.7, 136.6, 136.4, 136.1, 128.6, 128.5, 128.3, 128.1, 128.0, 127.9, 119.0, 117.0, 115.8, 114.1, 89.6, 67.8, 67.4, 53.7, 46.7, 46.4, 46.1, 41.6, 38.2, 29.8, 29.2, 28.3, 20.8, 8.95, 8.86; ¹H NMR (500 MHz, pyridine-d5) δ 7.51 (d, 2H, J = 7.5 Hz), 7.38 (t, 2H, J = 7.5 Hz), 7.31 (t, 1H, J = 7.0 Hz), 5.71 (br, 1H), 5.37 (d, 1H, J = 12.5 Hz), 5.33 (d, J = 13.0 Hz), 4.49 (br, 1H), 3.28 (d, 1H, J = 20.5 Hz), 3.13 (dd, 1H, J = 22.5, 4.3 Hz), 2.80 (br, 1H), 2.14 (br, 1H), 1.93 (br, 1H), 1.78 (br, 2H), 1.45 (td, 1H, J = 16.0, 6.5 Hz), 1.37 (br, 1H), 0.96 (br, 3H); ¹³C NMR (126 MHz, pyridine-d5) δ 165.5, 155.3, 138.1, 137.80, 129.3, 128.78, 128.75, 118.5, 118.4, 88.9, 67.8, 47.5, 42.4, 39.1, 31.3, 29.0, 21.6, 9.8; IR (ATR) 3233, 2920, 2871, 2208, 1695, 1659, 1458, 1409, 1348, 1278, 1235, 1089, 891 cm⁻¹; HRMS (ESI) *m/z*: [M–H]⁻ Calcd for C₂₀H₂₁N₂O₃ 337.1558; Found: 337.1553.



Compound 47b: To a solution of **44b** (9.7 mg, 0.0370 mmol) in CH₂Cl₂ (10.5 ml) was added BF₃·OEt₂ (4.6 μ L, 0.037 mmol) at room temperature. After 30 min, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over MgSO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:1) to afford **47b** (9.3 mg, 0.035 mmol, 96%, mixture of tautomers) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 6.55 (br, 0.5H), 5.77 (br, 0.5H), 5.61 (br, 0.5H), 4.30 (br, 0.5H), 4.22-4.20 (m, 0.5H), 3.72-3.67 (m, 3.5H), 3.18-3.10 (m, 1.5H), 3.02-2.96 (m, 1H), 2.80 (t, 0.5H, *J* = 11.9 Hz), 2.07-2.03 (m, 1H), 1.95-1.80 (m, 1.5H), 1.76-1.70 (m, 1H), 1.67-1.56 (m, 1.5H), 1.36-1.24 (m, 1H), 0.89-0.81 (m, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 197.8, 163.7, 155.6, 136.7, 136.6, 118.8, 117.0, 116.0, 114.1, 89.4, 53.8, 53.1, 52.8, 46.6, 46.4, 46.1, 41.6, 38.3, 29.7, 29.3, 28.3, 22.7, 20.7, 18.4, 14.1, 8.9, 8.7; IR (ATR) 3237, 2960, 2871, 2208, 1659, 1444, 1392, 1220, 1089, 896, 772 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₄H₁₉N₂O₃ 263.1390; Found: 263.1389.



Compound 47c To a solution of **44c** (2.4 mg, 0.0079 mmol) in CH₂Cl₂ (1.0 ml) was added MgBr₂·OEt₂ (2.0 mg, 0.0079 mmol) at room temperature. After 5 min, the reaction was quenched with aq. NaHCO₃, and the resultant solution was extracted with EtOAc. The organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:1) to afford **47c** (2.4 mg, 0.0079 mmol, quant. mixture of tautomers) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 5.84 (br, 0.5H), 5.63 (br, 0.5H), 5.49 (br, 0.5H), 4.24-4.21 (m, 0.5H), 4.13-4.12 (m, 0.5H), 3.57 (s, 0.5H), 3.12-2.88 (m, 2H), 2.84 (t, 0.5H, *J* = 9.8 Hz), 2.65 (t, 0.5H, *J* = 11.7 Hz), 1.99-1.85 (m, 1.5H), 1.80-1.74 (m, 1H), 1.67-1.63 (m, 1H), 1.61-1.48 (m, 1.5H), 1.37 (s, 9H), 1.28-1.18 (m, 1H), 0.82-0.77 (m, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 198.0, 154.0, 137.0, 118.6, 89.6, 53.8, 46.1, 45.8, 41.6, 38.3, 29.7, 28.3, 20.8, 9.1, 9.0; IR (ATR) 3266, 2976, 2920, 2210, 1698, 1470, 1394, 1236, 1090, 890 cm⁻¹; HRMS (ESI) *m/z*: [M–H][–] Calcd for C₁₇H₂₃N₂O₃ 303.1714; Found: 303.1720.



Compound 47d: To a solution of **43d** (31.2 mg, 0.0807 mmol) in CH₂Cl₂ (1.0 ml) was added Rh₂(esp)₂ (0.6 mg, 0.0008 mmol) at room temperature. After 25 min, the reaction was quenched with Et₃N. The solution was purified directly by silica gel column chromatography without concentration (CHCl₃/MeOH = 9:1, 1% Et₃N) to afford **47d** as a triethylammonium salt. The salt was diluted with EtOAc and washed with aq. HCl to afford **47d** (22.1 mg, 0.0617 mmol, 76%, mixture of tautomers) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, 2H, *J* =

8.1 Hz), 7.34-7.27 (m, 2H), 5.90 (t, 0.4H, J = 3.8 Hz), 5.69 (t, 0.6H, J = 3.5 Hz), 4.18-4.14 (m, 0.4H), 4.06-4.04 (m, 0.6H), 3.58 (s,0.4H), 3.12-3.03 (m, 1.8H), 2.95-2.86 (m, 1.2H), 2.44 (s, 3H), 2.09-1.49 (m, 6H), 0.73 (t, 1.8H), J = 7.2 Hz), 0.66 (t, 1.2H, J = 7.5); ¹³C NMR (100 MHz, CDCl₃) δ 197.4, 163.9, 144.0, 143.6, 137.9, 137.5, 136.4, 136.0, 129.8, 129.8, 127.2, 127.1, 117.1, 116.0, 115.2, 113.9, 88.9, 53.9, 48.4, 47.5, 45.6, 41.4, 38.6, 38.3, 37.5, 29.7, 28.3, 27.7, 21.54, 21.52, 20.9, 20.8, 8.8, 8.5; IR (ATR) 3272, 2925, 2857, 2206, 1714, 1691, 1656, 1600, 1450, 1397, 1339, 814, 752 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₃N₂O₃S 359.1424; Found: 359.1421.



Compound 47f: To a solution of **44f** (8.9 mg, 0.0190 mmol) in CH₂Cl₂ (1 ml) was added BF₃·OEt₂ (4.9 mg, 0.0190 mmol) at room temperature. After 5 min, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with EtOAc. The combined organic layers were dried over MgSO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:1) to afford **47f** (6.4 mg, 0.014 mmol, 80%, mixture of tautomers) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.35-7.23 (m, 10H), 6.40 (br, 0.5H), 5.75 (br, 0.5H), 5.57 (br, 0.5H), 5.15-5.05 (m, 2H), 4.42-4.25 (m, 2.5H), 4.12 (t, 0.5H, *J* = 7.0 Hz), 3.57 (s, 0.5H), 3.51-3.35 (m, 2H), 3.05-2.88 (m, 2.5H), 2.81 (t, 0.5H, *J* = 11.9 Hz), 2.23-2.18 (m, 0.5H), 2.14-2.05 (m, 1H), 1.99-1.58 (m, 4.5H); ¹³C NMR (126 MHz, CDCl₃) δ 195.2, 162.8, 154.8, 154.7, 138.3, 137.6, 136.7, 136.4, 136.0, 136.0, 128.6, 128.5, 128.34, 128.31, 128.28, 128.1, 128.1, 127.9, 127.8, 127.6, 127.53, 127.46, 119.1, 117.0, 115.9, 114.5, 90.0, 73.0, 71.9, 67.8, 67.5, 67.3, 65.7, 54.4, 46.7, 46.3, 43.7, 39.4, 37.7, 37.6, 34.8, 34.0, 29.7, 29.1, 20.9, 20.8; IR (ATR) 3241, 2974, 2921, 2208, 1698, 1469, 1406, 1278, 1236, 1090, 891 cm⁻¹; HRMS (ESI) *m*/*z*: [M+H]⁺ Calcd for C₂₇H₂₉N₂O4 445.2122; Found: 445.2102.



Compound 47g: To a solution of **44g** (8.9 mg, 0.019 mmol) in CH₂Cl₂ (1 ml) was added MgBr₂·OEt₂ (4.9 mg, 0.019 mmol) at room temperature. After 5 min, the reaction was quenched with aq. NaHCO₃.The resultant mixture was extracted with EtOAc. The combined organic layers were dried over MgSO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:1) to afford **47g** (8.6 mg, 0.018 mmol, quant, mixture of tautomers) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.36 (m, 5H), 5.78 (br, 0.5H), 5.61 (br, 0.5H), 5.20-5.12 (m, 2H), 4.37 (br, 0.5H), 4.24 (br, 0.5H), 3.62-3.56 (m, 2.5H), 3.13-2.93 (m, 2.5H), 2.84 (t, 0.5H, *J* = 11.9 Hz), 2.18-2.07 (m, 1.5H), 1.99-1.63 (m, 4.5H), 0.91-0.87 (m, 9H), 0.04-0.03 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 196.2, 162.5, 154.8, 136.8, 136.3, 136.0, 128.6, 128.5, 128.3, 128.1, 127.9, 127.8, 118.9, 116.8, 115.9, 114.4, 90.3, 67.8, 67.6, 59.8, 59.3,

54.0, 46.7, 46.4, 43.6, 39.3, 38.0, 37.7, 37.3, 29.7, 29.1, 26.0, 25.9, 25.8, 20.75, 20.70, 18.5, 18.2, -5.4, -5.5; IR (ATR) 3223, 2951, 2856, 2210, 1703, 1659, 1450, 1407, 1345, 1277, 1214, 1148, 1026, 836 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₆H₃₇N₂O₄Si 469.2517; Found: 469.2539.



Compound 47i: To a solution of compound **47g** (7.4 mg, 0.016 mmol) was added CSA (0.4 mg, 0.0016 mmol) at room temperature. After the solution was stirred for 20 min, satd. aq. NaHCO₃ was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:1) to afford **47i** (4.2 mg, 0.0119 mmol, 75%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 7.37-7.31 (m, 5H), 5.83 (br, 0.5H), 5.73 (br, 0.5H), 5.15 (dd, 1H, J = 12.0, 6.6 Hz), 5.08 (dd, 1H, J = 12.0, 1.2 Hz), 4.20 (1H, d, J = 12.6 Hz), 3.83 (m, 2H), 3.02-2.85 (m, 2.5H), 2.64 (dd, 0.5H, J = 3.0, 19.2 Hz), 2.56 (s, 0.5H), 2.47 (t, 0.5H, J = 16.2 Hz), 2.14-2.09 (m, 0.5H), 1.92 (br, 1H), 1.79-1.57 (m, 4H), 1.45 (d, 0.5H, J = 13.8 Hz), 1.36 (td, 0.5H, J = 13.1, 4.8 Hz), 1.25 (2H, s), 0.87 (1H, d, J = 7.2 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 155.2, 155.1, 136.2, 136.1, 133.9, 132.2, 128.62, 128.61, 128.4, 128.3, 128.04, 128.00, 121.6, 121.2, 117.8, 116.8, 94.4, 93.3, 67.8, 67.7, 62.6, 62.4, 47.3, 47.1, 46.0, 45.9, 40.7, 39.9, 36.9, 35.8, 35.7, 34.9, 32.4, 29.7, 21.2, 20.8; IR (ATR) 3393, 2923, 2242, 1698, 1402 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₂₂N₂O₄Na 377.1472; Found: 377.1455.



Compound 46a: To a solution of **43a** (370 mg, 1.01 mmol) in CH₂Cl₂ (20 mL) was added Rh₂(esp)₂ (0.8 mg, 0.010 mmol) at room temperature. After 15 min, the resulting solution was added to a suspended solution of NaBH(OAc)₃ (2.14 g, 10.1 mmol) and TFA (0.463 mL, 6.06 mmol) via canula at room temperature. After 2 h, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CHCl₃. The organic layers were dried over Mg₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **46a** along with **47a** (164.9 mg, 0.0485 mmol, 48%, **82a:81a** = 4.0:1, mixture of tautomers and rotamers) as yellow viscous foam: ¹H NMR (600 MHz, CDCl₃) δ 7.41-7.34 (m, 5H), 5.14-5.06 (m, 2H), 4.43-4.35 (m, 1H), 3.79 (d, 0.15H, *J* = 9.0 Hz), 3.42-3.37 (m, 0.6H), 3.25 (s, 0.15H), 3.13-2.57 (m, 3H), 2.48-2.26 (m, 2H), 2.16 (br, 0.3H), 2.02-1.50 (m, 6.8H), 1.05 (t, 0.9H, *J* = 8.0 Hz), 0.97 (t, 0.45H, *J* = 8.0 Hz), 0.78 (t, 1.65H, *J* = 7.5 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 199.6, 198.3, 166.1, 155.4, 155.3, 155.2, 136.7, 136.5, 136.4, 128.58, 128.56, 128.51, 128.21, 128.16, 128.1, 128.3, 127.98, 127.9, 117.2, 116.3, 114.6, 90.8, 67.1, 67.0, 66.9, 66.5, 65.0, 62.6, 53.7, 49.4, 48.93, 48.88, 48.8, 45.2, 44.9, 40.4, 38.6, 38.1, 36.0, 34.1, 31.7, 29.7, 29.0, 27.0, 26.9, 24.6, 22.4, 22.1, 21.5, 20.7, 19.0, 8.55, 8.49, 6.6; IR (ATR) 3224, 2942, 2205, 1681, 1658, 1469, 1384, 1269, 1236, 1200, 1090, 891 cm⁻¹; HRMS (ESI) *m*/*z*: [M-H]⁻ Calcd for C₂₀H₂₃N₂O₃ 339.1714; Found: 339.1703.



Compound 46b: To a solution of **43b** (25.2 mg, 0.0844 mmol) in CH₂Cl₂ (20 mL) was added Rh₂(OAc)₄ (1.9 mg, 4.3 µmol) at room temperature. After 11 min, the resulting solution was added to a suspended solution of NaBH(OAc)₃ (178 mg, 0.844 mmol) and TFA (0.039 mL, 0.516 mmol) via canula at room temperature. After 2 h, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CHCl₃. The organic layers were dried over Mg₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **46b** along with **47b** (10.3 mg, 0.0390 mmol, 64%, **46b:47b** = 7.3:1, mixture of tautomers and rotamers) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 4.40-4.21 (m, 1H), 3.78 (dd, 0.38H, *J* = 12.7, 4.0 Hz), 3.71-3.65 (m, 3.24H), 3.38 (dd, 0.38H, *J* = 12.8, 3.4 Hz), 3.3 (s, 0.38H), 3.26 (s, 0.38H), 3.08-2.98 (m, 1H), 2.92 (td, 0.38H), 2.85-2.60 (m, 1.38H), 2.50-2.27 (m, 2.24H), 2.20-2.18 (m, 0.24H), 2.10-2.00 (m, 0.76H), 1.89-1.84 (m, 1H), 1.67-1.52 (m, 3H), 1.40-1.25 (m, 1H), 1.10 (t, 1.14H, *J* = 7.7 Hz), 1.00 (t, 1.14H, *J* = 7.6 Hz), 0.81 (t, 0.72H, *J* = 7.5 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 199.6, 198.3, 166.1, 156.1, 155.9, 116.3, 115.8, 90.8, 66.4, 64.8, 62.5, 53.8, 53.7, 52.4, 52.3, 52.1, 49.4, 48.8, 48.7, 45.2, 44.9, 40.4, 38.6, 38.1, 35.9, 34.1, 31.7, 29.7, 29.0, 26.69, 26.8, 24.6, 22.3, 22.1, 21.5, 20.7, 19.0, 8.55, 8.49, 6.6; IR (ATR) 2950, 2867, 2205, 1690, 1475, 1445, 1383, 1236, 1090, 892 cm⁻¹; HRMS (ESI) *m/z*: [M–H][–] Calcd for C₁₄H₁₉N₂O₃263.1401; Found: 263.1392.



Compound 46c: To a solution of **43c** (9.5 mg, 0.0256 mmol) in CH₂Cl₂ (1.0 mL) was added Rh₂(OAc)₄ (0.6 mg, 1.4 µmol) at room temperature. After 15 min, the resulting solution was added to a suspended solution of NaBH(OAc)₃ (54.3 mg, 0.256 mmol) and TFA (0.0118 mL, 0.154 mmol) via canula at room temperature. After 2 h, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CHCl₃. The organic layers were dried over Mg₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **47c** along with a **47c** (6.8 mg, 0.022 mmol, 77%, **46c**:47**c** = 6.5:1, mixture of tautomers and rotamers) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) & 4.39-4.20 (m, 1H), 3.75 (dd, 0.25H, *J* = 12.0, 3.7 Hz), 3.38-3.35 (m, 1H), 3.26 (s, 0.25H), 3.26-3.24 (m, 0.25H), 3.02-2.83 (m, 1H), 2.79-2.59 (m, 2H), 2.47-2.26 (m, 2.75H), 2.18-2.14 (m, 0.25H), 2.05-1.25 (m, 14H), 1.10 (t, 0.75H, *J* = 7.7 Hz), 1.02 (t, 0.75H, *J* = 7.6 Hz), 0.92-0.80 (m, 1.5H); ¹³C NMR (151 MHz, CDCl₃) & 199.2, 198.6, 166.0, 155.0, 154.7, 116.4, 114.7, 91.0, 80.4, 80.2, 79.8, 66.2, 64.6, 62.3, 53.8, 49.4, 49.0, 48.9, 48.7, 45.3, 45.0, 40.6, 38.7, 38.3, 36.4, 35.7, 34.4, 31.9, 29.7, 28.9, 28.5, 28.3, 27.4, 27.3, 24.6, 22.8, 22.0, 21.4, 20.8, 19.0, 8.73, 8.69, 6.7; IR (ATR) 3257, 2932, 2853, 2205, 1730, 1680, 1657, 1469, 1367, 1256, 11665, 1089, 892 cm⁻¹; HRMS (ESI) *m/z*: [M–H]⁻ Calcd for C₁₇H₂₅N₂O₃ 305.1871; Found: 305.1862.



Compound 46f: To a solution of **43f** (25.8 mg, 0.0546 mmol) in CH₂Cl₂ (1.0 mL) was added Rh₂(esp)₂ (0.4 mg, 0.5 μ mol) at room temperature. After 5 min, the resulting solution was added to a suspended solution of NaBH(OAc)₃ (115.7 mg, 0.546 mmol) and TFA (0.025 mL, 0.328 mmol) via canula at room temperature. After 2 h, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CHCl₃. The organic layers were dried over Mg₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **46f** along with a **47f** (10.2 mg, 0.0229 mmol, 47%, **46f:47f** = 3.3:1, mixture of tautomers and rotamers) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 7.40-7.25 (m, 10H), 5.15-5.09 (m, 2H), 4.52-4.22 (m, 3H), 3.91-3.17 (m, 3H), 3.08-2.71 (m, 2H), 2.66-2.30 (m, 2H), 2.24-1.35 (m, 8H); ¹³C NMR (151 MHz, CDCl₃) δ 199.8, 197.7, 166.1, 155.3, 155.2, 154.8, 138.4, 138.1, 137.7, 136.6, 136.5, 136.4, 128.7, 128.59, 128.56, 128.52, 128.48, 128.41, 128.39, 128.33, 128.31, 128.2, 128.1, 128.03, 1247.99, 127.8, 127.73, 127.71, 127.6, 127.5, 116.4, 115.8, 114.5, 90.8, 73.2, 73.1, 72.0, 67.8, 67.5, 67.2, 67.1, 66.7, 65.6, 65.5, 65.1, 62.9, 54.0, 50.4, 48.9, 48.8, 48.7, 44.9, 44.1, 43.7, 40.3, 39.4, 38.3, 37.2, 35.25, 32.3, 31.7, 29.0, 28.0, 26.9, 26.0, 24.8, 22.5, 22.1, 21.6; IR (ATR) 3226, 2944, 2866, 2205, 1688, 1454, 1385, 1274, 1236, 1197, 1090, 891 cm⁻¹; HRMS (ESI) *m*/z: [M+Na]⁺ Calcd for C₂₇H₃₀N₂O₄Na 469.2098; Found: 469.2078.



Compound 46g: To a solution of **47g** (17.1 mg, 0.0344 mmol) in CH₂Cl₂ (1.0 mL) was added Rh₂(OAc)₄ (0.8 mg, 1.7 µmol) at room temperature. After 20 min, the resulting solution was added to a suspended solution of NaBH(OAc)₃ (72.9 mg, 0.344 mmol) and TFA (0.016 mL, 0.206 mmol) via canula at room temperature. After 2 h, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CHCl₃. The organic layers were dried over Mg₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 2:1) to afford **46g** along with **47g** (7.1 mg, 0.015 mmol, 43%, **46g**:**47g** = 3.8:1, mixture of tautomers and rotamers) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.38-7.32 (m, 5H), 5.34-5.04 (m, 2H), 4.47-4.23 (m, 1H), 3.99-3.53 (m, 2.1H), 3.37-3.33 (m, 0.9H), 2.98-2.58 (m, 2H), 2.49-2.28 (m, 2H), 2.22-1.26 (m, 8H), 0.89-0.85 (m, 9H), 0.07-0.03 (m, 6H); ¹³C NMR (151 MHz, CDCl₃) δ 199.6, 198.0, 166.1, 155.3, 155.1, 154.8, 136.8, 136.5, 136.4, 128.64, 128.56, 128.5, 128.3, 128.15, 128.12, 128.08, 128.0, 127.9, 118.9, 116.8, 116.5, 90.5, 68.8, 67.9, 67.6, 67.0, 66.7, 63.0, 59.9, 59.4, 58.6, 54.1, 54.0, 50.2, 49.1, 48.8, 46.7, 46.4, 44.8, 44.1, 43.7, 39.3, 38.3, 37.8, 35.8, 33.3, 32.3, 29.7, 29.1, 28.1, 26.9, 26.0, 25.93, 25.87, 22.2, 21.4, 20.7, 18.5, 18.2, 18.1, -5.40, -5.42, -5.6; IR (ATR) 3227, 2951, 2856, 2207, 1704, 1395, 1360, 1257, 1195, 1146, 1052, 835 cm⁻¹; HRMS (ESI) *m*/*z*: [M–H]⁻ Calcd for C₂₆H₃₇N₂O₄Si 469.2528; Found: 469.2511.



Compound 93: To a solution of **47i** (14.6 mg, 0.0382 mmol) in CH₂Cl₂ (1.0 ml) was added Rh₂(esp)₂ (1.4 mg, 0.0019 mmol) at room temperature. After the solution was stirred for 10 min, BF₃·OEt₂ (0.090 mL, 0.076 mmol) was added to the solution. The solution was stirred for 30 min. The reaction was quenched with aq. NaHCO₃. The reaction mixture was extracted with CHCl₃. The organic layers were dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 1:1) to afford **93** (8.9 mg, 0.025 mmol, 66%, mixture of tautomers) as a colorless oil: ¹H NMR (600 MHz, CDCl₃) δ 7.41-7.33 (m, 5H), 5.22-5.13 (m, 2H), 4.26-4.19 (m, 1.4H), 4.11 (td, 0.6H, *J* = 9.6, 3.7 Hz), 4.01 (td, 0.4H, *J* = 9.1, 2.7 Hz), 3.98-3.87 (m, 1.2H), 2.86-2.77 (m, 2H), 2.66-2.60 (m, 0.4H), 2.57-2.51 (m, 0.6H), 2.48-2.40 (m, 1H), 2.27-2.19 (m, 2H), 2.06 (td, 0.6H, *J* = 12.6, 6.4 Hz), 1.98-1.94 (m, 0.4H), 1.72-1.53 (m, 4H); ¹³C NMR (151 MHz, CDCl₃) δ 198.7, 166.4, 156.3, 156.1, 136.7, 136.4, 128.54, 128.46, 128.1, 127.9, 127.93, 127.84, 116.8, 114.5, 92.9, 92.5, 90.2, 67.3, 67.0, 65.0, 63.6, 54.6, 51.1, 47.5, 44.3, 43.9, 36.3, 32.4, 32.3, 31.5, 26.1, 25.9, 25.6, 23.0, 20.1, 19.7; IR (ATR) 3263, 2942, 2205, 1688, 1455, 1391, 1342, 1274, 1235, 1186, 1090, 1026, 890 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₂₃N_{2O4} 355.1652; Found: 355.1642.



Compound 96a: To a solution of **43a** (17.2 mg, 0.0469 mmol) in CH₂Cl₂ (1.0 ml) was added Cu(OTf)₂ (0.8 mg, 0.0023 mmol) at room temperature. After the solution mixture was stirred for 10 h, the reaction mixture was purified directly by column chromatography without concentration (hexane/EtOAc = 3:1) to afford **96a** (11.4 mg, 0.0320 mmol, 70%) as a colorless oil: ¹H NMR (600 MHz, C₆D₆) δ 7.25 (d, 2H, *J* = 7.7 Hz), 7.12 (t, 2H, *J* = 7.4 Hz), 7.06 (t, 1H, *J* = 7.1 Hz), 5.09 (s, 2H), 4.22 (s, 1H), 2.91-2.87 (m, 2H), 2.32 (s, 2H), 2.22 (t, 2H, *J* = 5.2 Hz), 2.04 (br, 1H), 1.46-1.35 (m, 3H), 1.18-1.07 (m, 3H), 0.71 (t, 3H, *J* = 7.4 Hz); ¹³C NMR (151MHz, C₆D₆) δ 211.1, 198.4, 175.0, 138.2, 129.2, 129.0, 128.9, 109.0, 67.2, 53.3, 41.6, 36.7, 33.2, 30.8, 28.8, 28.3, 25.5, 12.3; IR (ATR) 3362, 2966, 2921, 2223, 2129, 1708, 1527, 1468, 1384, 1236, 1089, 891 cm⁻¹; HRMS (ESI) *m*/*z*: [M+Na]⁺ Calcd for C₂₀H₂₄N₂O₄Na 379.1628; Found: 379.1615.



Compound 97a: To a solution of **46a** (5.2 mg, 0.015 mmol) in THF (1.0 ml) were added Et_3N (0.045 mL, 0.061 mmol) and TBSOTf (0.011 mL, 0.046 mmol) at room temperature. After 5 min, the reaction was quenched with aq. NaHCO₃, and the resultant solution was extracted with EtOAc. The organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford **97a** (3.8 mg, 0.0084 mmol, 55%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.36-7.32 (m, 5H), 5.09 (s, 2H), 4.36 (d, 1H, *J* = 10.3 Hz), 3.01 (d, 1H, *J* = 12.9 Hz), 2.76-2.66 (m, 2H), 2.31 (d, 1H, *J* = 13.5 Hz), 2.26 (m, 2H), 2.16 (d, 1H, *J* = 13.7 Hz), 1.75-1.50 (m, 4H), 1.32-1.25 (m, 1H), 0.99-0.98 (m, 12H), 0.24-0.23 (m, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 164.6, 155.3, 136.7, 128.5, 128.02, 127.98, 117.6, 98.9, 66.8, 65.0, 48.8, 39.1, 34.2, 31.8, 25.5, 24.8, 23.0, 21.5, 18.2, 8.8, -3.7; IR (ATR) 2925, 2860, 2209, 1704, 1618, 1471, 1382 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₆H₃₉N₂O₃Si 455.2724; Found: 455.2703.



Compound 97b: To a solution of **46b** (10.3 mg, 0.0390 mmol) in THF (1.0 mL) were added Et₃N (0.011 mL, 0.078 mmol) and TBSOTf (0.0134 mL, 0.0584 mmol) at room temperature. After 40 min, the reaction was quenched with aq. NaHCO₃, and the resultant solution was extracted with EtOAc. The organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **97b** (10.7 mg, 0.0283 mmol, 72%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 4.32-4.29 (m, 1H), 3.65 (s, 3H), 3.01-2.98 (m, 1H), 2.79-2.65 (m, 2H), 2.32-2.27 (m, 3H), 2.17-2.13 (m, 1H), 1.75-1.51 (m, 4H), 1.32-1.25 (m, 1H), 1.03-0.99 (m, 12H), 0.28-0.23 (m, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 164.6, 156.0, 117.6, 98.9, 64.8, 52.1, 48.6, 39.1, 34.2, 31.8, 25.5, 24.7, 22.9, 21.4, 18.1, 8.7, -3.7; IR (ATR) 2931, 2860, 2209, 1707, 1619, 1472, 1443, 1373, 1263, 1235, 1200, 1151, 1089, 890, 864, 843 cm⁻¹; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₃₅N₂O₃Si 379.2411; Found: 379.2398.



Compound 97c: To a solution of **46c** (6.8 mg, 0.022 mmol) in THF (1.0 mL) were added Et₃N (0.062 mL, 0.044 mmol) and TBSOTf (0.077 mL, 0.033 mmol) at room temperature. After 10 min, the reaction was quenched with aq. NaHCO₃, and the resultant solution was extracted with EtOAc. The organic layers were washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **97c** (2.9 mg, 0.0069 mmol, 31%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 4.29 (d, 1H, *J* = 12.9 Hz), 2.97 (d, 1H, *J* = 10.6 Hz), 2.68-2.63 (m, 2H), 2.31-2.25 (m, 3H), 2.12 (d, 1H, *J* = 13.5 Hz), 1.67-1.45 (m, 13H), 1.31-1.25 (m, 1H), 1.05-0.98 (m, 12H), 0.25-0.24 (m, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 164.6, 154.9, 117.6, 99.1, 79.7, 64.6, 48.7, 39.2, 34.7, 32.1, 28.5, 25.5, 24.7, 23.4, 21.4, 18.4, 9.0, -3.7; IR (ATR) 2934, 2859, 1685, 1619, 1457, 1370, 1255, 1150, 839, 7875 cm⁻¹; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₄₀N₂O₃SiNa 443.2700; Found: 443.2702.

2. Details for DFT calculation

All of optimization was performed at ω B97XD/6-311G(d,p) level using Gaussian09 software package.⁷³

Compound 47a



 $E(R\omega B97XD) = -1110.48235868$

Zero-point correction=	0.392474 (Hartree/Particle)
Thermal correction to Energy=	0.414373
Thermal correction to Enthalpy=	0.415317
Thermal correction to Gibbs Free Energy=	0.341538
Sum of electronic and zero-point Energies=	-1110.089884
Sum of electronic and thermal Energies=	-1110.067986
Sum of electronic and thermal Enthalpies=	-1110.067042
Sum of electronic and thermal Free Energies=	-1110.140821

The coordinates of the structure

01			
Ν	0.42395100	2.13232900	0.32749500
С	1.25582700	1.02389500	0.66640600
С	1.53960700	0.75246100	1.93453200
Н	1.15195400	1.41273400	2.70232500
С	1.71896600	0.20050900	-0.52576100
С	2.27261600	-0.46948000	2.39234200
Н	1.65845100	-1.05832700	3.07977000
Н	3.17202000	-0.19356800	2.95899300
С	2.71403800	-1.39405100	1.28009700
0	2.96021800	-2.55378100	1.46118500
С	2.90695700	-0.70143000	-0.07328200
Н	3.76038100	-0.02914500	0.09414800
С	3.29953800	-1.64687800	-1.11326000
Ν	3.58903600	-2.35970400	-1.96668600
С	2.25362000	1.14956300	-1.62895700

Н	2.47172100	0.56298100	-2.52594700
Н	3.20544500	1.57694200	-1.28890300
С	0.96311500	3.05642900	-0.66982500
Н	0.21918200	3.83088900	-0.84028800
Н	1.86163400	3.52033300	-0.24846500
С	1.30537100	2.30287900	-1.94805200
Н	0.38346000	1.94006200	-2.41161800
Н	1.77819100	2.98102900	-2.66350100
С	-0.93315800	2.13217500	0.52793200
0	-1.69162200	2.92581400	0.01823300
0	-1.31655200	1.15137100	1.36343900
С	-2.73171100	0.91497900	1.46866200
Н	-3.26040100	1.84863300	1.27586200
Н	-2.89162100	0.60901400	2.50212800
С	-3.15145700	-0.17058200	0.51404700
С	-3.82400400	-2.20737400	-1.27265400
С	-3.44351900	-1.44917900	0.97849200
С	-3.20877700	0.08427900	-0.85717900
С	-3.53580400	-0.93081000	-1.74532400
С	-3.78376800	-2.46395300	0.09155200
Н	-3.39757900	-1.65640500	2.04298700
Н	-2.99418000	1.08385500	-1.22014900
Н	-3.57426200	-0.72485200	-2.80899400
Н	-4.00848300	-3.45618700	0.46558500
Н	-4.08226900	-2.99857900	-1.96718200
С	0.53441400	-0.62794700	-1.08061700
Н	0.85301400	-1.08484900	-2.02321500
Н	-0.27237300	0.06504500	-1.33453400
С	-0.02005000	-1.70372800	-0.15338300
Н	0.68405400	-2.52682900	-0.01368900
Н	-0.93366100	-2.12128500	-0.58082400
Н	-0.28285900	-1.28762700	0.82238300

Compound 98 (a -CN)



$E(R\omega B97XD) = -1185.71219127$

Zero-point correction=	0.399972 (Hartree/Particle)
Thermal correction to Energy=	0.421749
Thermal correction to Enthalpy=	0.422693
Thermal correction to Gibbs Free Energy=	0.348772
Sum of electronic and zero-point Energies=	-1185.312219
Sum of electronic and thermal Energies=	-1185.290442
Sum of electronic and thermal Enthalpies=	-1185.289498
Sum of electronic and thermal Free Energies=	-1185.363419

The coordinates of the structure

01			
Ν	0.05802300	1.50290900	-0.33170900
С	0.81716000	2.45598500	-1.14784400
Н	1.42805300	3.09155600	-0.49008100
Н	0.08911500	3.09668200	-1.63920200
С	1.71643300	1.77002500	-2.15806000
Н	1.10871200	1.30006300	-2.93554400
Н	2.33346400	2.52409100	-2.65304600
С	2.60598400	0.74376700	-1.46939000
Н	3.32706300	1.26205700	-0.82462400
Н	3.19490700	0.18568300	-2.20169100
С	1.78806600	-0.23133800	-0.62287300
С	0.81144600	0.44980900	0.39117200
С	0.79736600	-1.10188000	-1.41785700
Н	1.27802800	-2.00236100	-1.80437500
Н	0.39172600	-0.55309700	-2.26598600
С	-0.31073400	-1.40371100	-0.39462400
Н	-0.33320900	-2.44594800	-0.07196200
Н	-1.30264200	-1.14087600	-0.77227800

0	-0.01078300	-0.61813900	0.76193500
С	2.73030300	-1.18465700	0.18791300
Н	2.10454100	-1.96911200	0.62763700
С	3.40328900	-0.46977300	1.36740600
0	4.59298300	-0.34237000	1.46247300
С	2.40154400	0.07002900	2.35577100
Н	2.93666400	0.56076600	3.16858600
Н	1.82394600	-0.76597200	2.76217400
С	1.45230100	1.03797100	1.64563600
Н	0.64517700	1.34409200	2.31230200
Н	2.00371200	1.93827500	1.35943000
С	-1.21543400	1.89804300	0.00884100
0	-1.88579200	2.65319800	-0.65788300
0	-1.62894200	1.37025500	1.17173100
С	-3.05146100	1.25184700	1.33762000
Н	-3.19749400	1.17178900	2.41389400
Н	-3.53664500	2.15446600	0.96551500
С	-3.53478400	0.01853400	0.62317900
С	-4.24136600	-2.29953200	-0.76042300
С	-3.46091600	-1.22568700	1.24628700
С	-3.96790600	0.09285400	-0.69964200
С	-4.31911500	-1.06242600	-1.38875900
С	-3.81418000	-2.37970100	0.56081700
Н	-3.10955500	-1.28874700	2.27080800
Н	-4.00810900	1.05874500	-1.19070500
Н	-4.65468900	-0.99553400	-2.41744600
Н	-3.75504000	-3.34274200	1.05526500
Н	-4.51699500	-3.20004100	-1.29758400
С	3.69771600	-1.83926000	-0.68569500
Ν	4.42415800	-2.36473600	-1.40457600

Compound 98 (β -CN)



 $E(R\omega B97XD) = -1185.71046486$

Zero-point correction=	0.400342 (Hartree/Particle)
Thermal correction to Energy=	0.421900
Thermal correction to Enthalpy=	0.422844
Thermal correction to Gibbs Free Energy=	0.349779
Sum of electronic and zero-point Energies=	-1185.310122
Sum of electronic and thermal Energies=	-1185.288565
Sum of electronic and thermal Enthalpies=	-1185.287620
Sum of electronic and thermal Free Energies=	-1185.360686

The coordinations of the structure

01			
Ν	0.21466500	-1.59978400	0.05537500
С	0.94650800	-2.71252700	0.66386300
Н	1.64960300	-3.13346700	-0.07022000
Н	0.21321600	-3.48114500	0.89542300
С	1.70968000	-2.28962200	1.90324300
Н	1.00544600	-2.03955800	2.70091500
Н	2.30800300	-3.13192500	2.25994200
С	2.61512500	-1.10894800	1.58315000
Н	3.41861700	-1.44128100	0.91399000
Н	3.10298100	-0.73697200	2.48976000
С	1.85135500	0.04214700	0.92164400
С	0.97248200	-0.37535500	-0.30775800
С	0.78378100	0.68616900	1.82862400
Н	1.19666800	1.51378600	2.40841200
Н	0.38370800	-0.04362800	2.53089200
С	-0.30745000	1.14526500	0.84455900
Н	-0.42504700	2.22681200	0.80184700
Н	-1.27656800	0.69006100	1.06905500
0	0.13326400	0.72884700	-0.44848700
С	2.91262100	1.11151300	0.48533700
С	3.62207400	0.70537100	-0.82212500
0	4.80265800	0.48496500	-0.84340200
С	2.68581200	0.52547300	-1.98351100
Н	3.26128000	0.28516600	-2.87713900
Н	2.12501700	1.44974500	-2.14824700
С	1.71099300	-0.60142400	-1.62617300
Н	0.95492600	-0.71528500	-2.40356800

Н	2.26068300	-1.54502000	-1.55788200
С	-1.01348600	-1.92045600	-0.47833600
0	-1.70001300	-2.83466900	-0.08178700
0	-1.35830300	-1.12304100	-1.50041700
С	-2.76757700	-0.99482900	-1.75283800
Н	-2.83057500	-0.64021800	-2.78067500
Н	-3.24167900	-1.97307800	-1.67005200
С	-3.35722800	-0.00068300	-0.78939500
С	-4.26426700	1.85783400	1.08292900
С	-3.24316700	1.36567900	-1.03906800
С	-3.93105400	-0.42941100	0.40598200
С	-4.38317100	0.49723600	1.33880100
С	-3.69519900	2.29179800	-0.10983900
Н	-2.77853600	1.70305500	-1.95943900
Н	-4.00135800	-1.49212200	0.60955800
Н	-4.82792700	0.15541300	2.26657000
Н	-3.59896200	3.35240400	-0.31228200
Н	-4.61624300	2.58041900	1.81057600
Н	3.68161600	1.15990300	1.26107500
С	2.38716500	2.46646800	0.33097300
Ν	2.01452000	3.54806000	0.21232100

Compound 47h (α -CN)



$E(R\omega B97XD) = -1185.71058861$

Zero-point correction=	0.400650 (Hartree/Particle)
Thermal correction to Energy=	0.422043
Thermal correction to Enthalpy=	0.422987
Thermal correction to Gibbs Free Energy=	0.350419
Sum of electronic and zero-point Energies=	-1185.309939
Sum of electronic and thermal Energies=	-1185.288546

Sum of electronic and thermal Enthalpies=	-1185.287601
Sum of electronic and thermal Free Energies=	-1185.360169

The coordinates of the structure

01			
Ν	0.11904800	2.22560800	-0.38212400
С	-0.10387800	3.17397700	0.70951200
Н	-0.98893600	3.77056200	0.46579300
Н	0.75869200	3.83357400	0.76035000
С	-0.31481400	2.40477000	2.00692100
Н	0.59937400	1.84944800	2.24175800
Н	-0.49317800	3.09821700	2.83301900
С	-1.50679600	1.46370900	1.85426800
Н	-2.41292700	2.07363500	1.74700600
Н	-1.64422000	0.85492800	2.75238600
С	-1.40590300	0.53304900	0.63012000
С	-0.45574500	-0.65931700	0.87867200
Н	-0.76326500	-1.17159200	1.79587200
Н	0.57324200	-0.31716500	1.02270300
С	-0.48361800	-1.63101500	-0.29532900
Н	0.01311900	-2.56273400	-0.02867800
Н	0.04360700	-1.19984500	-1.15266600
0	-1.80541100	-2.00235200	-0.67352100
С	-2.80525200	-0.04138200	0.30562100
Н	-3.49031400	0.77896900	0.07000900
С	-2.32684200	-0.09380200	-2.14664900
Н	-3.25029200	0.31022300	-2.57232700
Н	-1.90117800	-0.75959600	-2.90420900
С	1.42456700	1.97888300	-0.72463800
0	2.36274500	2.62642300	-0.31790200
0	1.54560100	0.93500100	-1.56687400
С	2.87035300	0.38424900	-1.68913100
Н	2.88432500	-0.08822000	-2.67053500
Н	3.59916800	1.19390500	-1.65912100
С	3.10381700	-0.62391500	-0.59494300
С	3.35381600	-2.47576300	1.48044700
С	2.86274400	-1.97649700	-0.82117300
С	3.49027700	-0.20713800	0.68042100
С	3.60971400	-1.12867200	1.71249600

С	2.98744600	-2.90031700	0.20936500
Н	2.56447800	-2.30915700	-1.81052700
Н	3.68177400	0.84502700	0.85757100
Н	3.90735200	-0.79531000	2.70020300
Н	2.79594900	-3.95051900	0.02026000
Н	3.44738900	-3.19396500	2.28699400
С	-2.70899700	-0.95504500	-0.94103800
0	-3.92189000	-1.55764200	-1.23861900
Н	-4.04965000	-2.26871400	-0.60345900
С	-1.36586600	1.01298800	-1.83105100
Н	-0.95502800	1.57049700	-2.66565700
С	-0.92744700	1.28424300	-0.60685100
С	-3.37355800	-0.78396600	1.42776900
Ν	-3.82075500	-1.38672900	2.29922900

Compound 47h (β -CN)



$E(R\omega B97XD) = -1185.70700004$

Zero-point correction=	0.400257 (Hartree/Particle)
Thermal correction to Energy=	0.421830
Thermal correction to Enthalpy=	0.422774
Thermal correction to Gibbs Free Energy=	0.349892
Sum of electronic and zero-point Energies=	-1185.306743
Sum of electronic and thermal Energies=	-1185.285170
Sum of electronic and thermal Enthalpies=	-1185.284226
Sum of electronic and thermal Free Energies=	-1185.357108

The coordinations of the structure

0 1			
Ν	-0.23908700	1.97917500	-0.61087200
С	-0.54636000	3.04565900	0.34327700

Н	-1.55403600	3.41316100	0.12709000
Н	0.16464800	3.85241500	0.18435800
С	-0.46983000	2.48344400	1.75697700
Н	0.55291000	2.13992300	1.94592700
Н	-0.68900900	3.26620200	2.48793300
С	-1.47875200	1.34632500	1.90224500
Н	-2.48220600	1.78081300	1.84463000
Н	-1.39541600	0.87018900	2.88453900
С	-1.34635200	0.25972000	0.81663600
С	-0.18050400	-0.70670400	1.13225700
Н	-0.31752300	-1.10341000	2.14400300
Н	0.77663900	-0.17698800	1.11382800
С	-0.12541900	-1.85308400	0.13340900
Н	0.55838000	-2.62769300	0.47852200
Н	0.23307700	-1.49402300	-0.83692500
0	-1.38780700	-2.49378900	-0.00525800
С	-2.63630400	-0.59908200	0.77714800
С	-2.35556300	-0.99164100	-1.69439100
Н	-3.36583900	-0.80164300	-2.06936100
Н	-1.88831300	-1.70729800	-2.38102600
С	1.05869200	1.90096500	-1.04452500
0	1.89186100	2.75587500	-0.84316300
0	1.30737100	0.76255000	-1.72282000
С	2.69765500	0.43198200	-1.89015000
Н	2.72961500	-0.19234200	-2.78230500
Н	3.26597900	1.34643000	-2.05910100
С	3.18896700	-0.31972400	-0.68081400
С	3.92079300	-1.71841300	1.62332200
С	3.18463300	-1.71208300	-0.66718500
С	3.58127200	0.36900100	0.46869200
С	3.94049000	-0.32784800	1.61503100
С	3.54953600	-2.41066000	0.47738100
Н	2.88420800	-2.25509600	-1.55790600
Н	3.58785200	1.45295200	0.45854300
Н	4.24130500	0.21590900	2.50337600
Н	3.54247100	-3.49483800	0.47457500
Н	4.20284400	-2.26108000	2.51839300
С	-2.48772400	-1.66761900	-0.31832700
0	-3.60653000	-2.48826600	-0.25808500

Н	-3.42220800	-3.25842300	-0.80088300
С	-1.57280600	0.28832000	-1.67817600
Н	-1.33581700	0.74339700	-2.63329200
С	-1.10723300	0.84995600	-0.56893200
С	-3.83599500	0.20781200	0.56095000
Ν	-4.76805400	0.85973100	0.39286400
Н	-2.75392300	-1.12982700	1.72678700

第二章 Lyconesidine B の全合成

1. Experimental Procedure



Compound 133: To a solution of Compound **131**⁵¹ (21.4 g, 64.5 mmol) in THF (600 mL) were added a solution of (*E*)-ethyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate, prepared from ethyl propiolate (104 mmol) and bis(pinacolato)diboron (104 mmol) by following Yun's procedure⁵² in THF (90 mL), 2-(di-*tert*-butylphosphino)biphenyl (1.92 g, 6.45 mmol), KF (11.2 g, 193.5 mmol) and Pd(OAc)₂ (726 mg, 3.23mmol) at room temperature. After stirring for 40 h at 55 °C (oil bath), the reaction mixture was diluted with Et2O. The resultant mixture was washed with water and brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (hexane/EtOAc = 8:1) to give **133** (17.4 g, 61.8 mmol, 96%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 7.20 (1H, d, *J* = 15.1 Hz), 5.91 (1H, d, *J* = 15.8 Hz), 5.63 (1H, t, *J* = 3.8 Hz), 4.20 (2H, q, *J* = 7.1 Hz), 3.56-3.55 (2H, m), 2.25 (2H, td, *J* = 6.9, 4.1 Hz), 1.82-1.79 (2H, m), 1.44 (9H, s), 1.29 (3H, t, *J* = 6.9 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 167.1, 153.7, 143.7, 137.0, 120.9, 116.1, 81.3, 60.2, 44.0, 28.2, 23.8, 22.9, 14.3; IR (ATR) 2979, 1698, 1636, 1364 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₄NO₄ 282.1705; Found 282.1704.



a suspension of $Cu(OAc)_2 \cdot H_2O$ (31.7 mg, 0.159 Compound 134: To mmol) and 1.2bis(diphenylphosphino)benzene (BDP) (80.2 mg, 0.180 mmol) in toluene (20 mL) was added t-BuOH (1.03 mL, 10.8 mmol). After stirring at room temperature for 20 min, poly(methylhydrosiloxane) (PMHS) (9.5 mL, 124 mmol) was added and stirred for 5 min at the same temperature. To the reaction mixture was added a solution of 133 (1.02 g, 3.61 mmol) in toluene (16 mL). After stirring at room temperature for 15 h, the reaction was quenched by addition of water. The resultant mixture was extracted with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford 134 (831 mg, 2.93 mmol, 81%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 4.93 (1H, s), 4.04 (2H, q, J = 7.2 Hz), 3.42 (2H, t, *J* = 5.3 Hz), 2.72 (2H, t, *J* = 7.6 Hz), 2.32 (2H, t, *J* = 7.6 Hz), 1.98 (2H, m), 1.69-1.64 (2H, m), 1.41 (9H, s), 1.17 (3H, t, *J* = 7.0 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 173.0, 153.3, 138.2, 112.9, 80.4, 60.0, 44.7, 32.8, 30.9, 28.1, 23.1, 22.9, 14.1; IR (ATR) 2978, 2924, 1737, 1698, 1367 cm⁻¹; HRMS (FAB) m/z: [M+Na]⁺ Calcd for C₁₅H₂₅NO₄Na 306.1681; Found 306.1687.



Compound 135: To a solution of **134** (12.6 g, 44.5 mmol) in DMF (440 mL) was added (chloromethylene)dimethyliminium chloride (8.78 g, 68.6 mmol) at 0 °C. After stirring at room temperature for 6.5 h, a solution of NaOAc (20.5 g, 250 mmol) in water (200 mL) was added at 0 °C and stirred for 10 min at 0 °C. The reaction mixture was diluted with water and extracted with Et₂O. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 8:1) to afford **135** (10.7 g, 34.4 mmol, 77%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 10.04 (1H, s), 4.10 (2H, q, *J* = 7.1 Hz), 3.52 (2H, t, *J* = 5.6 Hz), 3.40 (2H, t, *J* = 7.6 Hz), 2.57 (2H, t, *J* = 7.6 Hz), 2.24 (2H, t, *J* = 6.7 Hz), 1.77-1.72 (2H, m), 1.49 (9H, s), 1.22 (3H, t, *J* = 7.2 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 189.8, 172.1, 156.5, 152.5, 123.4, 82.6, 60.6, 45.8, 34.2, 28.0, 24.0, 22.1, 20.8, 14.2; IR (ATR) 2979, 2938, 1733, 1710, 1657, 1601 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₆H₂₆NO₅ 312.1811; Found 312.1818.



Compound 136: To a solution of 135 (11.9 g, 37.9 mmol) in MeOH (150 mL) was added NaBH₄ (1.47 g, 38.9 mmol) at 0 °C. After stirring at 0 °C for 10 min, the reaction was quenched by addition of aq. NH4Cl. The resultant mixture was extracted with CHCl₃. The organic layer was dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. To a solution of the resultant residue in DMF (80 mL) were added imidazole (3.64 g, 53.5 mmol) and TBSCl (6.95 g, 46.1 mmol) at room temperature. After stirring at room temperature for 1 h, additional imidazole (1.43 g, 21.0 mmol) and TBSCl (2.45 g, 16.3 mmol) were added to the reaction mixture. After stirring for 14 h at room temperature, additional imidazole (1.21 g, 17.8 mmol) and TBSCI (2.34 g, 15.5 mmol) were added to the reaction mixture and stirred for 20 min and additional imidazole (1.01 g, 14.8 mmol) and TBSCl (2.38 g, 15.8 mmol) were added. After stirring for 1 h, the reaction was quenched by addition of water. The resultant mixture was extracted with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 20:1) to afford 136 (14.9 g, 34.8 mmol, 92% in 2 steps) as a colorless oil: ¹H NMR (600 MHz, CDCl₃) δ 4.18 (2H, s), 4.11 (2H, q, *J* = 7.1 Hz), 3.42 (2H, t, J = 5.5 Hz), 2.86 (2H, t, J = 7.9 Hz), 2.41 (2H, t, J = 7.6 Hz), 2.16 (2H, t, J = 6.9 Hz), 1.78-1.75 (2H, m), 1.48 (9H, s), 1.24 (3H, t, *J* = 7.2 Hz), 0.90 (9H, s), 0.07 (6H, s); ¹³C NMR (151 MHz, CDCl₃) δ 173.3, 154.1, 135.0, 124.8, 80.5, 62.8, 60.2, 44.9, 33.0, 28.3, 25.9, 25.6, 25.5, 23.7, 18.3, 14.2, -5.3; IR (ATR) 2933, 2858, 1736, 1699, 1657 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₄₂NO₅Si 428.2832; Found 428.2834.



Compound S1: To a solution of diisopropyamine (12.4 mL, 88.2 mmol) in THF (170 mL) was added *n*BuLi (1.3 M hexane solution) (55.0 mL, 88.0 mmol), dropwise at -78 °C. After stirring at -78 °C for 40 min, CH₃CN (4.70 mL, 89.3 mmol) was added dropwise at -78 °C. After stirring at the same temperature for 1 h, a solution of **136** (16.5 g, 35.2 mmol) in THF (120 mL) was added dropwise via cannula. The solution was stirred for 30 min, then aq. NH₄Cl was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The combined organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **S1** (13.3 g, 31.5 mmol, 89%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 4.14 (2H, s), 3.49 (2H, s), 3.41-3.39 (2H, m), 2.87 (2H, t, *J* = 7.2 Hz), 2.76 (2H, t, *J* = 7.4 Hz), 2.15 (2H, t, *J* = 6.9 Hz), 1.79-1.74 (2H, m), 1.47 (9H, s), 0.90 (9H, s), 0.08 (6H, s); ¹³C NMR (126 MHz, CDCl₃) δ 197.2, 154.0, 134.5, 124.9, 113.7, 80.6, 62.8, 45.1, 41.1, 31.7, 28.3, 25.9, 25.6, 24.3, 23.5, 18.3, -5.3; IR (ATR) 2932, 2858, 2259, 1732, 1693 cm⁻¹; HRMS (FAB) *m/z*: [M+Na]⁺ Calcd for C₂₂H₃₈N₂O₄SiNa 445.2499; Found 445.2495.



Compound 48: To a solution of **S1** (6.93 g, 16.4 mmol) in THF (160 mL) were added 4-methylmorpholine (1.96 mL, 18.0 mmol) and 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (ADMP)³³ (5.15 g, 18.1 mmol) at 0 °C then allowed to warm to room temperature. After stirring for 15 min, water was added for quenching the reaction. The resultant mixture was extracted with Et₂O. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 9:1) to afford **48** (6.84 g, 15.2 mmol, 93%) as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 4.16 (2H, s), 3.42 (2H, t, *J* = 5.4 Hz), 2.93 (2H, t, *J* = 7.4 Hz), 2.77 (2H, t, *J* = 7.4 Hz), 2.16 (2H, t, *J* = 6.9 Hz), 1.79-1.74 (2H, m), 1.48 (9H, s), 0.90 (9H, s), 0.08 (6H, s); ¹³C NMR (126 MHz, CDCl₃) δ 189.6, 154.0, 134.4, 125.1, 108.3, 80.7, 62.7, 57.0, 45.1, 38.2, 28.3, 25.9, 25.6, 24.8, 23.6, 18.3, -5.3; IR (ATR) 2932, 2858, 2223, 2127, 1670cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₃₇N₄O₄Si 449.2584; Found 449.2589.



Compound 49: To a solution of **48** (1.29 g, 2.88 mmol) in CH_2Cl_2 (144 mL) was added $Rh_2(NHCO'Bu)_4^4$ (7.2 mg, 0.0117 mmol) at room temperature. After 10 min, the reaction solution was cooled to -78 °C then NaBH(O₂CCF₃)₃ (6 mL, 3.02 mmol, 0.5 M THF solution), which was prepared from NaBH₄ (114 mg, 3.01 mmol)

and TFA (0.960 mL, 9.02 mmol),⁵ was added dropwise at -78 °C then warmed to room temperature. After 30 min, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CHCl₃. The organic layer was dried over MgSO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 8:1) to afford **49** (876 mg, 2.07 mmol, 72%) as a yellow oil. Epimers on C7 and an enol isomer were observed in CDCl₃. ¹H and ¹³C spectra are described about a major isomer: ¹H NMR (600 MHz, CDCl₃) δ 4.35 (1H, d, *J* = 15.1 Hz), 4.08 (1H, d, *J* = 10.3 Hz), 3.65 (1H, dd, *J* = 10.3, 1.4 Hz), 3.48-3.41 (1H, m), 3.37 (1H, d, *J* = 13.1 Hz), 3.13 (1H, s), 2.71-2.66 (1H, m), 2.63-2.61 (1H, m), 2.30-2.23 (2H, m), 2.14-2.12 (1H, m), 1.56-1.53 (1H, m), 1.48-1.46 (11H, m), 0.90 (9H, s), 0.10 (6H, s); ¹³C NMR (151 MHz, CDCl₃) δ 196.3, 154.3, 114.5, 80.1, 64.4, 64.1, 52.7, 49.0, 46.5, 40.1, 37.7, 28.4, 26.9, 25.8, 22.3, 18.4, -5.9, -6.1; IR (ATR) 2931, 2859, 2208, 2129, 1732, 1701 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₃₉N₂O4Si 423.2679; Found 423.2676.



Compound 139: To a solution of **49** (14.3 g, 33.9 mmol) in acetone (340 mL) were added Cs₂CO₃ (16.5 g, 50.7 mmol) and allyl bromide (4.90 mL, 57.5 mmol) at room temperature. After 7 h, the reaction mixture was filtered through celite with EtOAc and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 8:1) to afford **139** (13.5 g, 29.2 mmol, 86%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 5.97-5.91 (1H, m), 5.40 (1H, dd, *J* = 17.2, 1.4 Hz), 5.26 (1H, dd, *J* = 10.3, 1.4 Hz), 4.58-4.50 (2H, m), 4.27 (1H, dd, *J* = 13.4, 4.5 Hz), 3.79 (1H, d, *J* = 9.6 Hz), 3.65 (1H, d, *J* = 10.3 Hz), 3.00 (1H, dd, *J* = 13.1, 2.8 Hz), 2.80-2.76 (1H, m), 2.67 (1H, td, *J* = 13.3, 3.0 Hz), 2.51-2.47 (1H, m), 2.43 (1H, d, *J* = 13.8 Hz), 2.34-2.30 (1H, m), 2.15-2.13 (1H, m), 1.67-1.43 (11H, m), 1.29 (1H, td, *J* = 13.6, 4.6 Hz), 0.91 (9H, s), 0.07 (3H, s), 0.06 (3H, s); ¹³C NMR (151 MHz, CDCl₃) δ 166.6, 154.7, 132.7, 117.9, 116.6, 95.0, 79.8, 68.7, 64.0, 63.0, 48.8, 41.1, 33.5, 28.5, 27.3, 25.9, 23.4, 21.7, 18.2, -5.5, -5.8; IR (ATR) 2932, 2858, 2212, 2128, 1733, 1694, 1625 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₅H₄₃N₂O₄Si 463.2992; Found 463.2997.



Compound 140: A solution of **139** (442 mg, 0.955 mmol) in toluene (9.5 mL) was stirred under reflux. After 16 h, the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 9:1) to afford **140** (327 mg, 0.707 mmol, 74%) as white solid and **158b** (89.1 mg, 0.193 mmol, 20%) as a colorless oil. **140**: ¹H NMR (600 MHz, CDCl₃) δ 5.75-5.68 (1H, m), 5.17 (1H, br s), 5.15 (1H, br d, J = 4.8 Hz), 4.32 (1H, br d, J = 13.8 Hz), 4.17 (1H, d, J = 10.3 Hz), 3.69-3.64 (2H, m), 3.43 (1H, qd, J = 13.4, 4.0 Hz), 2.80 (1H, dd, J = 14.5, 5.5 Hz), 2.69-2.64 (1H, m), 2.55 (1H, dd, J = 13.8, 9.0 Hz), 2.49

(1H, dq, J = 15.5, 2.4 Hz), 2.30-2.26 (1H, m), 2.23-2.17 (1H, m), 1.81-1.72 (2H, m), 1.59-1.54 (1H, m), 1.52-1.43 (10H, m), 0.91 (9H, s), 0.11 (3H,s), 0.10 (3H, s); ¹³C NMR (151 MHz, CDCl₃) δ 198.6, 154.6, 130.3, 119.7, 117.9, 80.0, 65.7, 59.8, 48.9, 48.9, 47.3, 37.5, 37.0, 31.4, 28.5, 26.9, 25.7, 21.8, 18.5, -6.0, -6.2; IR (ATR) 2930, 2857, 2242, 1726, 1703 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₅H₄₃N₂O₄Si 463.2992; Found 463.2988. **141**: ¹H NMR (600 MHz, CDCl₃) δ 5.95-5.88 (1H, m), 5.21-5.17 (2H, m), 4.29 (1H, d, *J* = 13.8 Hz), 3.92 (1H, d, *J* = 13.1, 4.1 Hz), 3.79 (1H, d, *J* = 11.7 Hz), 3.55 (1H, d, *J* = 11.0 Hz), 3.25-3.17 (1H, m), 3.00-2.92 (2H, m), 2.77 (1H, td, *J* = 13.1, 2.1 Hz), 2.51 (1H, dq, *J* = 13.9, 2.4 Hz), 2.34-2.25 (2H, m), 2.11 (1H, d, *J* = 13.8 Hz), 1.91 (1H, td, *J* = 13.4, 4.8 Hz), 1.62-1.59 (1H, m), 1.44 (9H, s), 0.87 (9H, s), 0.05 (3H, s), 0.04 (1H, s); ¹³C NMR (151 MHz, CDCl₃) δ 199.5, 154.5, 133.8, 119.2, 119.0, 79.9, 62.4, 61.1, 58.8, 49.7, 48.8, 38.5, 32.1, 30.8, 28.4, 27.9, 25.7, 22.4, 18.2, -5.8, -6.1; IR (ATR) 2938, 2865, 2222, 1735, 1700 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₅H₄₃N₂O₄Si 463.2992; Found 463.2990.



Compound 142 To a solution of ⁱPr₂NH (462 µL, 3.27 mmol) in THF (9 mL) was added *n*BuLi (1.6 M hexane solution, 2.00 mL, 3.60 mmol) at -78 °C. After stirring for 30 min at the same temperature, a solution of 158a (304 mg, 0.657 mmol) in THF (9 mL) was added via canula at -78 °C and stirred for 2.5 h. Et₃N (5.4 mL) and TMSCl (804 μ L, 6.57 mmol) was added at -78 °C the stirred at room temperature. After stirring for 1.5 h, the reaction was quenched with water. The resultant mixture was extracted with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was dissolved in THF (9 mL). To the resultant solution were added 36-38% aq. formaldehyde (1.8 mL) and Sc(OTf)₃ (32.1 mg, 0.0652 mmol). After stirring at room temperature for 18 h, the reaction mixture was concentrated under reduced pressure. To the residue was added water and extracted with Et₂O. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford 159 (173.4 mg, 0.352 mmol, 54%) as white solid and 158a (56.0 mg, 0.121 mmol, 18%) was recovered: ¹H NMR (600 MHz, CDCl₃) δ 5.80-5.73 (1H, m), 5.21 (1H, s), 5.18 (1H, d, *J* = 6.0 Hz), 4.36 (1H, d, *J* = 10.3 Hz), 4.03 (1H, td, *J* = 9.0, 4.4 Hz), 3.84-3.76 (3H, m), 3.36-3.26 (2H, m), 3.07 (1H, q, *J* = 6.2 Hz), 2.92-2.87 (1H, m), 2.80 (1H, dd, *J* = 13.8, 6.9 Hz), 2.60 (1H, dd, *J* = 13.8, 6.9 Hz), 2.28 (1H, br s), 2.14 (1H, br d, *J* = 11.0 Hz), 1.86 (1H, br d, *J* = 13.1 Hz), 1.65-1.61 (2H, dq, J = 13.9, 4.0 Hz), 1.48 (9H, s), 0.92 (10H, s), 0.15 (1H, s), 0.11 (3H, s); ¹³C NMR (151 MHz, CDCl₃) δ 203.7, 154.7, 132.0, 120.0, 118.6, 80.3, 64.0, 63.8, 59.0, 57.5, 49.5, 47.9, 46.4, 33.8, 28.9, 28.4, 28.0, 25.8, 20.9, 18.4, -5.9, -6.1; IR (ATR) 3470, 2930, 2250, 1703 cm⁻¹; HRMS (FAB) m/z: [M+H]⁺ Calcd for C₂₆H₄₅N₂O₅Si 493.3098; Found 493.3105.



Compound 143: To a solution of **142** (141 mg, 0.286 mmol) in THF (2.9 mL) was added Li naphthalenide (prepared from 34.1 mg of Li, 650 mg of naphthalene and 5 mL of THF under sonication) at -40 °C until the reaction solution become green. After stirring for 10 min, the reaction was quenched with aq. NH₄Cl. The mixture was extracted with EtOAc, the organic layer was dried over Na₂SO₄, filtrated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 3:1) to afford **143** (64.1 mg, 0.137 mmol, 48%) as a colorless oil: ¹H NMR (600 MHz, CDCl₃) δ 5.94-5.87 (1H, m), 4.99 (1H, d, J = 17.2 Hz), 4.92 (1H, d, *J* = 9.6 Hz), 4.28 (1H, d, *J* = 13.1 Hz), 3.88-3.81 (3H, m), 3.60 (1H, dd, J = 13.8, 4.1 Hz), 3.48-3.42 (2H, m), 2.76-2.67 (3H, m), 2.16 (1H, dd, J = 13.4, 3.8 Hz), 2.12-2.06 (3H, m), 1.73-1.64 (1 H, br m), 1.53-1.49 (1H, m), 1.45 (9H, s), 0.87 (9H, s), 0.045 (3H, s), 0.025 (3H, s); ¹³C NMR (151 MHz, CDCl₃) δ 204.5, 154.6, 139.2, 114.6, 79.5, 46.8, 62.7, 62.2, 57.1, 52.1, 49.0, 47.2, 35.8, 29.1, 28.5, 27.4, 25.8, 22.6, 08.2, -5.8, -6.1; IR (ATR) 3432, 2929, 2858, 1702 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂H₅₀N₅O₅Si 468.3145; Found 468.3143.



Compound 146: To a solution of 143 (18.0 mg, 0.0384 mmol) in MeOH (1 mL) and THF (100 μ L) was added CeCl₃·7H₂O (28.7 mg, 0.0770 mmol) at room temperature. The reaction mixture was cooled to -78 °C. To the reaction mixture was added NaBH₄ (8.4 mg, 0.222 mmol) at -78 °C then arrowed to warm to room temperature. After stirring for 1 h, water was added. The resultant mixture was extracted with EtOAc. The organic layer was dried over Na₂SO₄, filtrated and concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (1 mL). To the solution was added PhCH(OMe)₂ (11.5 µL, 0.0768 mmol) and (+)-10-camphorsulfonic acid (8.8 mg, 0.0379 mmol) at room temperature. After stirring for 3 days, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtrated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford 146 (7.1 mg, 0.160 mmol, 42%) as a colorless oil: ¹H NMR (600 MHz, CDCl₃) & 7.49-7.48 (2H, m), 7.37-7.31 (3H, m), 6.02-5.96 (1H, m), 5.73 (1H, s), 5.03 (1H, dd, *J* = 17.2, 1.4 Hz), 4.92 (1H, br d, *J* = 9.0 Hz), 4.75 (1H, dd, *J* = 12.4, 5.5 Hz), 4.23-4.17 (2H, m), 3.90 (1H, dd, *J* = 11.4, 5.2 Hz), 3.78-3.70 (2H, m), 3.32 (1H, td, *J* = 14.5, 6.9 Hz), 3.21 (1H, dd, J = 9.0, 6.2 Hz), 3.06 (1H, dd, J = 14.5, 4.8 Hz), 2.81-2.73 (2H, m), 2.49-2.37 (2H, m), 2.32-2.28 (1H, m), 2.02 (1H, br d, *J* = 13.8 Hz), 1.66-1.56 (3H, m), 1.46 (9H, s), 1.25-1.17 (1H, m); ¹³C NMR (151 MHz, CDCl₃) & 156.5, 139.5, 138.7, 128.7, 128.2, 126.2, 115.2, 93.3, 80.2, 75.7, 66.4, 62.5, 62.2, 50.5, 44.3, 43.8, 35.9, 33.3, 31.8, 28.4, 27.9, 22.7; IR (ATR) 3469, 2929, 1669 cm⁻¹; HRMS (FAB) m/z: [M+H]⁺ Calcd for



Compound 147: To a solution of **146** (29.5 mg, 0.0665 mmol) in CH₃CN (1 mL) were added 4-methylmorpholine *N*-oxide (12.3 mg, 0.105 mmol) and activated MS 4A. After stirring at room temperature for 30 min, TPAP (2.2 mg, 0.00626 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 h the concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford **147** (26.0 mg, 0.0589 mmol, 89%) as a colorless oil: ¹H NMR (600 MHz, CDCl₃) δ 10.05 (1H, s), 7.41-7.40 (2H, m), 7.31-7.26 (3H, m), 5.78-5.71 (1H, m), 5.64 (1H, s), 4.95 (1H, d, *J* = 17.4 Hz), 4.89 (1H, d, *J* = 10.2 Hz), 4.44 (1H, dd, *J* = 12.4, 5.5 Hz), 4.18 (1H, t, *J* = 12.1 Hz), 3.98 (1H, d, *J* = 13.1 Hz), 3.93 (1H, dd, *J* = 11.0, 4.8 Hz), 3.28 (1H, td, *J* = 14.3, 6.0 Hz), 3.20 (1H, dd, *J* = 14.5, 3.4 Hz), 2.86-2.83 (1H, m), 2.73-2.68 (1H, m), 2.59 (1H, br d, *J* = 13.8 Hz), 2.40-2.37 (1H, m), 2.26-2.22 (2H, m), 1.84 (1H, br d, *J* = 14.5 Hz), 1.74-1.66 (1H, m), 1.56-1.53 (1H, m), 1.34 (9H, s), 1.20-1.14 (1H, m); ¹³C NMR (151 MHz, CDCl₃) δ 203.8, 155.0, 138.2, 137.5, 128.9, 128.3, 126.1, 116.7, 93.5, 80.3, 74.8, 66.0, 61.1, 55.4, 49.1, 43.3, 33.6, 33.1, 31.3, 28.3, 27.5, 23.1; IR (ATR) 2929, 1694 cm⁻¹; HRMS (FAB) *m*/*z*: [M+H]⁺ Calcd for C₂₆H₃₆NO₅ 442.2593; Found 442.2599.



Compound S2: **139** (13.5 g, 29.2 mmol) was dissolved in a 1 M solution of TBAF in THF (88.0 ml, 88.0 mmol) at room temperature. After stirring at room temperature for 5 h, water was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 2:1) to afford **S2** (9.01 g, 25.9 mmol, 89%) as brown foam: ¹H NMR (500 MHz, CDCl₃) δ 5.89-5.84 (1H, m), 5.33 (1H, d, *J* = 17.5 Hz), 5.19 (1H, d, *J* = 10.6 Hz), 4.53-4.45 (2H, m), 4.13 (1H, dd, *J* = 13.3, 3.9 Hz), 3.76 (1H, d, *J* = 12.3 Hz), 3.49 (1H, d, *J* = 9.5 Hz), 3.05 (1H, brs), 2.96-2.85 (2H, m), 2.74-2.69 (1H, m), 2.50 (1H, dd, *J* = 17.9, 4.7 Hz), 2.31-2.24 (1H, m), 2.03-1.94 (2H, m), 1.68-1.60 (1H, m), 1.52-1.27 (11H, m); ¹³C NMR (126 MHz, CDCl₃) δ 167.9, 155.7, 132.3, 117.6, 116.1, 92.8, 80.2, 68.4, 63.6, 63.0, 49.2, 40.3, 34.1, 28.1, 26.8, 23.3, 21.5; IR (ATR) 3460, 2940, 2867, 2208, 1673 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₉N₂O₄ 349.2127; Found 349.2123.



Compound 149: To a solution of compound **S2** (4.65 g, 13.3 mmol) in CH₃CN (66 mL) were added 4methylmolpholine *N*-oxide (2.53 g, 21.6 mmol) and dried MS 4A (10 g) at room temperature. After stirring at room temperature for 30 min, tetrapropylammonium perruthenate (502 mg, 1.43 mmol) was added. After stirring at room temperature for 1 h, the reaction mixture was concentrated under reduced pressure directly. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford **149** (3.86 g, 11.1 mmol, 84%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 9.83 (1H, s), 5.97-5.92 (1H, m), 5.41 (1H, d, *J* = 17.2 Hz), 5.30 (1H, d, *J* = 10.6 Hz), 4.67-4.59 (2H, m), 4.21 (1H, d, *J* = 10.0 Hz), 3.15 (1H, dd, *J* = 13.2, 2.3 Hz), 2.97-2.93 (1H, m), 2.76 (1H, td, *J* = 13.5, 2.5 Hz), 2.68 (1H, dd, *J* = 18.3, 4.6 Hz), 2.62 (1H, d, *J* = 13.2 Hz), 2.51-2.44 (1H, m), 2.32 (1H, dd, *J* = 13.5, 6.0 Hz), 1.84-1.74 (1H, m), 1.62 (1H, d, *J* = 14.0 Hz), 1.44-1.43 (10H, m); ¹³C NMR (126 MHz, CDCl₃) δ 198.1, 170.0, 154.3, 131.8, 118.1, 114.8, 87.6, 80.3, 68.9, 61.6, 50.3, 48.7, 31.6, 28.1, 26.9, 23.3, 22.4; IR (ATR) 2976, 2922, 2209, 1689 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₇N₂O₄ 347.1971; Found 347.1966.



Compound 150: To a solution of compound **149** (6.72 g, 19.4 mmol) in MeOH (100 mL) were added dimethyl (1-diazo-2-oxopropyl)phosphonate (Ohira-Bestmann reagent) (3.52 ml, 23.3 mmol) and K₂CO₃ (4.05 g, 29.3 mmol) at room temperature. After stirring at room temperature for 9.5 h, water was added for quenching the reaction. The resultant mixture was extracted with EtOAc. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 4:1) to afford **150** (5.46 g, 15.9 mmol, 82%) as a white solid: ¹H NMR (500 MHz, CDCl₃) δ 5.87-5.83 (1H, m), 5.32 (1H, d, *J* = 17.2 Hz), 5.20 (1H, d, *J* = 10.6 Hz), 4.54-4.47 (2H, m), 4.23 (1H, d, *J* = 12.3 Hz), 2.82 (1H, d, *J* = 12.6 Hz), 2.67-2.48 (3H, m), 2.32-2.25 (4H, m), 1.93 (1H, q, *J* = 13.6 Hz), 1.53 (1H, d, *J* = 14.0 Hz), 1.45-1.37 (10H, m); ¹³C NMR (126 MHz, CDCl₃) δ 167.3, 154.3, 132.0, 117.8, 115.4, 92.5, 82.9, 79.6, 73.3, 68.6, 62.8, 47.9, 38.2, 37.7, 28.1, 27.2, 24.9, 21.9; IR (ATR) 3236, 2967, 2936, 2880, 2203, 1674, 1623 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₀H₂₇N₂O₃ 343.2022; Found 343.2016.



Compound 152: A solution of **150** (5.46 g, 15.9 mmol) in toluene (80 mL) was stirred for 9.5 h under reflux (oil bath). The reaction solution was concentrated under reduced pressure. The resultant residue was used for the next

reaction without purification. To a solution of the residue in THF (520 mL) was added solution lithium naphthalenide in THF (20 mL), which was prepared from lithium pole (996 mg, 150 mmol), naphthalene (19.2 g, 150 mmol) and THF (150 mL) under sonication, at -40 °C. After stirring for 30 min at the same temperature, to the reaction solution was added MeOH for quenching. The resultant mixture was diluted with EtOAc and washed with aq. NH₄Cl. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **152** (2.26 g, 7.12 mmol, 45% for 2 steps) as a pale yellow solid: ¹H NMR (500 MHz, CDCl₃) δ 5.87-5.79 (1H, m), 5.02 (1H, d, *J* = 17.2 Hz), 4.95 (1H, d, *J* = 10.0 Hz), 4.15 (1H, d, *J* = 13.7 Hz), 3.52 (1H, d, *J* = 12.0 Hz), 2.96-2.74 (3H, m), 2.52-2.49 (1H, m), 2.44-2.27 (4H, m), 2.21 (1H, s), 2.11 (1H, dd, *J* = 14.5, 7.3 Hz), 1.90-1.83 (1H, m), 1.68-1.66 (1H, m), 1.53-1.44 (10H, m); ¹³C NMR (126 MHz, CDCl₃) δ 206.7, 154.6, 137.4, 115.4, 81.6, 79.6, 74.9, 64.4, 58.5, 45.6, 45.5, 41.1, 36.1, 29.2, 28.2, 27.8, 21.8; IR (ATR) 3259, 2966, 2948, 2871, 1713, 1678 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₈NO₃ 318.2069, Found 318.2075.



Compound 50: To a solution of compound **152** (204 mg, 0.643 mmol) in CH₂Cl₂ (6 mL) was added TFA (1 mL) at room temperature. After stirring at the same temperature for 1 h, aq. NaOH was added for quenching the reaction. The resultant mixture was extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl₃/MeOH = 8:1) to afford **50** (132 mg, 0.607 mmol, 94%) as a colorless oil: ¹H NMR (600MHz, CDCl₃) δ 5.88-5.82 (1H, m), 5.02 (1H, dq, *J* = 17.2, 1.6 Hz), 4.95 (1H, dd, *J* = 10.3, 1.4 Hz), 3.16-3.12 (1H, m), 2.82 (1H, dd, *J* = 11.4, 4.5 Hz), 2.72-2.64 (2H, m), 2.48-2.37 (2H, m), 2.29-2.27 (2H, m), 2.24-2.21 (1H, m), 2.16-2.11 (1H, m), 2.00-1.91 (2H, m), 1.82-1.71 (1H, m), 1.63-1.58 (2H, m), 1.45 (1H, td, *J* = 13.1, 3.4 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 207.8, 137.7, 115.5, 82.2, 75.8, 62.1, 57.7, 46.4, 45.6, 40.4, 35.7, 30.7, 27.4, 23.4; IR (ATR) 3288, 3075, 2939, 2858, 1713, 1639 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₄H₂₀NO 218.1545, Found 218.1548.

Compound 53: To a solution of compound **50** (132 mg, 0.607 mmol) in CH₃CN (6 mL) were added K₂CO₃ (690 mg, 4.99 mmol) and crotyl bromide (309 μ L, 3.04 mmol) at room temperature. After stirring at the same temperature for 1 h, the mixture was filtered through celite with EtOAc. The filtrate was concentrated under reduced pressure. The residue was dissolved in CH₃CN (6 mL). To the solution was added crotyl bromide (309 μ L, 3.04 mmol) at room temperature. After stirring at 70 °C (oil bath) for 9 h, the rection mixture was cooled to room temperature. The volatile components were removed under reduced pressure. The residue was dissolved in CH₂Cl₂ (24 mL). To the solution was added Grubbs 2nd (38.6 mg, 0.0454 mmol) at room temperature. After stirring at 40 °C (oil bath) for 18 h, additional Grubbs 2nd (19.0 mg, 0.0224 mmol). The reaction mixture was stirred at 40 °C (oil bath) for 48 h. After cooling to room temperature, to the reaction solution was added SH-silica gel (SCAVENGER SH Silica, Fuji Silysia Chemical) and stirred for 10 min at room temperature for the

removal of Ru. The mixture was filtered through cotton with CHCl₃/MeOH = 5:1 and concentrated under reduced pressure. The residue was dissolved in CH₃CN (6 mL). To the solution was added Na₂S·9H₂O (300 mg, 1.22 mmol) at room temperature. After stirring under reflux (oil bath) for 1 h, the reaction solution was diluted with EtOAc and washed with water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl₃/MeOH = 5:1) to afford compound **53** (93.4 mg, 0.407 mmol, 67% for 4 steps) as a brown oil: ¹H NMR (500 MHz, CDCl₃) δ 6.22 (1H, dd, *J* = 12.0, 2.3 Hz), 5.73 (1H, s), 5.47 (1H, dd, *J* = 12.3, 4.9 Hz), 3.88 (1H, d, *J* = 20.0 Hz), 3.45 (1H, dd, *J* = 19.8, 4.9 Hz), 3.36 (1H, dd, *J* = 12.5, 2.8 Hz), 3.23-3.16 (2H, m), 2.94 (1H, dd, *J* = 17.5, 2.5 Hz), 2.60-2.52 (2H, m), 2.43 (1H, td, *J* = 13.5, 3.0 Hz), 2.34 (1H, d, *J* = 6.3 Hz), 2.05-1.85 (4H, m), 1.70 (1H, td, *J* = 12.5, 4.0 Hz), 1.36 (1H, d, *J* = 14.0 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 221.9, 146.3, 133.7, 130.9, 126.6, 61.5, 60.1, 56.2, 55.1, 52.8, 41.3, 39.3, 31.0, 26.3, 22.6; IR (ATR) 2920, 2360, 1458, 1234 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₀NO 230.1545, Found 230.1548.



Compound 157: To a solution of iPr_2NH (40 µL, 0.285 mmol) in THF (1 mL) was added *n*BuLi (1.6M haexane solution, 170 µL, 272 mmol) at -78 °C. After stirring for 30 min, a solution of 53 (31.4 mg, 0.137 mmol) in THF (2 mL) was added then the reaction solution was stirred for 45 min Et₃N (95 µ, 0.685 mmol) and TMSCl (85 µL, 0.673 mmol) were added. The reaction solution was arrowed to worm to room temperature and stirred for 30 min the reaction was quenched by addition of water. The resultant mixture was extracted with CHCl₃. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue (156) was used for the next reaction without further purification. $Sc(OTf)_3$ (6.6 mg, 0.0134 mmol) was dissolved in THF (1 mL) and 37% formalin (0.5 mL). To the solution was added a solution of 156 in THF (1.5 mL). After stirring at room temperature for 13 h, additional Sc(OTf)₃ (26.6 mg, 0.0540 mmol) was added. After stirring for 4.5 h., the reaction was quenched by addition of aq. NaHCO₃. The resultant mixture was extracted with CHCl₃. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (Dual Pore) (EtOAc/MeOH = 10:1) to afford 157 as a mixture of C15 diastereomers (2:5) (16.9 mg, 0.0652 mmol, 48%,) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 6.33 (minor, 1H, dd, *J* = 12.3, 2.1 Hz), 6.21 (major, 1H, dd, *J* = 11.7, 2.7 Hz), 5.74 (major, 1H, br s), 5.72 (minor, 1H, br s), 5.53 (minor, 1H, dd, J = 13.2, 6.0 Hz), 5.45 (major, 1H, dd, J = 11.4, 4.8 Hz), 3.94 (minor, 1H, br d, J = 10.8 Hz), 3.84 (major, br d, J = 19.2 Hz), 3.79-3.71 (minor, 2H, m), 3.79-3.71 (major, 1H, m), 3.65 (major, 1H, dd, J = 11.1, 4.5 Hz), 3.51-3.42 (major, 2H, m), 3.51-3.42 (minor, 1H, m), 3.23-3.11 (major, 2H, m), 3.23-3.11 (minor, 1H, m), 3.00 (major, 1H, dd, J = 11.1, 3.3 Hz), 2.83-2.76 (minor, 2H, m), 2.65 (minor, 1H, dd, J = 18.3, 2.7 Hz), 2.63-2.58 (major, 1H, m), 2.50-2.48 (minor, 1H, m), 2.50-2.48 (major, 1H, m), 2.40 (major, 1H, d, J = 6.0 Hz), 2.15 (minor, 1H, td, J = 12.6, 8.8 Hz), 2.05-1.87 (major, 4H, m), 2.05-1.87 (minor, 3H, m), 1.79-1.65 (major, 2H, m), 1.79-1.65 (minor, 1H, m), 1.41-1.37 (minor, 1H, m), 1.41-1.37 (major, 1H, m); ¹³C NMR (151 MHz, CDCl₃) δ 215.5 (minor), 214.1 (major), 146.5 (minor), 146.1 (major), 133.8 (major), 132.2 (minor), 130.9 (major), 129.7 (minor), 126.7 (minor), 126.6 (major), 62.85 (minor), 62.81 (major), 61.1 (major), 60.4 (major), 60.2 (minor), 57.6 (minor), 56.3 (minor), 56.1 (major), 56.0 (major), 54.5 (minor), 52.6 (major), 52.2 (minor), 52.0 (major), 48.5 (minor), 39.5 (minor), 39.2 (major), 33.5 (minor), 29.8 (major), 29.6 (major), 26.9 (minor), 22.6 (major), 21.7 (minor); IR (ATR) 3369, 2927, 2852, 1698 cm⁻¹; HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₆H₂₁NO₂ 260.1645, Found 261.1634.



Compound 158: To a solution of compound **53** (13.6 mg, 0.0593 mmol) in THF (1 mL) was added L-Selectride[®] (1.0 M THF solution, 89 μ L, 0.089 mmol) at -78 °C. After stirring for 40 min at -78 °C, water was added for quenching the reaction at -78 °C. To the resultant mixture was extracted with CH₂Cl₂. The combined organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl₃/MeOH = 5:1) to afford **158** (10.7 mg, 0.0463 mmol, 78%) as a brown oil: ¹H NMR (600 MHz, CDCl₃) δ 6.24 (1H, dd, *J* = 12.1, 2.4 Hz), 5.86 (1H, br s), 5.51 (1H, dd, *J* = 12.4, 4.8 Hz), 3.91 (1H, br d, *J* = 19.8 Hz), 3.82 (1H,br s), 3.41 (1H, dd, *J* = 19.6, 5.2 Hz), 3.20-3.10 (2H, m), 2.94 (1H, dd, *J* = 12.7, 3.1 Hz), 2.65 (1H, br dd, *J* = 17.2, 4.8 Hz), 2.34 (1H, dd, *J* = 17.2, 3.4 Hz), 2.09 (1H br s), 2.06 (1H, t, *J* = 5.4 Hz), 2.00-1.79 (4H, m), 162-1.55 (1H, m), 1.55-1.47 (2H, m), 1.30 (1H, br d, *J* = 13.8 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 149.1, 133.3, 132.2, 126.3, 69.8, 63.0, 56.4, 53.4, 52.6, 51.8, 40.7, 32.3, 31.8, 23.3, 21.5; IR (ATR) 3400, 2924, 2852, 1708, 1647 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₂NO 232.1701; Found 232.1703.



Compound S1: To a solution of compound **158** (10.7 mg, 0.0463 mmol) in CH₂Cl₂ (1 mL) were added Et₃N (19.3 μ L, 0.139 mmol), Ac₂O (8.8 μ L, 0.926 mmol) and DMAP (0.7 mg, 0.00573 mmol). After stirring at room temperature for 16 h, the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (Dual Pore) (EtOAc) to afford **S1** (9.3 mg, 0.0340 mmol, 73%) as a brown oil: ¹H NMR (600 MHz, CDCl₃) δ 6.32 (1H, d, J = 12.4 Hz), 5.75 (1H, br s), 5.40 (1H, dd, J = 12.1, 4.5 Hz), 5.11- 5.09 (1H, m), 3.94 (1H, br d, J = 19.3 Hz), 3.49 (1H, dd, J = 19.6, 5.2 Hz), 3.27-3.20 (2H, m), 3.15-3.12 (1H, m), 2.58 (1H, dd, J = 17.9, 6.2 Hz), 2.23 (1H, t, J = 5.9 Hz), 2.06-1.86 (7H, m), 1.83-1.77 (1H, m), 1.72-1.63 (3H, m), 1.57 (1H, td, J = 13.1, 4.1 Hz), 1.42 (1H, dd, J = 13.8, 2.1 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 170.7, 146.1, 133.5, 127.7, 126.3, 70.3, 61.9, 55.3, 52.3, 51.7, 50.3, 40.2, 31.5, 28.2, 22.1, 21.4, 21.3; IR (ATR) 2934, 2853, 1730 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₇H₂₄NO₂ 274.1807; Found 274.1812.



Compound 160: To a solution of compound **S1** (9.3 mg, 0.0340 mmol) in CH₃CN (2.5 mL) was added NBS (6.4 mg, 0.0360 mmol) at 0 °C. After stirring for 10 min, aq. Na₂S₂O₃ was added. The resultant mixture was extracted with CHCl₃. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl₃/MeOH = 20:1) to afford **160** (5.1 mg, 0.0138 mmol, 41%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 6.12 (1H, d, *J* = 6.2 Hz), 4.99 (1H, t, *J* = 7.9 Hz), 5.00-4.94 (1H, m), 4.17 (1H, t, *J* = 5.2 Hz), 3.54 (1H, dd, *J* = 16.2, 4.5 Hz), 3.24 (1H, dd, *J* = 14.5, 4.8 Hz), 3.16-3.11 (2H, m), 2.83 (1H, d, *J* = 10.3 Hz), 2.54-2.49 (1H, m), 2.26-2.22 (2H, m), 2.07-1.97 (6H, m), 1.83-1.76 (2H, m), 1.60-1.55 (1H, m), 1.52-1.45 (2H, m), 1.37 (1H, d, *J* = 10.3 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 170.0, 149.7, 126.8, 71.6, 68.9, 62.1, 53.6, 52.8, 52.4, 51.7, 50.7, 37.7, 37.1, 29.5, 21.6, 21.0, 20.2; IR (ATR) 3412, 2934, 1735 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₇H₂₅BrNO₃ 370.1018; Found 370.1020.



Compound 163: To a solution of compound **53** (40.1 mg, 0.175 mmol) in CH₂Cl₂ (1 mL) were added a solution of KHCO₃ (162 mg, 1.62 mmol) in H₂O (1 mL), CCl₃CN (52.4 μ L, 0.523 mmol) and 30% aq. H₂O₂ (59.2 μ L, 0.523 mmol) at 0 °C and the reaction mixture was stirring at the same temperature for 1 h. Then the reaction mixture was warmed to room temperature. After stirring for 1 h at room temperature, additional a solution of KHCO₃ (169 mg, 1.69 mmol) in H₂O (1 mL), CCl₃CN (52.4 μ L, 0.523 mmol) and 30% aq. H₂O₂ (59.2 μ L, 0.523 mmol). the reaction mixture was stirred at room temperature at room temperature for 3 h. Then reaction mixture was concentrated under reduced pressure directly. The residue was purified by silica gel column chromatography (CHCl₃/MeOH = 10:1) to afford **163** (45.4 mg, 0.174 mmol, 99%) as a white solid: ¹H NMR (600 MHz, CDCl₃) δ 5.93 (1H, ddd, *J* = 12.0, 7.2, 2.4 Hz), 5.75 (1H, dd, *J* = 11.7, 3.4 Hz), 4.44 (1H, d, *J* = 17.9 Hz), 4.08 (1H, dd, *J* = 17.9, 6.9 Hz), 3.98 (1H, dd, *J* = 13.4, 4.5 Hz), 3.85 (1H, d, *J* = 11.0 Hz), 3.69 (1H, t, *J* = 13.2 Hz), 3.52 (1H, s), 3.28-3.25 (1H, m), 2.96-2.92 (1H, m), 2.85-2.81 (1H, m), 2.66-2.57 (1H, m), 2.50-2.44 (1H, m), 2.32-2.25 (1H, m), 2.05 (2H, m), 1.92-1.89 (1H, m), 1.85-1.80 (1H, m), 1.76 (1H, td, *J* = 13.8, 5.5 Hz); ¹³C NMR (151 MHz, CDCl₃) δ 205.3, 130.3, 128.6, 78.2, 73.0, 67.1, 64.8, 60.8, 54.1, 47.1, 39.8, 32.4, 29.2, 22.5, 19.8; IR (ATR) 3381, 3272, 2211, 2127, 1696 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₀NO₃ 262.1443, Found 262.1449.



Compound 165: To a suspension of compound **163** (84.4 mg, 0.323 mmol) in EtOAc (1 mL) was added Pd/C (Aldrich 10 wt%, 102 mg). The reaction mixture was stirred under H_2 atmosphere (1 atm) at room temperature

for 3.5 h. The reaction mixture was filtered through celite with CHCl₃/MeOH = 5:1. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DualPore) (CHCl₃/MeOH = 5:1) to afford compound **165** (68.4 mg, 0.277 mmol, 86%) as a colorless oil: ¹H NMR (600 MHz, C₆D₆) δ 5.71 (1H, d, *J* = 7.6 Hz), 4.15 (1H, dd, *J* = 6.0, 1.2 Hz), 3.04 (2H, td, *J* = 14.1, 4.4 Hz), 2.97 (1H, td, *J* = 13.4, 3.2 Hz), 2.88-2.85 (1H, m), 2.78 (1H, dd, *J* = 12.0, 3.6 Hz), 2.64 (1H, dd, *J* = 15.1, 5.5 Hz), 2.43-2.33 (3H, m), 2.13-2.00 (2H, m), 1.77 (1H, d, *J* = 7.6 Hz), 1.67 (2H, m), 1.56-1.49 (3H, m), 1.10-1.02 (2H, m); ¹³C NMR (151 MHz, C₆D₆) δ 210.4, 149.8, 126.2, 75.7, 62.2, 58.4, 53.8, 52.3, 46.3, 41.1, 40.6, 34.2, 31.6, 27.1, 23.5; IR (ATR) 3387, 2934, 1699, 1457 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₂NO₂ 248.1651; Found 248.1646.



Compound S3: To a solution of compound **165** (68.4 mg, 0.277 mmol) in CH₂Cl₂ (3 mL) were added 2,6-lutidine (70 µL, 0.601 mmol) and TESOTf (60 µL, 0.266 mmol) at -78 °C. After stirring at -78 °C for 10 min, MeOH was added for quenching the reaction at -78 °C. To the resultant solution was added aq. NaHCO₃ then extracted with CHCl₃/MeOH = 5/1. The combined organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DualPore) (CHCl₃/MeOH = 5:1) to afford **S3** (69.1 mg, 0.191 mmol, 69%) as a colorless oil: ¹H NMR (600 MHz, C₆D₆) δ 5.79 (1H, d, *J* = 8.3 Hz), 4.34-4.31 (1H, m), 3.29 (1H, td, *J* = 14.1, 4.4 Hz), 3.21-3.12 (2H, m), 2.92-2.88 (2H, m), 2.81-2.74 (1H, m), 2.67 (1H, dd, *J* = 17.9, 5.5 Hz), 2.58-2.51 (1H, m), 2.42-2.35 (1H, m), 2.20 (1H, t, *J* = 7.6 Hz), 2.11-2.06 (2H, m), 1.91-1.82 (3H, m), 1.72-1.69 (1H, m), 1.58 (1H, td, *J* = 13.8, 4.4 Hz), 1.45-1.41 (1H, m), 0.96 (9H, t, *J* = 7.9 Hz), 0.61 (6H, q, *J* = 7.8 Hz); ¹³C NMR (151 MHz, C₆D₆) δ 212.4, 148.9, 122.6, 74.5, 63.1, 57.4, 51.9, 50.4, 46.4, 41.4, 38.8, 37.9, 31.2, 24.8, 23.3, 6.8, 4.8; IR (ATR) 2952, 2877, 1707 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₁H₃₆NO₂Si 362.2515; Found 362.2521.



Compound 166: To a solution of compound **S3** (5.4 mg, 0.0149 mmol) in MeOH (1 mL) was added Pd/C (Aldrich 10 wt%, 5.2 mg). The reaction mixture was stirred under H₂ atmosphere (1 atm) at room temperature for 20 h. The reaction mixture was filtered through celite with CHCl₃/MeOH = 5:1 then the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DualPore) (CHCl₃/MeOH = 10:1) to afford compound **166** (5.2 mg, 0.0143 mmol, 96%) as a colorless oil: ¹H NMR (600 MHz, C₆D₆) δ 3.64 (1H, t, *J* = 3.1 Hz), 3.03-2.92 (2H, m), 2.84 (1H, dd, *J* = 13.8, 4.8 Hz), 2.77 (1H, d, *J* = 15.1 Hz), 2.71 (1H, dd, *J* = 12.4, 2.8 Hz), 2.57 (1H, dd, *J* = 17.2, 3.4 Hz), 2.51 (1H, d, *J* = 13.1 Hz), 2.35 (1H, qd, *J* = 12.6, 4.3 Hz), 2.05-1.91 (2H, m), 1.71 (1H, d, *J* = 7.6 Hz), 1.63-1.47 (4H, m), 1.40-1.32 (3H, m), 1.27-1.25 (1H, m), 1.12-0.97 (11H, m), 0.63-0.53 (6H, m); ¹³C NMR (151 MHz, C₆D₆) δ 208.5, 77.7, 63.5, 59.7, 54.9, 53.9, 52.2, 46.8, 44.8, 41.7, 37.9, 30.5, 28.0, 26.0, 23.8, 7.3, 5.1; IR (ATR) 2928, 2879, 1704 cm⁻¹; HRMS (FAB) *m/z*:

[M+H]⁺ Calcd for C₂₁H₃₈NO₂Si 364.2672; Found 364.2679.



Compound 167: To a solution of compound 166 (9.7 mg, 0.0267 mmol) in CH₂Cl₂ (1 mL) were added 2,6lutidine (15 µL, 0.13 mmol) and TMSOTf (18 µL, 0.089 mmol) at -78 °C. After stirring at room temperature for 5.5 h, the reaction was quenched with aq. NaHCO₃ at room temperature. The resultant mixture was extracted with CHCl₃/MeOH = 5:1. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was resolved in THF (1.2 mL). To the solution were added paraformaldehyde (16.2 mg, 0.539 mmol) and Sc(OTf)₃ (14.4 mg, 0.0293 mmol) at room temperature. After stirring at room temperature for 3 h, aq. NaHCO₃ was added for quenching the reaction. The resultant mixture was extracted with $CHCl_3/MeOH = 5:1$. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DualPore) $(CHCl_3/MeOH = 5:1)$ to afford **167** (8.0 mg, 0.0203 mmol, 76%) as a colorless oil: ¹H NMR (600 MHz, C₆D₆) δ 4.21 (1H, brs), 3.91-3.87 (2H, m), 3.64 (1H, t, *J* = 2.8 Hz), 3.38 (1H, dd, *J* = 13.4, 2.4 Hz), 3.06 (1H, td, *J* = 13.8, 3.4 Hz), 3.01-2.96 (1H, m), 2.85-2.79 (2H, m), 2.72 (1H, d, J = 14.5 Hz), 2.55 (1H, td, J = 13.3, 6.7 Hz), 2.43 (1H, d, J = 12.4 Hz), 1.97 (1H, d, J = 8.3 Hz), 1.94-1.90 (1H, m), 1.60-1.44 (3H, m), 1.36-1.27 (4H, m), 1.21-1.18 (1H, m), 1.14-1.09 (2H, m), 0.99 (9H, t, J = 7.9 Hz), 0.61-0.54 (6H, m); ¹³C NMR (151 MHz, C₆D₆) δ 212.4, 77.7, 64.6, 60.1, 59.3, 54.8, 53.5, 51.6, 51.3, 46.2, 43.8, 39.4, 29.1, 27.6, 27.5, 22.8, 7.2, 5.0; IR (ATR) 2951, 2875, 1764, 1696 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₄₀NO₃Si 394.2777; Found 394.2781.



Compound 168: To a solution of compound **167** (4.7 mg, 0.0119 mmol) in THF (400 μ L) and H₂O (200 μ L) was added TsOH·H₂O (22.3 mg, 0.117 mmol) at room temperature. After stirring at room temperature for 2.5 h, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CHCl₃/MeOH = 5:1. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂. To the solution were added 2,6-lutidine (14.0 μ L, 0.0601 mmol) and prepared 0.5 M solution of TESOTf in CH₂Cl₂ (25.0 μ L, 0.0125 mmol) at -78 °C. After stirring at -78 °C for 10 min, additional 0.5 M TESOTf in CH₂Cl₂ (12.5 μ L, 0.00625 mmol) was added at -78 °C and stirred for 10 min at the same temperature. MeOH was added for quenching the reaction. The resultant solution was poured on aq. NaHCO₃ and extracted with CHCl₃/MeOH = 5:1. After filtration, the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DualPore) (CHCl₃/MeOH = 40:1) to afford the mixture of **168** and **S4** (16:1) (3.2 mg, 0.00813 mmol, 68% for 2 steps) as a colorless oil: ¹H NMR (600 MHz, C₆D₆) δ : 4.06-4.01 (1H, m), 3.92 (0.6H, s), 3.77-3.72 (1H, m), 3.59 (0.4H, s), 3.55 (0.4H, dd, *J* = 13.4, 3.1 Hz), 3.20-3.10 (1.4H, m), 3.01 (0.6H, td, *J* = 13.8, 3.4 Hz), 2.92 (0.4H, dd, *J* = 14.7, 5.1), 2.88-2.81 (2H, m),

2.73-2.60 (1.6H, m), 2.50-2.47 (0.6H, m), 2.42-2.36 (1H, m), 2.18 (0.6H, q, J = 13.1 Hz), 2.09 (0.4H, q, J = 13.1 Hz), 2.00 (0.4H, d, J = 7.6 Hz), 1.97 (0.4H, dd, J = 13.1, 2.8 Hz), 1.93 (0.6H, s), 1.66-1.28 (7.4H, m), 1.23-1.15 (2.2H, m), 1.02-0.95 (9H, m), 0.61-0.53 (6H, m); ¹³C NMR (151 MHz, C₆D₆) δ 212.7, 103.9, 81.7, 76.7, 66.3, 64.9, 60.3, 59.0, 58.4, 54.7, 54.3, 54.1, 53.7, 53.2, 51.6, 51.3, 51.0, 46.8, 44.9, 43.4, 43.2, 40.6, 39.1, 33.9, 30.7, 30.2, 29.1, 28.1, 27.5, 27.1, 23.8, 23.5, 7.1, 7.0, 4.7, 4.6; IR (ATR) 2954, 2925, 2872, 1737 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₄₀NO₃Si 394.2777; Found 394.2771.



Compound 169: To a solution of compound **168** (4.3 mg, 0.0109 mmol) in CH₃CN (1 mL) were added NaBH(OAc)₃ (46.7 mg, 0.220 mmol) and AcOH (25.0 μ L, 0.437 mmol) at rt. Additional NaBH(OAc)₃ (46.7 mg, 0.220 mmol) and AcOH (25.0 μ L, 0.437 mmol) were added three times for 45 min. After stirring for 15 min the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by amino silica gel column chromatography (hexane/EtOAc = 1:1) to afford **169** (3.3 mg, 0.00834 mmol, 77%) as a colorless oil: ¹H NMR (600MHz, C₆D₆) δ 4.58 (1H, dd, *J* = 9.6, 4.8 Hz), 4.19 (1H, dd, *J* = 10.3, 8.3 Hz), 3.96 (1H, t, *J* = 5.5 Hz), 3.78 (1H, dd, *J* = 10.0, 5.8 Hz), 3.19-3.07 (3H, m), 2.84 (1H, dd, *J* = 14.1, 4.5 Hz), 2.74 (1H, d, *J* = 14.4 Hz), 2.53-2.50 (1H, m), 2.18 (1H, d, *J* = 13.8 Hz), 2.12 (1H, td, *J* = 13.4, 5.0 Hz), 1.87-1.76 (5H, m), 1.63-1.59 (1H, m), 1.53 (1H, m), 1.39-1.30 (3H, m), 1.23-1.15 (2H, m), 1.00 (9H, t, *J* = 7.9 Hz), 0.58 (6H, q, *J* = 8.0 Hz). ¹³C NMR (151 MHz, C₆D₆) δ : 76.1, 73.1, 63.5, 59.6, 54.2, 53.9, 52.5, 50.6, 48.3, 43.7, 41.0, 36.9, 30.2, 29.5, 27.0, 23.7, 7.1, 4.6; IR (ATR) 2977, 2920, 1469 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₄₂NO₃Si 396.2934; Found: 396.2937.



Compound S5: To a solution of compound **169** (3.3 mg, 0.00834 mmol) in CH₃CN (2 mL) were added 2,2⁻ bipyridyl (2.1 mg, 0.134 mmol), DMAP (3.0 mg, 0.0246 mmol) and AZADOL (0.6 mg, 0.00417 mmol) at room temperature then cooled to -20 °C. To the reaction mixture was added CuCl (1.3 mg, 0.0131 mmol) at -20 °C. After stirring for 30 min at the same temperature under air, the reaction was quenched with aq. NaHCO₃ and aq. Na₂S₂O₄. The resultant mixture was extracted with CH₂Cl₂ and dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DualPore) (CHCl₃/MeOH = 40:1) to afford **S5** (2.5 mg, 0.00635 mmol, 76%) as a colorless oil: ¹H NMR (600 MHz, C₆D₆) δ 4.01 (1H, t, *J* = 7.6 Hz), 3.61 (1H, dd, *J* = 10.0, 5.9 Hz), 3.20 (1H, dd, *J* = 9.6, 3.4 Hz), 3.08-2.99 (2H, m), 2.91 (1H, brm), 2.76 (1H, dd, *J* = 14.1, 5.2 Hz), 2.68 (1H, d, *J* = 16.5 Hz), 2.62-2.59 (1H, m), 2.38-2.33 (2H, m), 2.10 (1H, brs), 1.85 (1H, td, *J* = 13.4, 5.3 Hz), 1.77-1.73 (2H, m), 1.65-1.62 (1H, m), 1.49-1.46 (1H, m), 1.43-1.29 (4H, m), 1.14-1.07 (2H, m), 0.96 (9H, t, *J* = 7.9 Hz), 0.54 (6H, q, *J* = 8.0 Hz); ¹³C NMR (151 MHz, C₆D₆) δ 216.0, 74.3, 63.4, 59.4, 56.8, 53.9, 50.3, 45.8, 45.6, 42.4, 41.5, 40.8, 32.1, 30.2, 26.8, 23.8, 6.9, 4.5; IR

(ATR) 2919, 1734, 1467 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₄₀NO₃Si 394.2777; Found 349.2771.



Lyconesidine B: To a solution of compound **S5** (4.1 mg, 0.0104 mmol) in THF (1 mL) and H₂O (0.5 mL) was added TsOH·H₂O (2.1 mg, 0.0122 mmol) at room temperature. After stirring for 20 min at room temperature, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CHCl₃/MeOH = 5:1 then dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by diol silica gel column chromatography (CHCl₃/MeOH = 20:1) to afford **lyconesidine B** (1.8 mg, 0.00644 mmol, 62%) as a colorless solid: ¹H NMR (600 MHz, CD₃OD) δ 3.89 (1H, dd, *J* = 9.97, 6.3 Hz), 3.71 (1H, dd, *J* = 9.6, 9.6 Hz), 3.28-3.20 (2H, m), 3.16 (1H, ddd, *J* = 13.2, 13.2, 3.0 Hz), 3.09 (1H, m), 3.07 (1H, m), 2.84 (1H, br d, *J* = 15.0 Hz), 2.76 (1H, dd, *J* = 16.2, 7.2 Hz), 2.38 (1H, d, *J* = 18.0 Hz), 2.31 (1H, dd, *J* = 12.6, 2.4 Hz), 2.22 (1H, m), 2.18 (1H, m), 2.13 (1H, ddd, *J* = 13.5, 13.5, 4.4 Hz), 2.02 (1H, d, *J* = 12.0 Hz), 1.96 (1H, m). 1.90-1.76 (4H, m), 1.68 (1H, dd, *J* = 13.5, 13.5 Hz), 1.60 (1H, m), 1.58 (1H, ddd, *J* = 13.8, 13.8, 3.0 Hz). ¹³C NMR (151 MHz, CD₃OD) δ 220.20, 73.84, 60.47, 59.65, 57.91, 54.20, 51.21, 46.59, 46.10, 42.92, 42.69, 41.74, 31.80, 28.45, 27.30, 23.87; IR (ATR) 3304, 2958, 1717, 1522 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₆H₂₆NO₃ 280.1913, Found 280.1911.

Comparison of ¹H NMR data of synthetic with natural lyconesidine B.



1 H NMR (CD ₃ OD, 600MHz)		1 H NMR (CD ₃ OD, 500 MHz)		
No.		synthetic lyconesidine B	natural lyconesidine B	
16b	3.89	(1H, dd, <i>J</i> = 9.9, 6.3 Hz)	3.90 (1H, dd, <i>J</i> = 10.9, 5.8 Hz)	
16a	3.71	(1H, dd, J = 9.6, 9.6 Hz)	3.71	(1H, dd, <i>J</i> = 10.9, 8.9 Hz)
8	2 28 2 20		3.23	(1H, m)
1b	5.26-5.20	(21, 11)	3.20	(1H, m)
9b	3.16	(1H, ddd, J = 13.2, 13.2, 3.0 Hz)	3.14	(1H, ddd, <i>J</i> = 13.6, 13.6, 3.6 Hz)
13	3.09	(1H, m)	3.07	(1H, m)
9a	3.07	(1H, m)	3.04	(1H, m)
1a	2.84	(1H, br d, J = 15.0 Hz)	2.81	(1H, br d, J = 15.4 Hz)
6b	2.76	(1H, dd, <i>J</i> =16.2, 7.2 Hz)	2.75	(1H, dd, <i>J</i> =18.1, 7.2 Hz)
ба	2.38	(1H, d, <i>J</i> =18.0 Hz)	2.36	(1H, d, <i>J</i> =18.1 Hz)
4	2.31	(1H, dd, <i>J</i> =12.6, 2.4 Hz)	2.29	(1H, dd, <i>J</i> =12.4, 3.1 Hz)
3b	2.22	(1H, m)	2.20	(1H, m)
15	2.18	(1H, m)	2.17	(1H, m)
14b	2.13	(1H, ddd, <i>J</i> = 13.5, 13.5, 4.4 Hz)	2.13	(1H, ddd, <i>J</i> = 13.5, 13.5, 4.6 Hz)
11b	2.02	(1H, d, J = 12.0 Hz)	2.01	(1H, d, J = 13.1 Hz)
10b	1.96	(1H, m)	1.94	(1H, m)
7			1.86	(1H, d, J = 10.2 Hz)
2	1.90-1.76	(4H, m)	1.80	(2H, m)
14a			1.77	(1H, m)
3a	1.68	(1H, dd, <i>J</i> = 13.5, 13.5 Hz)	1.67	(1H, dd, <i>J</i> = 12.3, 12.3 Hz)
10a	1.60	(1H, m)	1.59	(1H, m)
11a	1.58	(1H, ddd, J=13.8, 13.8, 3.0 Hz)	1.57	(1H, ddd, J=13.1, 13.1, 3.2 Hz)

Comparison of ¹³C NMR data of synthetic with natural lyconesidine B.



Asymmetric cyclopropanation

Ru catalyst **124a** is commercially available. Known **127c-f** were prepared by reported procedure.⁷¹⁻⁷⁵ **124g** and **55** were synthesized by follow procedure.



Compound S6: To a suspension of (15,2R)-(+)-2-amino-1,2-diphenylethanol (235 mg, 1.1 mmol) in CH₂Cl₂ (3 mL) were added Et₃N (554 µL, 4.0 mmol) and methacryloyl chloride (100 µL, 1.0 mmol) at 0 °C. After stirring at room temperature overnight, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ then Et₃N (170 µL), MsCl (90 µL in 5 mL CH₂Cl₂) and DBU (180 µL) were added. After stirring for 3.5 h, MsCl (50 µL), Et₃N (90 µL) and DBU (90 µL) were added at 0 °C. After stirring for 10 min, the reaction mixture was extracted with CH₂Cl₂ then dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **S6** (122 mg, 0.463 mmol, 46%) as a white solid: [α] $_D$ ¹⁶ +118.3 (*c* 0.42, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.41-7.34 (5H, m), 7.32-7.30 (3H, m), 7.26-7.24 (2H, m), 6.03 (1H, s), 5.58 (1H, s), 5.28 (1H, d, *J* = 8.3 Hz), 5.11 (1H, d, *J* = 7.6 Hz), 2.16 (3H, s); ¹³C NMR (151 MHz, CDCl₃) δ 164.96, 141.79, 140.52, 132.62, 128.85, 128.78, 128.33, 127.73, 126.71, 125.58, 122.68, 88.71, 79.09, 19.48; IR (ATR) 3071, 3031, 2969, 2925, 1653, 1606 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₁₈H₁₈NO 264.1388, Found 264.1391.



Compound S7: To a solution of compound (1S,2R)-(+)-2-amino-1,2-diphenylethanol (235 mg, 1.1 mmol) in CH₂Cl₂ (3 mL) were added Et₃N (550 µL, 4.0 mmol) and 3,5-dimethylbenzoyl chloride (150 µL, 1.0 mmol). After stirring at room temperature overnight, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in CHCl₃ (6 mL) then SOCl₂ (360 µL, 5.0 mmol) was added at 0 °C. After stirring at room temperature overnight, the reaction was quenched with aq. NaHCO₃, extracted with CHCl₃ then dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford **S7** (265 mg, 0.809 mmol, 81%) as a white solid: $[\alpha]_D^{15}$ –13.8 (*c* 0.52, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.77 (2H, s), 7.42-7.35 (7H, m), 7.33-7.29 (3H, m), 7.18 (1H, s), 5.40 (1H, d, J = 7.6 Hz), 5.20 (1H, d, J = 7.6 Hz), 2.38 (6H, s).¹³C NMR (151 MHz, CDCl₃) δ 164.37, 142.01, 140.51, 138.16, 133.41, 128.91, 128.84, 128.42, 127.75, 127.12, 126.76, 126.31, 125.69, 88.88, 78.94, 21.16; IR (ATR) 3031, 2920, 1641, 1597 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₃H₂₂NO 328.1701, Found 328.1699.



Compound 55: To a solution of **S6** (53 mg, 0.2 mmol), [(benzene)RuCl₂]₂ (50 mg, 0.1 mmol) and KPF₆ (147 mg, 0.8 mmol) in CH₃CN (3.5 mL) was added 1 M aq. NaOH (200 μ L, 0.2 mmol). After refluxing for at 80 °C 24 h, the reaction mixture was extracted with CH₂Cl₂ then dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CH₂Cl₂/CH₃CN = 20:1) to afford **55** (107 mg, 0.159 mmol, 80%) as a yellow solid: ¹H NMR (600 MHz, CD₃CN) δ 9.99 (1H, s), 7.43-7.40 (5H, m), 7.34 (1H, t, *J* = 6.9 Hz), 7.29 (2H, d, *J* = 7.6 Hz), 7.25 (2H, d, *J* = 8.3 Hz), 5.58 (1H, d, *J* = 6.9 Hz), 4.73 (1H, d, *J* = 6.9 Hz), 2.36 (3H, s), 2.19 (3H, s), 2.11 (3H, s), 2.09 (4H, s), 1.96 (3H, s). ¹³C NMR (151 MHz, CD₃CN) δ 208.89, 176.65, 142.60, 140.70, 130.00, 129.85, 129.38, 129.01, 128.57, 126.71, 125.90, 123.07, 123.00, 122.94, 91.86, 76.79, 18.29, 4.20, 4.00, 3.91; IR (ATR) 2913, 2270, 1603 cm⁻¹; Anal. Calcd for C₂₆H₂₈F₆N₅OPRu: C, 46.43; H, 4.20; N, 10.41; F, 16.95. Found: C, 46.46; H, 4.21; N, 10.35; F, 16.78.



Compound 124g: To a solution of **S7** (57 mg, 0.2 mmol), [(benzene)RuCl₂]₂ (50 mg, 0.1 mmol) and KPF₆ (147 mg, 0.8 mmol) in CH₃CN (3.5 mL) was added 1 M aq. NaOH (200 μ L, 0.2 mmol). After refluxing at 85 °C for 24 h, the reaction mixture was extracted with CH₂Cl₂ then dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CH₂Cl₂/CH₃CN = 10:1) to afford **124g** (106 mg, 0.179 mmol, 90%) as a yellow solid: ¹H NMR (600 MHz, CD₃CN) δ 7.46-7.38 (5H, m), 7.37 (1H, m), 7.33-7.32 (2H, m), 7.29 (2H, m), 7.22 (1H, s), 6.91 (1H, s), 5.70 (1H, d, *J* = 6.2 Hz), 4.97 (1H, d, *J* = 6.2 Hz), 2.50 (3H, s), 2.34 (3H, s), 2.28 (3H, s), 2.14 (4H, s), 2.04 (3H, s), 1.95 (3H, d, *J* = 4.8 Hz); ¹³C NMR (151 MHz, CD₃CN) δ 179.57, 176.00, 150.90, 141.90, 140.33, 135.19, 133.18, 131.00, 130.13, 130.07, 129.53, 129.25, 128.57, 126.79, 124.89, 124.44, 92.19, 77.38, 26.48, 20.51, 4.23, 3.96, 3.91; IR (ATR) 2933, 2269, 1627 cm⁻¹; Anal. Calcd for C₃₁H₃₂F₆N₅OPRu: C, 50.54; H, 4.38; N, 9.51; F, 15.47. Found: C, 50.44; H, 4.46; N, 9.42; F, 15.44.



Compound (+)-142: (+)-142 was prepared from (+)-49 (23:77 er) by the same procedure to racemic 142: $[\alpha]_D^{19}$ 0.21 (*c* 1.62, CHCl₃).



Compound (-)-**49**: To a solution of **48** (95 mg, 0.21 mmol) in THF (5.3 mL) was added Ru catalyst **55** (6.9 mg, 0.010 mmol) at room temperature. After 30 min, the reaction solution was cooled to -78 °C then NaBH(O₂CCF₃)₃ (450 µL, 0.23 mmol, 0.5 M THF solution), which was prepared from NaBH₄ (37.8 mg, 1.0 mmol) and TFA (230 µL, 3.0 mmol),⁵ was added dropwise at -78 °C then warmed to 0 °C. After 30 min, the reaction was quenched with aq. NaHCO₃. The resultant mixture was extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford (-)-**49** (47.3 mg, 0.11 mmol, 53%) as a yellow oil. Epimers on C7 and an enol isomer were observed in CDCl₃: $[\alpha]_D^{17}$ –11.0 (*c* 4.73, CHCl₃); ¹H NMR (600 MHz, CDCl₃, major isomer) δ 4.35 (1H, d, *J* = 13.1 Hz), 4.08 (1H, d, *J* = 11.0 Hz), 3.69-3.65 (1H, m), 3.48-3.41 (1H, m), 3.37-3.36 (1H, m), 3.14 (1H, s), 2.72-2.67 (1H, m), 2.64-2.61 (1H, m), 2.31-2.25 (2H, m), 2.14-2.12 (1H, m), 1.56-1.53 (1H, m), 1.49-1.43 (11H, m), 0.90 (9H, s), 0.09 (6H, m) ; ¹³C NMR (151 MHz, CDCl₃, major isomer) δ 196.4, 154.4, 114.6, 80.1, 64.3, 64.1, 52.7, 49.0, 46.5, 40.1, 37.7, 28.4, 26.9, 25.7, 22.3, 18.4, -6.0, -6.1; IR (ATR) 2940, 2862, 2251, 1698 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₂H₃₉N₂O₄Si 423.2679; Found 423.2676.



Compound (-)-**139**: To a solution of (-)-**49** (47.3 mg, 0.11 mmol) in acetone (1.1 mL) were added Cs₂CO₃ (107 mg, 0.33 mmol) and allyl bromide (19 µL, 0.22 mmol) at room temperature. After stirring overnight, the reaction was filtered through celite with EtOAc and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc = 5:1) to afford (-)-**139** (43.4 mg, 0.091 mmol, 81%, 76 %ee) as a yellow solid: $[\alpha]_D^{16}$ -96.3 (*c* 3.98, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 5.97-5.91 (1H, m), 5.39 (1H, dd, 17.4, 1.2 Hz), 5.27-5.24 (1H, m), 4.55-4.50 (2H, m), 4.28-4.26 (1H, m), 3.79 (1H, d, *J* = 9.6 Hz), 3.65 (1H, d, *J* = 10.3 Hz), 3.00 (1H, dd, *J* = 13.1, 2.8 Hz), 2.82-2.74 (1H, m), 2.67 (1H, td, *J* = 13.3, 3.2 Hz), 2.51-2.48 (1H, m), 2.43 (1H, d, *J* = 13.8 Hz), 2.36-2.29 (1H, m), 2.16-2.12 (1H, m), 1.62-1.48 (11H,m), 1.29 (1H, td, *J* = 13.1, 2.8 Hz), 0.91 (9H, s), 0.06 (6H, m); ¹³C NMR (151 MHz, CDCl₃) δ 166.6, 154.6, 132.7, 117.9, 116.6, 95.0, 79.7, 68.7, 63.9, 62.9, 48.8, 41.1, 33.4, 28.4, 27.2, 25.8, 23.3, 21.7, 18.2, -5.5, -5.8; IR (ATR) 2936, 2862, 2210, 1691, 1626 cm⁻¹; HRMS (FAB) *m/z*: [M+H]⁺ Calcd for C₂₅H₄₃N₂O₄Si 463.2992; Found 463.2988. The enantiomeric excess was determined by UPC analysis: IC-3/SFC, 1.0 mL/min, 5% MeOH/CO₂, λ = 210-400 nm, t_R(*ent*-**139**) = 11.4 min, t_R(**139**) = 12.5 min



2. Crystallographic Data

The data of compound **142**, (+)-**142**, **22**·**HCl** were collected with a Rigaku XtaLAB P200 diffractometer using multi-layer mirror monochromated Cu-Kα radiation at 100 K.

2-1. Compound 142

142 was crystalized from hexane/EtOAc solvent system as clear plate crystal.ORTEP Diagram of 142 Showing Thermal Ellipsoids at the 50% Probability Level



CCDC 2059098 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via <u>www.ccdc.cam.ac.uk/data_request/cif</u>.

Bond precision: C-C = 0.0023 A Wavelength=1.54184 Cell: a=12.7065(2) b=13.0358(2) c=33.6268(5) alpha=90 beta=90 gamma=90 Temperature: 93 K

	Calculated	Reported
Volume	5569.92(15)	5569.92(15)
Space group	P b c a	P b c a
Hall group	-P 2ac 2ab	-P 2ac 2ab
Moiety formula	C26 H44 N2 O5 Si	C26 H44 N2 O5 Si
Sum formula	C26 H44 N2 O5 Si	C26 H44 N2 O5 Si
Mr	492.72	492.72
Dx, g cm-3	1.175	1.175
Z	8	8
Mu (mm-1)	1.034	1.034
F000	2144.0	2144.0
F000'	2151.96	
h,k,lmax	15,16,41	15,16,41
Nref	5611	5556
Tmin,Tmax	0.883,0.902	0.738,1.000
Tmin'	0.733	
Correction method= # Report	ed T Limits: Tmin=0.738 Tmax	=1.000
AbsCorr = MULTI-SCAN		
Data completeness= 0.990	Theta(max)= 73.5	560
R(reflections)= 0.0489(5192)) wR2(reflections)=	= 0.1344(5556)
S = 1.063 N	Jpar= 324	

2-2. Compound (+)-142

(+)-142 was crystalized from hexane/EtOAc solvent system as clear plate crystal.

ORTEP Diagram of (+)-142 Showing Thermal Ellipsoids at the 50% Probability Level



CCDC 2059096 contains the supplementary crystallographic data for this paper. These data can be obtained free

Bond precision:	C-C = 0.0025 A	Wavelength=1.	54184
Cell:	a=7.60718(4)	b=12.22825(3)	c=31.00880(18)
alpha=90 beta=	90 gamma=90)	
Temperature:	93 K		
		Calculated	Reported
Volume		2884.52(3)	2884.52(3)
Space group		P 21 21 21	P 21 21 21
Hall group		P 2ac 2ac	P 2ac 2ac
Moiety formula	a	C26 H44 N2 O5 Si	C26 H44 N2 O5 Si
Sum formula		C26 H44 N2 O5 Si	C26 H44 N2 O5 Si
Mr		492.72	492.72
Dx, g cm-3		1.135	1.135
Ζ		4	4
Mu (mm-1)		0.999	0.999
F000		1072.0	1072.0
F000'		1075.98	
h,k,lmax		9,15,38	9,15,38
Nref		5809[3319]	5671
Tmin,Tmax		0.791,0.867	0.606,1.000
Tmin'		0.500	
Correction metho	d= # Reported T	Limits: Tmin=0.606 Tn	nax=1.000
AbsCorr = GAUS	SSIAN		
Data completenes	ss= 1.71/0.98	Theta(max)=	73.432
R(reflections)= 0	.0297(5646)	wR2(reflection	ns)= 0.0807(5671)
S = 1.061	Npar=	316	

of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

2-3. Compound 166·HCl

166•**HCl** was crystalized from hexane/toluene solvent system as clear plate crystal. ORTEP Diagram of **166**•**HCl** Showing Thermal Ellipsoids at the 50% Probability Level



CCDC 2040075 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via <u>www.ccdc.cam.ac.uk/data_request/cif</u>.

Bond precision:	C-C = 0.0041 A	Wavelength=1.54184	
Cell: alpha=82.849(2) Temperature:	a=8.8964(2) beta=79.063(2) 100 K	b=12.6421(3) c=20.2671(4 gamma=89.715(2)	4)
		Calculated	Reported
Volume		2220.21(9)	2220.21(9)
Space group		P -1	P -1
Hall group		-P 1	-P 1
Moiety formula	a	C21 H38 N O2 Si, Cl	Cl, C21 H38 N O2 Si
Sum formula		C21 H38 Cl N O2 Si	C21 H38 Cl N O2 Si
Mr		400.06	400.06
Dx, g cm-3		1.197	1.197
Z		4	4
Mu (mm-1)		2.145	2.145
F000		872.0	872.0
F000'		876.42	
h,k,lmax		11,15,25	10,15,25
Nref		8959	8549
Tmin,Tmax		0.712,0.778	0.581,1.000
Tmin'		0.188	

Correction method= # Reported T Limits: Tmin=0.581 Tmax=1.000

AbsCorr = MULTI-SCAN

Data completeness= 0.954

Theta(max)=73.642
S = 1.070 Npar= 528

3. Details for DFT calculation

3-1. Epoxidation of tetracyclic diene 53

The molecular geometries for the transition states were first estimated by Reaction plus software package, based on the nudged elastic band (NEB) method,⁷³ and were subsequently re-optimized at ω B97XD/6-311G(d,p) level using Gaussian09 software package.⁷⁴

Diene N-Oxide



E(RwB97XD)=-788.089080

Zero-point correction=	0.322587 (Hartree/Particle)
Thermal correction to Energy=	0.336210
Thermal correction to Enthalpy=	0.337155
Thermal correction to Gibbs Free Energy=	0.283692
Sum of electronic and zero-point Energies=	-787.766493
Sum of electronic and thermal Energies=	-787.752869
Sum of electronic and thermal Enthalpies=	-787.751925
Sum of electronic and thermal Free Energies=	-787.805388

The coordinates of the structure

01

С	1.84901100	-0.18723200	-0.83039000
С	2.47075800	1.02553000	-0.11153700
С	1.58981900	2.23163800	0.12272700
С	0.20185400	1.84132200	0.62654100
С	-0.41889900	0.89003400	-0.37722200

С	0.34559100	-0.43326800	-0.50783100
Н	2.11053700	2.89908000	0.80975200
Н	1.98641200	0.00227900	-1.90228200
Н	0.28614000	1.36881500	1.61138400
Н	-0.44580300	2.71450400	0.70655200
Н	-0.40263700	1.38632600	-1.35292400
Н	1.48899600	2.75678100	-0.83637600
С	-0.30186200	-1.26715400	-1.63430400
Н	0.21922200	-2.22171700	-1.73979200
Н	-0.18286700	-0.72256600	-2.57955800
С	-1.78767600	-1.49200000	-1.37514500
Н	-2.24688700	-2.00002900	-2.22799100
Н	-1.93525000	-2.13664700	-0.50673600
С	-2.49522400	-0.15883900	-1.19879900
Н	-3.54918900	-0.25952800	-0.94240700
Н	-2.43583000	0.44174500	-2.10716600
0	3.63196800	1.02023300	0.21300700
Ν	-1.91457400	0.75949600	-0.15812600
С	-2.29390600	0.34427000	1.23593900
Н	-2.08453300	1.23630800	1.82946200
Н	-3.38113900	0.27284800	1.19409600
С	0.46906500	-1.29313300	0.74967700
С	-0.56525100	-1.51272800	1.74883800
Н	-0.34668800	-2.31025700	2.45459800
С	2.54762600	-1.47261600	-0.36069000
Н	3.57511800	-1.26751200	-0.05776400
Н	2.57956700	-2.23594500	-1.14722100
С	1.66214000	-1.89928300	0.77420700
Н	1.95934000	-2.62971300	1.51839100
С	-1.71514600	-0.85790500	1.91747500
Н	-2.33708100	-1.17540400	2.75111200
0	-2.48232000	1.98130900	-0.34365300

CCl₃C=NHOOH



E(RwB97XD)=-1663.087637

Zero-point correction=	0.050313 (Hartree/Particle)
Thermal correction to Energy=	0.058834
Thermal correction to Enthalpy=	0.059778
Thermal correction to Gibbs Free Energy=	0.015159
Sum of electronic and zero-point Energies=	-1663.037325
Sum of electronic and thermal Energies=	-1663.028803
Sum of electronic and thermal Enthalpies=	-1663.027859
Sum of electronic and thermal Free Energies=	-1663.072479

01			
С	-0.51736400	-0.03299300	0.00020100
С	0.93648600	0.46836600	-0.00045600
0	1.76682900	-0.57583200	-0.00053600
0	3.11918700	-0.16932000	0.00019200
Н	3.02909500	0.80768400	-0.00081000
Ν	1.37765100	1.64497100	-0.00073400
Н	0.66292200	2.36086600	-0.00067900
Cl	-1.63502600	1.35639700	-0.00053000
Cl	-0.79866800	-1.01241300	-1.45862200
Cl	-0.79797800	-1.01071200	1.45979300

Epoxidation TS₁₆₄ (+1.4 kcal/mol)



E(RwB97XD)=-2451.154869

Zero-point correction=	0.372297 (Hartree/Particle)
Thermal correction to Energy=	0.395679
Thermal correction to Enthalpy=	0.396623
Thermal correction to Gibbs Free Energy=	0.317472
Sum of electronic and zero-point Energies=	-2450.782572
Sum of electronic and thermal Energies=	-2450.759191
Sum of electronic and thermal Enthalpies=	-2450.758246
Sum of electronic and thermal Free Energies=	-2450.837397

Imaginary frequency =-544.88i

01			
С	-2.66830300	1.72385600	-0.83705100
С	-4.10088000	1.94715500	-0.31278600
С	-5.03910300	0.76291700	-0.33168000
С	-4.37613800	-0.47933400	0.26358000
С	-3.12130200	-0.77727200	-0.53431000
С	-2.06079300	0.33502200	-0.46854700
Н	-5.94799200	1.04310900	0.20070400
Н	-2.72589800	1.83325000	-1.92652000
Н	-4.14265900	-0.30191200	1.31949500
Н	-5.03175900	-1.34699100	0.18944700
Н	-3.42096900	-0.87234800	-1.58218600
Н	-5.30980000	0.56013900	-1.37578200
С	-0.93189700	-0.03715400	-1.46023500

Н	-0.16692900	0.73431400	-1.48195400
Н	-1.38343200	-0.10311000	-2.45767400
С	-0.32204400	-1.38253000	-1.09228200
Н	0.43727100	-1.66218300	-1.82754700
Н	0.19258600	-1.32196900	-0.12985900
С	-1.39359000	-2.45871800	-1.10370700
Н	-1.03468000	-3.43556300	-0.78184100
Н	-1.81820400	-2.57870100	-2.10062300
0	-4.45529300	3.03068400	0.07859400
Ν	-2.61551300	-2.18191700	-0.26381700
С	-2.37750500	-2.46855000	1.18774100
Н	-3.38583200	-2.57645600	1.59470600
Н	-1.95527100	-3.47415700	1.19740300
С	-1.48950000	0.64661100	0.91062700
С	-1.25718700	-0.27594100	1.99701300
Н	-0.74407500	0.15222000	2.85347700
С	-1.71425500	2.74171000	-0.19057500
Н	-2.24708300	3.65231700	0.08148600
Н	-0.88156000	3.00926200	-0.84480300
С	-1.20828400	1.99109500	1.00907300
Н	-0.93156700	2.47843800	1.93433900
С	-1.59254800	-1.56730200	2.07954100
Н	-1.33163100	-2.06792800	3.00905800
0	0.61005700	1.50121100	0.47124600
0	-3.57712700	-3.06230200	-0.65116800
Н	0.85932700	0.83041800	1.16036800
0	2.31884000	1.42895300	-0.09641900
С	2.83193800	0.42699100	0.52275300
С	4.20963400	0.02740900	-0.08184200
Ν	2.24380400	-0.19553300	1.47080300
Н	2.77638200	-0.96267400	1.85744500
Cl	3.89263700	-0.72809100	-1.67228400
Cl	5.23411800	1.46289500	-0.28870000
Cl	5.06703700	-1.15077400	0.95510400

Epoxidation TS₁₆₃



E(RwB97XD)=-2451.159034

Zero-point correction=	0.372445 (Hartree/Particle)
Thermal correction to Energy=	0.395610
Thermal correction to Enthalpy=	0.396554
Thermal correction to Gibbs Free Energy=	0.319453
Sum of electronic and zero-point Energies=	-2450.786589
Sum of electronic and thermal Energies=	-2450.763424
Sum of electronic and thermal Enthalpies=	-2450.762480
Sum of electronic and thermal Free Energies=	-2450.839581

Imaginary frequency =-547.49i

01			
С	-2.04533700	2.11697500	0.37875900
С	-0.77514300	2.18236800	1.24821600
С	-0.32357500	0.95431700	2.00897200
С	-0.74206100	-0.38421300	1.40779000
С	-2.21455300	-0.33179300	1.04848100
С	-2.53699900	0.70241100	-0.03891400
Н	0.75885200	1.02898300	2.11376400
Н	-2.81423600	2.61441200	0.97928900
Н	-0.13357600	-0.59810100	0.52734600
Н	-0.60787500	-1.18918800	2.13027300
Н	-2.76760200	-0.04591000	1.94937000
Н	-0.75197000	1.05216100	3.01564200
С	-4.07037500	0.74436500	-0.26116400

Н	-4.31786100	1.45413200	-1.05518200
Н	-4.52104900	1.12590100	0.66255200
С	-4.65545700	-0.63082900	-0.56236200
Н	-5.74769500	-0.57543100	-0.56564100
Н	-4.35825400	-0.97607100	-1.55363800
С	-4.24906900	-1.62440500	0.51342100
Н	-4.56965700	-2.64369600	0.30154500
Н	-4.66197700	-1.34824000	1.48419500
0	-0.22124400	3.24293400	1.38227000
Ν	-2.77462600	-1.71967800	0.79804400
С	-2.04605900	-2.48330600	-0.27028700
Н	-1.06813500	-2.68755800	0.17202900
Н	-2.56342800	-3.44237600	-0.29433900
С	-1.87037100	0.52213900	-1.39132800
С	-1.74350900	-0.71370200	-2.13193500
Н	-1.47919000	-0.60109700	-3.17966100
С	-1.81448900	2.85690600	-0.95154900
Н	-1.02331200	3.60063000	-0.85791700
Н	-2.71918100	3.36686500	-1.30034600
С	-1.46568800	1.73892500	-1.88488800
Н	-1.15688100	1.89672100	-2.91065200
С	-1.84760300	-1.95851000	-1.65662000
Н	-1.66912700	-2.76068700	-2.36836000
0	0.27324300	1.23499200	-1.07129500
0	-2.63740300	-2.45456700	1.93073700
Н	0.46357500	0.38901000	-1.55937400
0	1.93909600	1.15565000	-0.42422000
С	2.37984700	-0.00355900	-0.76621300
С	3.69679000	-0.35947000	-0.01879400
Ν	1.75918400	-0.78350400	-1.56427900
Н	2.22807800	-1.66213500	-1.73657400
Cl	4.50677900	-1.77151500	-0.76002000
Cl	4.81484600	1.01784400	-0.03117800
Cl	3.24902000	-0.76867100	1.66413200

Compound 164 (+4.1 kcal/mol)



E(RwB97XD)=-863.281388

Zero-point correction=	0.327555 (Hartree/Particle)
Thermal correction to Energy=	0.341712
Thermal correction to Enthalpy=	0.342657
Thermal correction to Gibbs Free Energy=	0.287867
Sum of electronic and zero-point Energies=	-862.953833
Sum of electronic and thermal Energies=	-862.939675
Sum of electronic and thermal Enthalpies=	-862.938731
Sum of electronic and thermal Free Energies=	-862.993521

01			
С	1.77938800	0.17548800	-0.89910100
С	2.23227600	1.44256500	-0.14250200
С	1.22408700	2.55332900	0.00893000
С	-0.08557900	1.99714700	0.56263300
С	-0.59982800	0.94367700	-0.40130600
С	0.31491900	-0.28414600	-0.58468200
Н	1.65553400	3.32052000	0.65172200
Н	1.86834300	0.42684100	-1.96415900
Н	0.08283700	1.57957500	1.56073400
Н	-0.84502100	2.77657200	0.62834600
Н	-0.67088000	1.42640200	-1.38082900
Н	1.04062800	2.99726700	-0.97749300
С	-0.26653200	-1.12213100	-1.73565000
Н	0.36882300	-1.98225700	-1.93966000
Η	-0.30185500	-0.50440300	-2.64067700
С	-1.67493500	-1.57394300	-1.36358400

Н	-2.11748000	-2.15781800	-2.17521600
Н	-1.64201000	-2.22878800	-0.48868500
С	-2.56770400	-0.36829700	-1.12957300
Н	-3.57214300	-0.62997300	-0.79886200
Н	-2.66627200	0.22461200	-2.03887200
0	3.34956100	1.53779700	0.30161500
Ν	-2.06501000	0.65038300	-0.13939600
С	-2.35052400	0.27411200	1.28586900
Н	-2.34494400	1.23906200	1.79566400
Н	-3.39317700	-0.04707600	1.28313500
С	0.52679400	-1.20221700	0.64532600
С	-0.32406400	-1.24147300	1.84819900
Н	0.07278700	-1.89052500	2.62366200
С	2.68188800	-0.99841500	-0.49153400
Н	3.66785700	-0.63410600	-0.20763300
Н	2.79266700	-1.73284100	-1.29152100
С	1.94135100	-1.62524000	0.67298800
Н	2.45637400	-1.87778700	1.59561600
С	-1.51253400	-0.68880500	2.06213900
Н	-1.97486500	-0.90599800	3.02286100
0	0.93477600	-2.53488000	0.26849100
0	-2.77635700	1.79185000	-0.35901500

Compound 163



E(RwB97XD)=-863.288557

Zero-point correction=	0.327724 (Hartree/Particle)
Thermal correction to Energy=	0.341838
Thermal correction to Enthalpy=	0.342782
Thermal correction to Gibbs Free Energy=	0.288531

Sum of electronic and zero-point Energies=	-862.960833
Sum of electronic and thermal Energies=	-862.946719
Sum of electronic and thermal Enthalpies=	-862.945775
Sum of electronic and thermal Free Energies=	-863.000026

0 1			
С	-1.71500700	0.00494300	0.98108900
С	-2.38721500	1.13797100	0.18891200
С	-1.51368200	2.26589900	-0.31959800
С	-0.13305800	1.82555700	-0.80042400
С	0.52109800	1.00116600	0.29260200
С	-0.23641100	-0.29367300	0.59608500
Н	-2.07194900	2.79129500	-1.09484200
Н	-1.77029500	0.31693400	2.02991700
Н	-0.23673400	1.24640800	-1.72139000
Н	0.50744700	2.68590300	-0.99323200
Н	0.53755000	1.61188600	1.20162900
Н	-1.39661100	2.96467600	0.52040500
С	0.44488200	-1.03234200	1.76913600
Н	-0.03202800	-2.00224700	1.93376100
Н	0.26734300	-0.43560500	2.67153900
С	1.95235100	-1.21118400	1.59961200
Н	2.38921500	-1.53442000	2.54904200
Н	2.17525000	-1.99093900	0.87244900
С	2.61624700	0.10055700	1.21345800
Н	3.67170800	-0.00989000	0.96706000
Н	2.54471500	0.83709400	2.01474800
0	-3.58583800	1.16467500	0.06548400
Ν	2.00713400	0.82153900	0.04293700
С	2.33989300	0.14606500	-1.26231200
Н	2.00658400	0.85781500	-2.01925500
Н	3.42822600	0.18395600	-1.27927000
С	-0.42361900	-1.24121600	-0.59207200
С	0.69892300	-1.83405500	-1.34955400
Н	0.51355800	-2.81258900	-1.78214700
С	-2.46053000	-1.32021900	0.74615500
Н	-3.51942300	-1.13747200	0.56094600
Н	-2.36467400	-2.00359200	1.59371300

С	-1.74260000	-1.87489000	-0.45988700
Н	-1.94967700	-2.87043800	-0.84033700
С	1.85596500	-1.23532100	-1.60990200
Н	2.56026900	-1.77634000	-2.23694900
0	-1.52516600	-0.87620600	-1.44958400
0	2.58427700	2.04793800	-0.01691900

CCl₃CONH₂



E(RwB97XD)=-1587.995684

Zero-point correction=	0.046325 (Hartree/Particle)
Thermal correction to Energy=	0.054168
Thermal correction to Enthalpy=	0.055112
Thermal correction to Gibbs Free Energy=	0.012104
Sum of electronic and zero-point Energies=	-1587.949359
Sum of electronic and thermal Energies=	-1587.941516
Sum of electronic and thermal Enthalpies=	-1587.940572
Sum of electronic and thermal Free Energies=	-1587.983580

01			
С	-0.21232200	0.01200600	0.00007100
С	1.26697000	-0.52625400	0.00024400
0	1.49572400	-1.70343700	0.00028100
Ν	2.20113400	0.44736400	0.00072600
Н	1.97662900	1.42646800	-0.00139500
Cl	-0.47051600	1.01908300	-1.46158700
Cl	-1.34377500	-1.33455100	0.00079200
Cl	-0.47064200	1.02083100	1.46037300
Н	3.16560700	0.16378200	-0.00065000

<u>3-2. Structure of Ru catalysts</u>

All of optimization was performed at ω B97XD/(LANL2DZ: Ru; 6-31G(d): others) level using Gaussian09 software package.⁷⁷

Compound 174a



$E(R\omega B97XD) = -1333.19077672$

Zero-point correction=	0.430702 (Hartree/Particle)
Thermal correction to Energy=	0.463907
Thermal correction to Enthalpy=	0.464851
Thermal correction to Gibbs Free Energy=	0.360057
Sum of electronic and zero-point Energies=	-1332.760075
Sum of electronic and thermal Energies=	-1332.726870
Sum of electronic and thermal Enthalpies=	-1332.725926
Sum of electronic and thermal Free Energies=	-1332.830720

The coordinates of the structure

1 1

С	2.12444800	-0.70460400	-0.37361600
С	1.74035800	-2.06404000	-0.29838500
С	0.37229400	-2.23649200	0.14016600
Ν	-0.36975400	-1.19790600	0.35542300
0	-0.17955500	-3.42386300	0.38698400
С	-1.56124500	-3.16860200	0.71531600
С	-1.63239300	-1.63647000	0.94611100
Ru	0.64941700	0.62584900	0.11620800
Н	-1.81797300	-3.76245100	1.59229500

Ν	1.23101400	0.48222700	2.07856300
С	1.61613100	0.32559600	3.15435600
С	2.11581100	0.12216700	4.50849500
Н	1.31669000	-0.25788400	5.15019200
Н	2.48098700	1.06790800	4.91718200
Н	2.93594200	-0.60053400	4.49313700
Ν	0.14803100	0.67938200	-1.86849600
С	-0.07517100	0.65149800	-2.99966000
С	-0.35654300	0.60189600	-4.42889300
Н	-0.26413400	1.60037200	-4.86391700
Н	-1.37199800	0.23315600	-4.59693700
Н	0.35230800	-0.06915100	-4.92115100
Ν	1.83606300	2.29904400	-0.13513100
С	2.51789900	3.22040600	-0.27000700
С	3.38809800	4.37786400	-0.44074400
Н	3.12012700	5.15659500	0.27807100
Н	3.28292700	4.77692300	-1.45297600
Н	4.42964400	4.08705800	-0.27990700
Ν	-1.13039100	1.86621800	0.61563700
С	-2.16454100	2.35321700	0.77032600
С	-3.48432600	2.94404800	0.94778300
Н	-3.91588500	2.60712800	1.89345100
Н	-4.13425300	2.61644500	0.13229100
Н	-3.41356400	4.03459400	0.94903200
С	3.44023300	-0.46431200	-0.78406400
Н	3.80284200	0.55718300	-0.86624200
С	2.59492600	-3.12692100	-0.60396000
Н	2.24389400	-4.15187000	-0.52479700
С	4.30530000	-1.51297000	-1.09402700
Н	5.32193600	-1.29261500	-1.41009200
С	3.89170100	-2.84493700	-1.00626000

Н	4.57793900	-3.64926800	-1.25044900
Н	-1.60892100	-1.40312500	2.01918700
Н	-2.17359200	-3.48072900	-0.13573600
С	-2.86440600	-1.00434700	0.34173900
С	-5.19362400	0.07048700	-0.77739100
С	-2.93679500	-0.75121900	-1.02860000
С	-3.96558200	-0.71219100	1.14624400
С	-5.12921600	-0.18450100	0.59023900
С	-4.09124900	-0.20967600	-1.58424800
Н	-2.07629200	-0.97276500	-1.65277100
Н	-3.91820700	-0.90625100	2.21546000
Н	-5.98553900	0.02383900	1.22468600
Н	-4.13955600	-0.01613700	-2.65195900
Н	-6.10062700	0.47699500	-1.21454600

Compound 174e



$E(R\omega B97XD) = -1564.17074127$

Zero-point correction=	0.512676 (Hartree/Particle)
Thermal correction to Energy=	0.550274
Thermal correction to Enthalpy=	0.551218
Thermal correction to Gibbs Free Energy=	0.436701
Sum of electronic and zero-point Energies=	-1563.658065
Sum of electronic and thermal Energies=	-1563.620468
Sum of electronic and thermal Enthalpies=	-1563.619523
Sum of electronic and thermal Free Energies=	-1563.734040

1 1

С	1.52319100	-1.60159900	-1.01764000
С	0.40967900	-1.59887200	-1.89318400
С	-0.61084900	-0.66025100	-1.48450100
Ν	-0.40534500	0.09381700	-0.45677500
0	-1.80363200	-0.53358700	-2.07492400
С	-2.62170300	0.23607300	-1.16738900
С	-1.58029100	0.91466000	-0.21527200
Ru	1.38786300	-0.27131500	0.53244600
Ν	0.31631400	-1.66381900	1.59955100
С	-0.42123600	-2.41635600	2.06855600
С	-1.37132600	-3.35618600	2.64843300
Н	-1.36613700	-3.27252500	3.73823200
Н	-1.10331800	-4.37750700	2.36550900
Н	-2.37399900	-3.13082800	2.27132500
Ν	2.31853300	1.13217400	-0.62682500
С	2.74743900	1.94774900	-1.31965100
С	3.25859100	2.99253900	-2.19652200
Н	2.57322700	3.84465900	-2.17805300
Н	3.33728900	2.61466000	-3.21928500
Н	4.24610600	3.31851800	-1.86010900
Ν	3.18014700	-0.82921200	1.40309600
С	4.17659500	-1.16943900	1.87562500
С	5.43540600	-1.60930300	2.46538700
Н	5.75564900	-0.90351000	3.23619500
Н	6.20703100	-1.66880100	1.69325200
Н	5.30825000	-2.59662100	2.91713600
Ν	1.00706100	1.32995600	2.03524400
С	0.73123100	2.29040200	2.61239600
С	0.37585700	3.51942100	3.31039400

Н	-0.04130200	4.22926300	2.59021200
Н	1.26211900	3.95599900	3.77777400
Н	-0.36822800	3.31098400	4.08347100
С	2.54359900	-2.50398900	-1.33633300
Н	3.42913300	-2.56112500	-0.70873300
С	0.29714100	-2.43506000	-3.00757000
Н	-0.58606900	-2.39098600	-3.63896300
С	2.45071600	-3.34019300	-2.44814300
Н	3.26213000	-4.02952100	-2.66798000
С	1.33308400	-3.31336500	-3.28710600
Н	1.27702100	-3.97313900	-4.14676000
Н	-1.89919500	0.79192100	0.82440600
Н	-3.16669000	0.96737900	-1.76735100
С	-1.33028800	2.38260900	-0.48472300
С	-0.93801800	5.10828800	-0.99439300
С	-0.63554600	2.79557700	-1.62347100
С	-1.82950200	3.34639700	0.39082400
С	-1.63533600	4.70392200	0.14050700
С	-0.44375600	4.14995400	-1.87823900
Н	-0.24544300	2.05206200	-2.31350200
Н	-2.38164800	3.03255000	1.27468700
Н	-2.03954500	5.44482800	0.82439700
Н	0.07702500	4.46196600	-2.77946500
Н	-0.79230200	6.16463800	-1.19737000
С	-3.56732300	-0.67230900	-0.41402900
С	-5.28388700	-2.27308300	1.10520200
С	-4.57933800	-0.09246300	0.35494900
С	-3.42176200	-2.05841300	-0.42245000
С	-4.28285300	-2.85488700	0.33218500
С	-5.43155500	-0.88685800	1.11343100
Н	-4.70386000	0.98861700	0.35625100

Н	-2.65372800	-2.51921400	-1.03518200
Н	-4.17860600	-3.93585300	0.30070300
Н	-6.21895600	-0.42623800	1.70182700
Н	-5.95758000	-2.89585400	1.68549500

参考文献

- (1) (a) Kitajima M., Takayama H., *"Topics in Current Chemistry," Vol. 309, ed. by Knölker H. J., Springer, Berlin, Heidelberg*, **2012**, 1–31. (b) Hirasawa, Y.; Kobayashi, J.; Morita, H. *Heterocycles* **2009**, 77, 679–729. (c) Ma, X.; Gang, D. R. *Nat. Prod. Rep.* **2004**, *21*, 752–772. (d) Ayer, W. A. *Nat. Prod. Rep.* **1991**, *8*, 455–463.
- (2) Bcdeker, K. Justus Liebigs Ann. Chem. 1881, 208, 363-367.
- (3) Liu, J.-S.; Zhu, Y.-L.; Yu, C.-M.; Zhou, Y.-Z.; Han, Y.-Y.; Wu, F.-W.; Qi, B.-F. *Can. J. Chem.* **1986**, *64*, 837–839
- (4) Z. Da-Yuan, B. Dong-Lu, T. Xi-Can, Drug Dev. Res. 1996, 39, 147–157.
- (5) J. He, X.-Q. Chen, M.-M. Li, Y. Zhao, G. Xu, X. Cheng, L.-Y. Peng, M.-J. Xie, Y.-T. Zheng, Y.-P. Wang, Q.-S. Zhao, Org. Lett. 2009, 11, 1397–1400.
- (6) Hirasawa, Y.; Morita, H.; Kobayashi, J. Tetrahedron 2002, 58, 5483-5488.
- (7) X.-J. Wang, G.-J. Zhang, P.-Y. Zhuang, Y. Zhang, S.-S. Yu, X.-Q. Bao, D. Zhang, Y.-H. Yuan, N.-H. Chen, S.-G. Ma, J. Qu, Y. Li, *Org. Lett.* 2012, *14*, 2614 2617
- (8) (a) W. Marshall, T. Nguyen, D. Maclean and I. Spenser, *Can. J. Chem.*, **1975**, *53*, 41–50. (b) M. Castillo, R. N. Gupta, Y. K. Ho, D. B. MacLean and I. D. Spenser, *Can. J. Chem.*, **1970**, *48*, 2911–2912.
- (9) Ayer, W. A.; Trifonov, L. S. in *The Alkaloids: Chemistry and Pharmacology, Vol. 45* (Ed.: Cordell, G. A.; Brossi, A.), Academic Press, **1994**, pp. 233–266.
- (10) R. H. Burnell, J. Chem. Soc. 1959, 3091.
- (11) Y. Inubushi, H. Ishii, T. Harayama, R. H. Burnell, W. A. Ayer, B. Altenkirk *Tetrahedron Letters*. **1967**, *12*, 4069–4072.
- (12) Selected reports of total synthesis of fawcettimine-type alkaloids containing aminal- or enamine-type skeletons: (a) Harayama, T.; Takatani, M.; Inubushi, Y. Tetrahedron Lett. 1979, 20, 4307-4310. (b) Harayama, T.; Takatani, M.; Inubushi, Y. Chem. Pharm. Bull. 1980, 28, 2394-2402. (c) Heathcock, C. H.; Smith, K. M.; Blumenkopf, T. A. J. Am. Chem. Soc. 1986, 108, 5022-5024. (d) Heathcock, C. H.; Blumenkopf, T. A.; Smith, K. M. J. Org. Chem. 1989, 54, 1548-1562. (e) Linghu, X.; Kennedy-Smith, J. J.; Toste, F. D. Angew. Chem., Int. Ed. 2007, 46, 7671-7673. (f) Kozak, J. A.; Dake, G. R. Angew. Chem., Int. Ed. 2008, 47, 4221–4223. (g) Nakayama, A.; Kogure, N.; Kitajima, M.; Takayama, H. Org. Lett. 2009, 11, 5554-5557. (h) Jung, M. E.; Chang, J. J. Org. Lett. 2010, 12, 2962-2965. (i) Otsuka, Y.; Inagaki, F.; Mukai, C. J. Org. Chem. 2010, 75, 3420-3426. (j) Zhang, X.-M.; Tu, Y.-Q.; Zhang, F. M.; Shao, H.; Meng, X. Angew. Chem., Int. Ed. 2011, 50, 3916-3919. (k) Nakayama, A.; Kogure, N.; Kitajima, M.; Takayama, H. Angew. Chem., Int. Ed. 2011, 50, 8025-8028. (1) Yang, Y.-R.; Shen, L.; Huang, J.-Z.; Xu, T.; Wei, K. J. Org. Chem. 2011, 76, 3684–3690. (m) Li, H.; Wang, X.; Lei, X. Angew. Chem., Int. Ed. 2012, 51, 491–495. (n) Pan, G.; Williams, R. M. J. Org. Chem. 2012, 77, 4801-4811. (o) Zaimoku, H.; Nishide, H.; Nishibata, A.; Goto, N.; Taniguchi, T.; Ishibashi, H. Org. Lett. 2013, 15, 2140-2143. (p) Zeng, C.; Zheng, C.; Zhao, J.; Zhao, G. Org. Lett. 2013, 15, 5846-5849. (q) Itoh, N.; Iwata, T.; Sugihara, H.; Inagaki, F.; Mukai, C. Chem. - Eur. J. 2013, 19, 8665-8672. (r) Hou, S.-H.; Tu, Y.-Q.; Liu, L.; Zhang, F.-M.; Wang, S.-H.; Zhang, X.-M. Angew. Chem., Int. Ed. 2013, 52, 11373-11376. (s) Li, H.; Wang, X.; Hong, B.; Lei, X. J. Org. Chem. 2013, 78, 800-821. (t) Xu, K.; Cheng, B.; Li, Y.; Xu, T.; Yu, C.; Zhang, J.; Ma, Z.; Zhai, H. Org. Lett. 2014, 16,

196–199. (u) Zhang, J.; Wu, J.; Hong, B.; Ai, W.; Wang, X.; Li, H.; Lei, X. *Nat. Commun.* 2014, *5*, 4614.
(v) Zaimoku, H.; Taniguchi, T. *Chem. - Eur. J.* 2014, *20*, 9613–9619. (w) Zeng, C.; Zhao, J.; Zhao, G. *Tetrahedron* 2015, *71*, 64–69. (x) Hong, B.; Li, H.; Wu, J.; Zhang, J.; Lei, X. *Angew. Chem., Int. Ed.* 2015, 54, 1011–1015. (y) Hong, B.; Hu, D.; Wu, J.; Zhang, J.; Li, H.; Pan, Y.; Lei, X. *Chem. - Asian J.* 2017, *12*, 1557–1567. (z) Tanimura, S.; Yokoshima, S.; Fukuyama, T. *Org. Lett.* 2017, 19, 3684–3686. (aa) Kaneko, H.; Takahashi, S.; Kogure, N.; Kitajima, M.; Takayama, H. *J. Org. Chem.* 2019, *84*, 5645–5654. (ab) Zeng, X.; Jia, Z.; Qiu, F. G. *Tetrahedron Lett.* 2020, 61, 152329.

- (13) Recent review of total synthesis of fawcettimine-type alkaloids. (a) Nakayama, A.; Kitajima, M.; Takayama, H. *Synlett* 2012, *23*, 2014–2024. (b) Murphy, R. A.; Sarpong, R. *Chem. Eur. J.* 2014, *20*, 42–56.
- (14) Ge, H.; Zhang, L.; Tan, R.; Yao, Z. J. Am. Chem. Soc. 2012, 134, 12323-12325.
- (15) (a) Douglas, C. J.; Overman, L. E. *Proc. Natl Acad. Sci. USA*, 2004, 101, 5363–5357. (b) Quasdorf, K. W.;
 Overman, L. E. *Nature*, 2014, 516, 181–191. (c) Zhou, F.; Zhu, L.; Pan, B.-W.; Shi, Y.; Liu, Y.-L.; Zhou, J. *Chem. Sci.* 2020, 11, 9341.
- (16) (a) Reissig, H.-U.; Zimmer, R. Chem. Rev. 2003, 103, 1151–1196. (b) Scheneider, T. F.; Kaschel, J.; Werz, D. B. Angew. Chem. Int. Ed. 2014, 53, 5504–5523. (c) Rassadin, V. A.; Six, Y. Tetrahedron 2016, 72, 4701–4757. (d) Sokolava, O. O.; Bower, J. F. Chem. Rev. impress, doi: org/10.1021/acs.chemrev.0c00109. (e) Pirenne, V.; Muriel, B.; Waser, J. Chem. Rev. impress, doi: org/10.1021/acs.chemrev.0c00109.
- (17) Salim, M.; Capretta, A. Tetrahedron, 2000, 56, 8063-8069.
- (18) Zhang, B.; Wee, A. G. H. Chem. Commun. 2008, 4837-4839.
- (19) Shen, L.; Zhang, M.; Wu, Y.; Qin, Y. Angew. Chem. Int. Ed. 2008, 47, 3618-3621.
- (20) Gagnon D.; Spino, C. J. Org. Chem. 2009, 74, 6035-6041.
- (21) Leng, L.; Zhou, X.; Lio, Q.; Wang, F.; Song, H.; Zhang, D.; Liu, X.-Y.; Qin, Y. Angew. Chem. Int. Ed. 2017, 56, 3703–3707.
- (22) Simone, F. D.; Gertsch, J.; Waser, J. Angew. Chem. Int. Ed. 2010, 49, 5767-5770.
- (23) Gharpure, S. J.; Vijayasree, U.; Reddy, S. R. B. Org. Biomol. Chem. 2012, 10, 1735.
- (24) Remy, D. C.; King, S. W.; Cachran, D. J. Org. Chem. 1985, 50, 4120-4125.
- (25) Castro, J. L.; Castedo, L.; Riguera R. Tetrahedron Lett. 1985, 26, 1561-1564.
- (26) Padwa, A.; Rashatasakhon, P.; Ozdemir, A. D.; Willis, J. J. Org. Chem. 2005, 70, 519-528.
- (27) Geiger, C.; Kreitmeier, P.; Reiser, O. Adv. Synth. Catal. 2005, 347, 249.
- (28) Kitamura, M.; Tashiro, N.; Miyagawa, S.; Okauchi, T. Synthesis 2011, 2011, 1037.
- (29) Padwa, A.; Austin, D. J.; Hornbuckle, S. F.; Semones, M. A.; Doyle, M. P.; Protopopova, M. N. *J. Am. Chem. Soc.* **1992**, *114*, 1874.
- (30) Espino, C. G.; Fiori, K. W.; Kim, M.; DuBois, J. J. Am. Chem. Soc. 2004, 126, 15378.
- (31) Kurose, T.; Tsukano, C.; Takemoto, Y. Org. Lett. 2017, 19, 4762-4765.
- (32) Hirasawa, Y.; Morita, H.; Kobayashi, J. Tetrahedron 2002, 58, 5483-5488.
- (33) Kim, S.-H.; Bowden, N.; Grubbs, R. H. J. Am. Chem. Soc. 1994, 116, 10801-10802.
- (34) (a) Shimizu, K.; Takimoto, M.; Mori, M. Org. Lett., 2003, 5, 2323–2325. (b) Kim, S.; Lee, J.; Lee, T.; Park, H.-G.; Kim, D. Org. Lett. 2003, 15, 2703–2706. (c) Honda, T.; Namiki, H.; Watanabe, M.; Mizutani, H. Tetrahedron Lett. 2004, 45, 5211–5212. (d) Honda, T.; Namiki, H.; Kanda K.; Mizutani, H. Org. Lett. 2004,

6, 87–89. (e) Boyer, F. D.; Hanna, I.; Ricard, L. Org. Lett. 2004, 6, 1817–1820. (f) Kummer, D. A.; Brenneman, J. B.; Martin, S. F. Org. Lett. 2005, 7, 4621–4623. (g) Shimizu, K.; Takimoto, M.; Sato, Y. Mori, M. J. Organomet. Chem. 2006, 691, 5466–5475. (h) Movassaghi, M.; Piizzi, G.; Siegel, D. S.; Piersanti G. Angew. Chem. Int. Ed. 2006, 45, 5859–5863. (i) Siegel, D. S.; Piizzi, Grazia.; Piersanti, G.; Movassaghi, M. J. Org. Chem. 2009, 74, 9292–9304. (j) Mukherjee, S.; Lee, D. Org. Lett. 2009, 11, 13, 2916–2919. (k) Li, J.; Lee, D. Chem. Asian J. 2010, 5, 1298–1302. (l) Baumgartner, C.; Ma, S.; Liu, Q.; Stoltz, B. M. Org. Biomol. Chem. 2010, 8, 2915–2917. (m) Ramharter, J.; Weinstabl, H.; Mulzer, J. J. Am. Chem. Soc. 2010, 132, 14338–14339. (n) Adachi, Y.; Kamei, N.; Yokoshima, S.; Fukuyama, T. Org. Lett. 2011, 13, 4446–4449. (o) Chang, L.; Jiang, H.; Fu, J.; Liu, B.; Li, C.-C. Yang, Z. J. Org. Chem. 2012, 77, 3609–3614. (p) Li, K.; Wang, C.; Yin, G.; Gao, S. Org. Biomol. Chem. 2013, 11, 7550–7558. (q) Wei, H.; Qiao, C.; Liu, G.; Yang, Z.; Li, C.-C. Angew. Chem. Int. Ed. 2013, 52, 620–624. (r) Letort, A.; Aouzal, R.; Cong Ma, C.; Long, D.-L.; Prunet, J. Org. Lett. 2014, 16, 3300–3303. (s) Ma, C.; Letort, A.; Aouzal, R.; Wilkes, A.; Maiti, G.; Farrugia, L. J.; Ricard, L.; Prunet, J. Chem. Eur. J. 2016, 22, 6891–6898. (t) Chu, S.; Mgnster, N.; Balan, T.; Smith, M. D. Angew. Chem. Int. Ed. 2016, 55, 14306–14309.

- (35) Yang, Q.; Xiao, W.-J.; Yu, Z. Org. Lett. 2005, 7, 871-874.
- (36) Hong, S. H.; Grubbs, R. H. J. Am. Chem. Soc. 2006, 128, 11, 3508-3509.
- (37) Nozaki, H.; Moriuti, S.; Takaya, H.; Noyori, R. Tetrahedon Lett. 1966, 43, 5239-5244.
- (38) (a) Pellissier, H. *Tetrahedron*, 2008, 64, 7041–7095. (b) Lebel, H.; Marcoux, J.-F.; Molinar, C.; Cherette, A. B. *Chem. Rev.* 2003, *103*, 977–1050.
- (39) Evans, D. A.; Woerpei, K. A.; Hinman, M. M.; Faul, M. M. J. Am. Chem. Soc. 1991, 113, 726-728.
- (40) Doyle, M. P.; Brandes, B. D.; Kazala, A. P.; Pleters, R. J.; Jarstfer, M. B.; Watkins, L. M.; Eagle, C. T. *Tetrahedron* **1990**, 6613–6616.
- (41) Nishiyama, H.; Itoh, Y.; Matsumoto, H. J. Am. Chem. Soc. 1994, 116, 2223-2224.
- (42) Fukuda, T.; Katsuki, T. Synlett, 1995, 528.
- (43) Chanthamath, S.; Iwasa, S. Acc. Chem. Res. 2016, 49, 2080–2090.
- (44) (a) Melby, T.; Hughes, R. A.; Hansen, T. Synlett 2007, 2277–2279. (b) Villar, I. S.; Gradillas, A.; Gómez-Ovalles, A.; Martínez-Murillo, R.; Martínez, A.; Pérez-Castells, J. Chem. Lett. 2008, 37, 1222–1223. (c) Denton, J. R.; Davies, H. M. L. Org. Lett. 2009, 11, 787–790. (d) Abu-Elfotoh, A.-M.; Phomkeona, K.; Shibatomi, K.; Iwasa, S. Angew. Chem. Int. Ed. 2010, 49, 8439–8443. (e) Villar, I. S.; Gradillas, A.; Pérez-Castells, J. Eur. J. Org. Chem. 2010, 5850–5862. (f) Gu, P.; Su, Y.; Wu, X.-P.; Sun, J.; Liu, W.; Xue, P.; Li, R. Org. Lett. 2012, 14, 2246–2249. (g) Özüduru, G.; Schubach, T.; Boysen, M. M. K. Org. Lett. 2012, 14, 4990-4993. (h) Schinnerl, M.; Böhm, C.; Seitz, M.; Reiser, O. Tetrahedron Asymmetry, 2003, 14, 765–771. (i) Chanthamath, S.; Phomkeona, K.; Shibatomi, K.; Iwasa, S. Chem. Commun. 2012, 48, 7750–7752. (j) Sambasivan, R.; Ball, Z. T. Angew. Chem. Int. Ed. 2012, 51, 8568–8572. (k) Chanthamath, S.; Nguyen, D. T.; Shibatomi, K.; Iwasa S. Org. Lett. 2013, 15, 772–775. (l) Sambasivan, R.; Burya, S. J.; Popp, B. V.; Turro, C.; Clementi, C.; Ball, Z. T. Chem. Sci., 2014, 5, 1401. (m) Joshi-Pangu, A.; Cohen, R. D.; Tudge, M. T.; Chen, Y. J. Org. Chem. 2016, 81, 3070–3075. (n) Xie, M.-S.; Zhou, P.; Niu, H.-Y.; Qu, G.-R.; Guo, H.-M. Org. Lett. 2016, 18, 4344–4347. (o) Chanthamath, S.; Mandour, H. S. A.; Tong, T. M. T.; Shibatomi, K.; Iwasa, S. Chem. Commun. 2016, 52, 7814. (p) Kotozaki, M.; Chanthamath, S.; Fuji, T.;

Shhibatomi, K.; Iwasa, S. *Chem. Commun.* 2018, *54*, 5110. (q) Wang, H.-X.; Guan, F.-J.; Xie, M.-S.; Qu, G.-R.; Guo, H.-M. *Adv. Synth. Catal.* 2018, *360*, 2233–2238. (r) Brandenberg, O. F.; Prier, C. K.; Chen, K.; Knight, A. M.; Wu, Z.; Arnold, F. H. *ACS Catal.* 2018, *8*, 2629–2634. (s) Chu, Z.; Tang, Z.; Zhang, K.; Wang, L.; Li, W.; Wu, H.-H. Zhang, J. *Organometallics* 2019, *38*, 4036–4042. (t) Fu, J.; Wurzer, N.; Lehner, V.; Reiser, O.; Davies, H. M. L. *Org. Lett.* 2019, *21*, 6102–6106. (u) Shao, X.; Malcolmson, S. J. *Org. Lett.* 2019, *21*, 7380–7385. (v) Montesinos-Magraner, M.; Costantini, M.; Ramírez-Contreras, R.; Muratore, M. E.; Johansson, M. J.; Mendoza, A. *Angew. Chem. Int. Ed.* 2019, *58*, 5930–5935. (w) Inoue, H.; Thanh, N. P. T.; Fujisawa, I.; Iwasa, S. *Org. Lett.* 2020, *22*, 1475–1479. (x) Liu, W.; Babl, T.; Röther, A.; Reiser, O.; Davies, H. M. L. *Chem. Eur. J.* 2020, *26*, 4236–4241. (y) Nag, E.; Gorantla, S. M. N. V. T.; Arumugam, S.; Kulkarni, A.; Mondal, K. C.; Roy S. *Org. Lett.* 2020, *22*, 6313–6318. (z) Wang, H.-X.; Li, W-P.; Zhang, M.-M.; Xie, M.-S.; Qu, G.-R.; Guo, H.-M. *Chem. Commun.* 2020, *56*, 11649. (aa) Zhou, L.; Yan, W.-G.; Sun, X.-L.; Wang, L.; Tang, Y. *Angewe. Chem., Int. Ed.* 2020, *59*, 18964–18969.

- (45) (a) Huang, K.-X.; Xie, M.-S.; Zhao, G.-F.; Qu, G.-R.; Guo, H.-M. *Adv. Synth. Catal.* 2016, 358, 3627–3632.
 (b) Xu, H.; Li, Y.-P.; Cai, Y.; Wang, G.-P.; Zhu, S.-P.; Zhou, Q.-L. *J. Am. Chem. Soc.* 2017, *139*, 7697–7770
- (46) Tsushima, K.; Hirade, T.; Hasegawa, H.; Murai, A. Chem. Lett. 1995, 24, 801-802.
- (47) Jung, H.-Y.; Feng, C.; Kim, H.; Yun, J. Tetrahedron 2012, 68, 3444-3449.
- (48) Baker, B. A.; Bosk ovic, Ž. V.; Lipshutz, B. H. Org. Lett. 2008, 10, 289-292.
- (49) Logan, M. M.; Toma, T.; Thomas-Tran, R.; Du Bois, J. Science 2016, 354, 865-869.
- (50) Kono, M.; Harada, S.; Nemoto, T. Chem. Eur. J. 2019, 25, 3119-3124.
- (51) Harada, S.; Kono, M.; Nozaki, T.; Menjo, Y.; Nemoto, T.; Hamada, Y. J. Org. Chem. 2015, 80, 10317-10333.
- (52) Kobayashi, S.; Hachiya, I.; Ishitani, H.; Araki, M. Synlett 1993, 1993, 472-474.
- (53) Liu, H. J.; Yip, J. Synlett 2000, 1119–1122.
- (54) (a) Meerwein, H.; Schmidt, R. Liebigs Ann. Chem. 1925, 444, 221. (b) Namy, J. L.; Souppe, J.; Collin, J.;
 Kagan, H. B. J. Org. Chem. 1984, 49, 2045–2049
- (55) Chen, K.-M.; Hardtmann, G. E.; Prasad, K.; Repič, O.; Shapiro, M. J. Tetrahedron Lett. 1987, 28, 155-158.
- (56) Fruhmann, P.; Hametner, C.; Mikula, H.; Adam, G.; Krska, R.; Fröhlich, J. Toxins, 2014, 6, 325–336.
- (57) Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. Synthesis 1994, 1994, 639-666.
- (58) Yang, Q.; Xiao, W.-J.; Yu, Z. Org. Lett. 2005, 7, 871-874.
- (59) von Holleben, M. L. A.; Livotto, P. R.; Schuch, C. M. J. Braz. Chem. Soc. 2001, 12, 42-46.
- (60) Sasano, Y.; Nagasawa, S.; Yamazaki, M.; Shibuya, M.; Park, J.; Iwabuchi, Y. *Angew. Chem., Int. Ed.* **2014**, *53*, 3236–3240.
- (61) Honma, M.; Sawada, T.; Fujisawa, Y.; Utsugi, M.; Watanabe, H.; Umino, A.; Matsumura, T.; Hagihara, T.; Takano, M.; Nakada, M. J. Am. Chem. Soc. 2003, 125, 2860–2861.
- (62) Davis, H. M. L.; Lee, G. H. Org. Lett. 2004, 6, 1233-1236.
- (63) Reddy, R. P.; Lee, G. H.; Davies, H. M. Org.Lett. 2006, 8, 3437-3440.
- (64) Qin, C.; Boyarskikih, V.; H, J. H.; Hardcastle, K. I.; Musaev, D. G.; Davis, H. M. L. J. Am. Chem. Soc. 2011, 133, 19198–19204
- (65) Abu Elfotoh, A. M.; Phomkeona, K.; Shibatomi, K.; Iwasa, S. Angew. Chem. Int. Ed. 2010, 49, 8439–8443.

- (66) Chi, L. T. L.; Suharto, A.; Da, H. L. Chanthamath, S. Shibatomi, K.; Iwasa, S. *Adv. Synth. Catal.* **2019**, *361*, 951–955.
- (67) Abu-Elfotoh, A. -M.; Nguyen, D. P. T.; Chanthamath, S.; Phomkeona, K.; Shibatomi, K. Iwasa, S. *Adv. Synth. Catal.* **2012**, *354*, 3435–3439.
- (68) Chanthamath, S.; Mandour, H. S. A.; Tong, T. M. T.; Shibatomi, K.; Iwasa, S. *Chem. Commun.* **2016**, *52*, 7814–7817.
- (69) Huang, K.-X.; Xie, M.-S.; Zhao, G.-F.; Qu, G.-R.; Guoa, H.-M.; Adv. Synth. Catal. 2016, 358, 3627–3632.
- (70) Chi, L. T. L.; Suharto, A.; Da, H. L.; Chanthamath, S.; Shibatomi, K.; Iwasa, S. *Adv. Synth. Catal.* **2019**, *361*, 951–955.
- (71) Nagasawa, Y.; Nakayama, N.; Goto, H.; Fujisawa, I.; Chanthamath, S.; Shibatomi, S.; Iwasa, S. *Chirality*. **2019**, *31*, 52–61.
- (72) Marcoux, D.; A. B. Charette Angew. Chem., Int. Ed. 2008, 47, 10155–10158.
- (73) Gaussian 09, Revision E.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2013.

⁽⁷⁴⁾ Henkelman, G.; Jónsson, H. J. Chem. Phys. 2000, 113, 9978–9985.

論文目録

第一章

Synthesis of Octahydro- and Decahydroquinolines by a One-Pot Cascade Reaction of Tetrasubstituted Enecarbamate

Tomohiro Kurose, Chihiro Tsukano, Yoshiji Takemoto Org. Lett. 2017, 19, 4762–4765.

第二章

Total Synthesis of Lyconesidine B, a *Lycopodium* Alkaloid with an Oxygenated, Amine-type Fawcettimine Core

Tomohiro Kurose, Chihiro Tsukano, Takeshi Nanjo, Yoshiji Takemoto *Org. Lett.* **2021**, *23*, 676–681.

Synthetic Studies toward Asymmetric Synthesis of Lyconesidine B. <u>Tomohiro Kurose</u>, Chihiro Tsukano, Takeshi Nanjo, Moeko Itoga, Yoshiji Takemoto 未発表

謝辞

本研究を遂行するにあたり、終始御指導頂いた京都大学大学院薬学研究科教授・竹本佳司先生に深 く感謝申し上げます。研究についての討論では、研究テーマを少しでも面白いものにと、新しいアイ デアを次々と御提案頂きました。くじけそうなことも多々ありましたが、常に正しい方向に導いてく ださいました。今の私があるのは間違いなく竹本先生のおかげです。感謝してもしきれぬほどであり、 厚く御礼申し上げます。

直接御指導頂いた京都大学大学院農学研究科准教授・塚野千尋先生に心より感謝致します。実験技術を一からご教授頂き、その基礎を築いてくださいました。また、NMR スペクトルをはじめ化合物の構造解析に必要な知識・技術を丁寧にご指導頂けたことも、かけがえのない財産です。ご栄転された後もお力添えを頂けたこと重ねて感謝申し上げます。5年間大変お世話になりました。

博士課程の後半より、研究について相談に乗って頂いた京都大学大学院薬学研究科助教・南條毅先 生に心より感謝申し上げます。時間を惜しむことなくとことん議論にお付き合い頂けたおかげで、一 歩ずつ着実にゴールまでたどり着くことができました。

本論文を査読して頂き、討論を含め多大なる御教示を賜りました京都大学化学研究所教授・川端猛 夫先生、ならびに本学薬学研究科教授・高須清誠先生に厚く御礼申し上げます。

Rh 触媒をご提供頂いた千葉大学大学院薬学研究科教授・根本哲宏先生ならびに講師・原田慎吾先生、lyconesidine B の¹H および¹³C NMR チャートをご提供頂いた星薬科大学薬学部教授・森田博史先生ならびに講師・平澤祐介先生に深く御礼申し上げます。

正確かつ丁寧な実験操作で常に信頼できる結果を出し、不斉シクロプロパン化の研究を大きく進展させて頂いた糸賀萌子学士に心より感謝申し上げます。

報告会でのご助言や機器測定、計算化学等でご協力を頂きました京都薬科大学薬学部准教授・小林 祐輔先生、京都大学大学院薬学研究科准教授・中寛史先生、研究員・柳田玲子先生、大阪府立大学理 学研究科助教・道上健一先生に心より御礼申し上げます。また、高分解能質量分析でお力添えを頂い た織田佳代子博士に深く感謝申し上げます。研究生活や事務手続きでは竹本寛子氏に多大なるご支援 を頂きました。心より感謝致します。

研究室配属当初から、議論を交わして下さった齊藤真人博士、安井基博博士、平家崇吉修士をはじ めとして薬品分子化学分野で関わったすべての方々に心より御礼申し上げます。

博士課程において藤多仁生奨学金の助成を頂きました。本助成のおかげでより一層集中して研究に 取り組むことが出来ました。金銭面だけでなく、助成を頂けているという心理的な余裕が生まれたこ とも私にとって大きかったように思います。また、奨学金の一部は教科書購入費などにも充てさせて 頂き、充実した研究生活を送ることが出来ました。故藤多哲朗名誉教授をはじめご遺族・関係者の皆 様に厚く御礼申し上げます。

最後に、京都大学大学院への進学の機会を与え、長きにわたる学生生活を支えて下さった父、母、 兄をはじめとした親族ならびに友人たちに心から感謝致します。

2021年3月 黒瀬 朋浩